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Scientific work must not be considered from the point of view of 
the direct usefulness of it. It must be done for itself,  
for the beauty of science, and then there is always the chance that 
a scientific discovery may become, like the radium, a benefit. 
 
 
Praca naukowa nie może być mierzona bezpośrednią użytecznością.  
Musi być uprawiana dla samej siebie,  
dla swojego piękna, a wówczas zawsze jest sposobność, by odkrycia naukowe 
stały się tym co rad, dobrodziejstwem. 
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  tumorigenesis	  protocol.	  	  Figure	  R-­‐1.	  	  	   Results	  of	  the	  DMBA/TPA	  experiment	  on	  WT,	  p38γ-­‐/-­‐,	  p38δ-­‐/-­‐	  and	  p38γ/δ-­‐/-­‐	  mice.	  	  	  Figure	  R-­‐2.	  	   Progressed	  skin	  tumour	  phenotype.	  	  Figure	  R-­‐3.	  	   Expression	  of	  p38α,	   p38γ	   and	  p38δ	   in	   isolated	  keratinocytes	   and	   in	  healthy	   skin	  and	  papilloma	  tissue.	  	  Figure	  R-­‐4.	  	   Expression	   of	   p38δ	   and	   phospho-­‐p38	   in	   healthy	   skin	   and	   papilloma	   tissue	   from	  WT,	  p38γ-­‐	  and	  p38δ-­‐deficient	  mice.	  	  Figure	  R-­‐5.	  	   Immunohistochemistry	  staining	  of	  β-­‐catenin	  in	  a	  WT	  skin	  papilloma.	  	  Figure	  R-­‐6.	  	   Expression	  of	  β-­‐catenin,	  phospho-­‐Akt	  and	  phospho-­‐STAT3	  in	  WT,	  p38γ-­‐/-­‐	  and	  p38δ-­‐/-­‐	  skin	  papillomas.	  	  Figure	  R-­‐7.	  	   Localisation	  of	  phosphorylated	  STAT3	  in	  benign	  and	  malignant	  skin	  papilloma.	  	  Figure	  R-­‐8.	  	   Neutrophils	   staining	   in	   skin	   papillomas	   and	  MPO	   expression	   in	   healthy	   skin	   and	  papilloma	  tissue	  from	  WT,	  p38γ-­‐	  and	  p38δ-­‐deficient	  mice.	  	  Figure	  R-­‐9.	  	   Immunofluorescence	  staining	  of	  BrdU-­‐positive	  nuclei	  in	  skin	  papillomas	  from	  WT,	  p38γ-­‐/-­‐	  and	  p38δ-­‐/-­‐	  mice.	  	  Figure	  R-­‐10.	  	   Epidermal	   thickness	   and	   immunofluorescent	   staining	   of	   BrdU	   in	   the	   skin	   of	  WT,	  p38γ-­‐/-­‐,	  p38δ-­‐/-­‐	  and	  p38γ/δ-­‐/-­‐	  mice	  treated	  with	  TPA.	  	  Figure	  R-­‐11.	  	   Fluorescent	  staining	  of	  TUNEL-­‐positive	  cells	  in	  the	  epidermis	  of	  WT,	  p38γ-­‐/-­‐,	  p38δ-­‐/-­‐	  and	  p38γ/δ-­‐/-­‐	  mice	  treated	  with	  DMBA.	  	  Figure	  R-­‐12.	  	   Skin	  thickness	  after	  a	  single	  treatment	  of	  TPA	  in	  WT	  and	  p38γ/δ-­‐/-­‐	  mice.	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  Figure	  R-­‐13.	  	   Cytokine	   and	   chemokine	   expression	  WT	   and	   p38γ/δ-­‐/-­‐	   mice	   at	   early	   hours	   after	  	   TPA	  treatment.	  	  Figure	  R-­‐14.	  	   Cytokine	  and	  chemokine	  expression	  WT,	  p38γ-­‐/-­‐	  and	  p38δ-­‐/-­‐	  mice	  at	  8	  hours	  after	  	   TPA	  treatment.	  	  	  Figure	  R-­‐15.	  	   CD3-­‐positive	  cells	  in	  TPA-­‐treated	  skin	  from	  WT	  and	  p38γ/δ-­‐/-­‐	  mice.	  	  Figure.	  R-­‐16.	  	   Neutrophils	   infiltration	   and	  MPO	   expression	   in	   the	   skin	   of	  WT	  mice	   at	   different	  times	  after	  TPA	  treatment.	  	  Figure	  R-­‐17.	  	   Neutrophils	  infiltration	  and	  MPO	  expression	  in	  the	  skin	  of	  WT	  and	  p38γ/δ-­‐/-­‐	  mice.	  	  Figure	  R-­‐18.	  	   Cytokine	   and	   chemokine	   expression	   in	   WT	   mice	   at	   different	   times	   after	   TPA	  treatment.	  	  Figure	  R-­‐19.	   Cytokine	   and	   chemokine	   expression	   WT	   and	   p38γ/δ-­‐/-­‐	   mice	   at	   late	   hours	   after	  	  TPA	  treatment.	  	  Figure	  R-­‐20.	  	   Activation	  of	  p38α,	  p38γ	  and	  p38δ	  in	  the	  skin	  from	  WT,	  p38γ/δ-­‐/-­‐	  mice	  in	  response	  to	  TPA.	  	  Figure	  R-­‐21.	  	   Activation	  of	  p38α,	  p38γ	  and	  p38δ	  in	  the	  skin	  from	  WT,	  p38γ-­‐/-­‐	  and	  p38δ-­‐/-­‐	  mice	  in	  response	  to	  TPA.	  	  Figure	  R-­‐22.	  	   Activation	  of	  ERK1/2,	  STAT3,	  NFκB	  and	  JNK1/2	  in	  the	  skin	  after	  TPA	  treatment.	  	  Figure	  R-­‐23.	  	   β-­‐catenin	  expression	  in	  the	  skin	  of	  WT	  and	  p38γ/δ-­‐/-­‐	  mice	  in	  response	  to	  TPA.	  	  Figure	  R-­‐24.	  	   Immunoblot	   of	   p38γ	   and	   p38δ	   in	   A-­‐431	   cells	   transduced	   with	   p38γ	   and	   p38δ	  shRNAs.	  	  Figure	  R-­‐25.	  	   Immunoblot	   of	   p38γ	   and	   p38δ	   in	   A-­‐431	   cells	   transduced	   with	   different	  combinations	  of	  three	  different	  vectors.	  	  Figure	  R-­‐26.	  	   Growth	   of	   A-­‐431	   xenograft	   tumours	   with	   p38γ	   and/or	   p38δ	   downregulation	   in	  	   athymic	  mice.	  	  Figure	  R-­‐27.	  	   Proliferation	  of	  WT	  and	  p38γ/δ-­‐/-­‐	  A-­‐431	  clones	  in	  vitro.	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La	   señalización	   dependiente	   de	   las	   proteínas	   quinasa	   activadas	   por	  mitógeno	   p38	   (p38	  MAPK)	  tiene	   un	   papel	   importante	   en	   el	   control	   de	   los	   procesos	   celulares	   tales	   como	   la	   proliferación,	  crecimiento	  celular	  y	  diferenciación.	  Hay	  cuatro	  miembros	  de	  la	  familia	  de	  las	  quinasas	  p38:	  p38α,	  p38β,	   p38γ	   y	  p38δ.	  Hasta	   ahora	  no	  existe	  mucha	   información	   sobre	   las	   funciones	  de	   las	  p38γ	   y	  p38δ.	   Utilizando	   modelos	   de	   ratón,	   nuestro	   grupo	   ha	   demostrado,	   en	   los	   últimos	   años,	   la	  importancia	  de	  las	  dos	  isoformas	  p38γ	  y	  p38δ	  en	  la	  inflamación	  y	  en	  la	  producción	  de	  citoquinas	  en	  condiciones	  de	  choque	  séptico,	  artritis	  reumatoide	  y	  cáncer	  de	  colon	  asociado	  a	  colitis	  (Risco	  et	  al.,	  2012;	  Criado	  et	  al.,	  2014,	  del	  Reino	  et	  al.,	  2014).	  Sin	  embargo,	  el	  involucramiento	  de	  las	  p38γ	  y	  p38δ	  en	  la	  tumorigénesis	  de	  piel	  asociada	  a	  inflamación	  hasta	  ahora	  no	  estaba	  bien	  descrita.	  Esta	  tesis	  representa	  un	  trabajo	  que	  se	  llevo	  a	  cabo	  para	  describir,	  por	  primera	  vez	  en	  este	  grupo,	  estas	  dos	  quinasas	  en	  la	  piel	  de	  ratón.	  	  Está	  ampliamente	  reconocido	  que	   las	  neoplasias,	   incluido	  el	  cáncer	  de	  piel,	  están	  provocadas,	  al	  menos	  parcialmente,	  por	   la	   inflamación	  crónica	  (Balkwill	  et	  al.,	  2005).	  La	  carcinogénesis	  de	  piel	  químicamente	   inducida	   es	   uno	   de	   los	   mejores	   modelos	   in	   vivo	   para	   investigar	   los	   distintos	  estadios	  del	  desarrollo	  tumoral.	  Representa	  un	  modelo	  clásico	  del	  tumor	  asociado	  a	   inflamación	  que	   consiste	   en	   la	   exposición	   a	   un	   carcinógeno	   (7,12-­‐dimetilbenzo(a)antraceno	   o	   DMBA)	   y,	  después,	   durante	   una	   fase	   de	   promoción,	   al	   compuesto	   12-­‐O-­‐tetradecanoilforbol-­‐13-­‐acetato	  (TPA),	  que	  es	  un	  potente	  inductor	  de	  la	  inflamación	  en	  la	  piel	  (DiGiovanni,	  1992).	  Los	  tumores	  de	  piel	  (también	  designados	  como	  papilomas	  de	  piel)	  desarrollados	  en	  este	  modelo	  representan	  un	  estadio	  intermedio	  entre	  la	  piel	  sana	  y	  un	  estadio	  maligno	  de	  carcinoma	  de	  piel,	  parecido	  al	  cáncer	  escamoso	  en	  los	  humanos.	  	  Aquí	  mostramos	  resultados	  sobre	  la	  implicación	  de	  p38γ	  y	  p38δ	  en	  la	  inflamación	  de	  piel	  de	  ratón	  y	  la	  promoción	  tumoral	  de	  la	  piel	  a	  través	  del	  protocolo	  del	  DMBA/TPA,	  así	  como	  usando	  sólo	  el	  tratamiento	   con	   el	   TPA.	   Las	   dos	   quinasas	   p38	   se	   fosforilan	   en	   respuesta	   al	   TPA,	   indicando	   su	  implicación	  en	  la	  regulación	  de	  la	  inflamación	  y	  la	  tumorigénesis	  en	  la	  piel.	  También	  mostramos	  que	   la	   ausencia	  de	  ambas	  proteínas	  quinasas	   suprime	   significativamente	   la	   tumorigénesis	  de	   la	  piel.	  Por	  otro	  lado,	  con	  el	  tratamiento	  tópico	  con	  TPA,	  hemos	  demostrado	  la	  importancia	  de	  p38γ	  y	  p38δ	   en	   la	   producción	   de	   citoquinas,	   reclutamiento	   de	   neutrófilos	   y	   en	   el	   control	   de	   la	  proliferación	  epidermal.	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1.	  Skin	  carcinogenesis.	  
	  
1.1.	  Skin	  structure	  and	  functions.	  The	  skin	  is	  the	  largest	  organ	  of	  the	  human	  body	  and	  a	  primary	  barrier	  against	  physical	  insults	  and	  microbial	  pathogens.	  It	  represents	  a	  complex	  environment	  in	  which	  skin	  cells	  maintain	  the	  tissue	  homeostasis	   and,	   under	   pathological	   conditions,	   are	   capable	   of	   provoking	   protective	   reactions.	  This	   protection	   is	   possible	   thanks	   to	   the	   unique	   anatomy	   and	   cellular	   composition	   of	   the	   skin,	  particularly	  the	  vast	  network	  of	  skin-­‐associated	  immune	  cells	  (Tay	  et	  al.,	  2013).	  	  
1.1.1.	  Skin	  anatomy.	  The	  skin	  is	  composed	  of	  epidermis,	  dermis	  and	  subcutaneous	  layer,	  which	  contain	  an	  array	  of	  cell	  types	  and	  skin	  structures	  (Fig.	  I-­‐1).	  
	  Figure	  I-­‐1.	  Cross-­‐section	  of	  the	  human	  skin	  with	  its	  characteristic	  elements.	  (*)	  The	  names	  of	  four	  layers	  of	  the	  epidermis	  (adapted	  from	  http://www.coenzyme-­‐a.com/skinmatrix_article.html).	  	  	  The	  epidermis	  is	  the	  top	  layer	  of	  the	  skin.	  Apart	  from	  predominant	  keratinocytes,	  which	  produce	  keratin,	   the	   epidermis	   is	   also	   comprised	   of	   melanocytes	   and	   Langerhans	   cells.	   Melanocytes	  produce	  a	  brown	  pigment,	  melanin,	  which	  gives	  dark	  colour	   to	   the	  skin	  and	  protects	   stem	  cells	  and	  proliferating	  keratinocytes	   in	   the	  deeper	   layers	   from	  the	  harmful	  effects	  of	  ultraviolet	   (UV)	  radiation	   in	   the	   sunlight	   (Teichert	   and	   Bikle,	   2011).	   Langerhans	   cells	   that	   are	   a	   specialised	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subpopulation	  of	  antigen-­‐presenting	  immune	  cells,	  called	  dendritic	  cells,	  are	  the	  frontline	  defense	  of	   the	   immune	   system	   in	   the	   skin.	   The	   epidermis	   is	   divided	   into	   four	   layers	   based	   on	  different	  levels	   of	   cell	   differentiation.	   Starting	   with	   the	   deepest	   one,	   situated	   just	   above	   the	   basement	  membrane,	  which	  is	  composed	  of	  the	  basal	  lamina	  and	  the	  reticular	  lamina,	  they	  are:	  basal	  layer	  (stratum	  basale),	  spinous	  layer	  (stratum	  spinosum),	  granular	  layer	  (stratum	  granulosum)	  and	  the	  outermost	  -­‐	  cornified	  layer	  (stratum	  corneum).	  The	  latter	  is	  made	  up	  of	  dead	  keratinocytes	  called	  corneocytes.	   Together	   with	   stratum	   granulosum,	   rich	   in	   tight	   junctions,	   corneocytes	   ensure	   an	  effective	  physical	  barrier	  between	  deeper	  layers	  and	  the	  environment.	  	  	  As	  for	  the	  dermis,	  its	  major	  cell	  type	  is	  fibroblasts,	  including	  the	  specialized	  group	  of	  fibroblasts	  in	  dermal	  papilla	  at	  the	  base	  of	  the	  hair	  follicle.	  Similarly	  to	  the	  epidermis,	  this	  skin	  fraction	  is	  highly	  complex	  and	  contains	  a	  range	  of	  structures,	  such	  as	  hair	  follicles,	  sweat	  glands	  (absent	  in	  mice),	  sebaceous	  glands,	  nerve	  endings,	  capillary	  blood	  vessels	  and	  lymphatic	  vessels,	  sustained	  in	  skin	  structure	  by	  collagen,	  a	  protein	  giving	  the	  skin	  its	  elasticity	  and	  strength.	  	  	  The	  deepest	  part	  of	  the	  skin,	  the	  subcutaneous	  layer	  or	  subcutis	  forms	  with	  the	  lowest	  parts	  of	  the	  dermis	  a	  network	  of	  collagen	  and	  adipocytes	  (fat	  cells)	  (www.cancer.org).	  	  
1.1.2.	  Skin	  immune	  cells.	  The	   group	   of	   skin-­‐resident	   immune	   cells	   is	   composed	   of	  myeloid	   cells	   (macrophages,	   dendritic	  cells,	  mast	   cells)	   and	   lymphocytes:	   γδ	   T	   cells,	  αβ	   T	   cells	   (CD4+	  and	  CD8+)	  and	   innate	   lymphoid	  cells	  (natural	  killer	  cells)	  as	  shown	  in	  Figure	  I-­‐2	  and	  reviewed	  by	  Tay	  et	  al.	  (2013).	  	  Macrophages	  within	  the	  skin	  exhibit	  a	  diverse	  distribution,	  they	  are	  either	  associated	  with	  blood	  vessels	   (perivascular	  macrophages),	   lymphatic	  vessels	  or	   they	  reside	   in	   the	   intervascular	  space.	  The	   perivascular	   macrophages	   regulate	   leukocyte	   extravasation	   thanks	   to	   their	   proximity	   to	  blood	   vessels,	   while	   those	   associated	   with	   lymphatic	   vessels	   are	   important	   during	  lymphangiogenesis	  (Weber-­‐Matthiesen	  and	  Sterry,	  1990).	  	  	  Dendritic	   cells	   are	   constituted	   by	   the	   mentioned	   Langerhans	   cells	   in	   the	   basal	   and	   suprabasal	  epidermis	   and	   by	   dermal	   dendritic	   cells.	   They	   are	   responsible	   for	   immune	   response	   initiation	  thanks	   to	   high	   efficiency	   at	   capturing	   dead	   cells	   and	  presenting	   antigens,	   such	   as	   viruses	   other	  intracellular	   pathogens	   or	   skin-­‐associated	   self	   antigens,	   to	   immune	   effectors,	   T	   cells,	   present	   in	  skin-­‐draining	  lymph	  nodes	  (Bedoui	  et	  al.,	  2009).	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Most	  of	  the	  T	  cells	  found	  in	  the	  healthy	  skin	  are	  tissue-­‐resident	  memory	  T	  (TRM)	  cells.	  This	  type	  of	  cells	  belongs	  to	  a	  group	  of	  memory	  T	  cells	  together	  with	  two	  subsets	  of	  circulating	  T	  cells:	  effector	  memory	   T	   (TEM)	   and	   central	   memory	   T	   (TCM)	   cells	   (Shin	   and	   Iwasaki,	   2013).	   The	   TRM	   in	   the	  epidermis	  are	  CD8+	  T	  cells.	  They	  are	  long-­‐term	  resident	  subset	  disconnected	  from	  the	  circulation,	  which	   get	   cytotoxic	   and	   kill	   target	   cells	   upon	   activation.	   CD4+	  T	   cells,	   found	   in	   the	   dermis,	   are	  either	   TRM	   or	   helper	   T	   cells	  with	  modulatory	   functions.	   As	   for	   the	   remaining	   dermis-­‐residing	   T	  lymphocytes,	  most	   of	   them	   express	   Vγ5/Vδ1	  T	   cell	   receptor	   (TCR)	   and	   are	   named	  dermal	   γδ	   T	  cells.	   They	   have	   been	   reported	   to	   enhance	   CD4+	   T	   cell	   immunity	   to	   some	   infections,	   which	  appears	  to	  be	  facilitated	  by	  the	  production	  of	  interleukin	  (IL)-­‐17	  by	  dermal	  γδ	  T	  cells,	   leading	  to	  neutrophil	  recruitment	  (Heath	  and	  Carbone,	  2013).	  	  Epidermal	  fraction	  of	  γδ	  T	  cells	  is	  constituted	  by	  so-­‐called	  dendritic	  epidermal	  T	  lymphocytes	  or	  DETCs	   (Sumaria	   et	   el.,	   2011).	   They	   are	   called	   so	   for	   their	   unique	  dendritic	  morphology.	  DETCs	  sense	   skin	   injury	   through	   recognition	  of	   an	  unknown	   ligand	  expressed	  by	   stressed	  or	  damaged	  keratinocytes.	  Similarly	  to	  dermal	  γδ	  T	  cells,	  the	  γδ	  TCR	  activation	  in	  a	  subset	  of	  DETCs	  is	  followed	  by	   IL-­‐17	  production,	  which	   induces	  expression	  of	  multiple	  host-­‐defense	  molecules	   in	  epidermal	  keratinocytes	  (MacLeod	  et	  al.,	  2013).	  	  
	  Figure	   I-­‐2.	   Schematic	   representation	  of	   skin	   resident	   immune	  cells.	  DETC:	  dendritic	  epidermal	  T	  cell.	  TRM	  cell:	  tissue-­‐residing	  memory	  T	  cell.	  TEM	  cell:	  effector	  memory	  T	  cell.	  Treg	  cell:	  regulatory	  T	  cell.	  DC:	  dendritic	  cell.	   ILC:	   innate	   lymphoid	   cell.	   NK:	   natural	   killer.	   Note	   that	   macrophages	   and	   mast	   cells	   are	   not	   shown	  (Heath	  and	  Carbone,	  2013).	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1.2.	  Squamous	  cell	  carcinoma.	  Skin	  cancers	  are	  commonly	  divided	  into	  two	  groups:	  melanomas	  and	  non-­‐melanoma	  skin	  cancers	  (NMSC).	  NMSC	  are	  the	  most	  common	  form	  of	  malignancy	  in	  humans.	   In	  the	  USA	  there	  are	  more	  than	  2	  million	  cases	  of	  NMSC	  each	  year.	  They	  represent	  almost	  95%	  of	  all	  cutaneous	  neoplasms	  (Dubas	  and	  Ingraffea,	  2013,	  Kim	  and	  Armstrong,	  2012).	  NMSC	  comprise	  two	  main	  groups:	  basal	  cell	  carcinoma	  (BCC)	  and	  squamous	  cell	  carcinoma	  (SCC),	  also	  called	  epidermoid	  carcinoma.	  BCC	  and	  SCC	  are	  named	  after	  the	  type	  of	  skin	  cells	  from	  which	  the	  tumours	  originate:	  basal	  cells	  of	  the	  basal	   layer	   and	   flat	   squamous	   cells	   of	   the	   spinous	   layer,	   respectively	   (www.cancer-­‐researchuk.org).	  Besides,	  there	  are	  other	  less	  common	  NMSC	  types:	  keratoacanthoma,	  Merkel	  cell	  carcinoma,	   Kaposi	   sarcoma,	   cutaneous	   (skin)	   lymphoma	   and	   skin	   adnexal	   tumours	   (starting	   in	  hair	  follicles	  and	  skin	  glands).	  	  	  Although	  SCC	  is	  less	  frequent	  in	  comparison	  with	  BCC	  (20%	  and	  80%,	  respectively),	  it	  belongs	  to	  the	  most	  common	  invasive	  cancers	  in	  the	  world,	  with	  an	  annual	  incidence	  of	  250,000	  in	  the	  USA	  (Fig.	   I-­‐3)	   (Chen	   at	   al.,	   2001).	   The	   elevated	   risk	   of	   metastasis	   of	   SCC	   is	   accompanied	   by	   many	  characteristics	  of	  lethal	  solid	  tumours	  of	  the	  internal	  organs,	  absent	  in	  BCC.	  In	  many	  countries	  the	  incidence	  of	  SCC	  is	  rising	  and	  its	  occurrence	  is	  usually	  associated	  with	  chronic	  UV	  exposure	  and,	  therefore,	  is	  especially	  common	  in	  people	  with	  sun-­‐damaged	  skin,	  fair	  skin	  and	  albinism.	  Another	  factors	  that	  contribute	  to	  SCC	  development	  are	  ionising	  radiation,	  chemical	  agents	  (e.g.	  polycyclic	  aromatic	  hydrocarbons),	   human	  papilloma	  virus	   infections	   and	   the	   genetic	  predispositions	   (e.g.	  hereditary	  defects	  in	  DNA	  repair	  genes	  in	  xeroderma	  pigmentosum	  patients).	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Figure	  I-­‐3.	  Clinical	  demonstration	  of	  the	  squamous	  cell	  carcinoma	  on	  the	  face	  skin	  of	  two	  elderly	  patients.	  Sources:	  (A)	  American	  Osteopathic	  College	  of	  Dermatology	  website.	  (B)	  American	  Academy	  of	  Dermatology	  website.	  	  	  Moreover,	  SCCs	  are	  more	  likely	  to	  arise	  in	  injured	  and	  chronically	  diseased	  skin	  (Mueller,	  2006).	  Patients	  with	  impaired	  immune	  functions,	  for	  example	  those	  receiving	  immunosuppressive	  drugs	  following	  allogenic	  organ	   transplantation	  or	  as	  a	   therapy	  of	   inflammatory	  disease	  (e.g.	   in	  Crohn	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disease)	  and	  those	  with	  lymphoma	  or	  leukaemia	  are	  also	  at	  higher	  risk	  of	  this	  tumour	  (Zitelli	  et	  al.,	   2013,	   Motley	   et	   al.,	   2002).	   Head	   and	   neck	   squamous	   cell	   carcinoma	   (HNSCC)	   is	   a	   clinical	  subtype	  of	  SCC	  and	  the	  sixth	  most	  common	  cancer	  in	  the	  world	  (American	  Cancer	  Society:	  Cancer	  Facts	   and	   Figures	   2008).	   It	   is	   a	   result	   of	   an	   aberrant	   proliferation	   of	   the	   squamous	   epithelium	  lining	  the	  mucosal	  surfaces	  of	  the	  head	  and	  neck.	  The	  primary	  epithelial	  tumours	  of	  this	  type	  can	  develop	  in	  any	  mucosa-­‐lined	  regions,	  such	  as	  the	  tympanic	  cavity,	  paranasal	  sinuses,	  nasal	  cavity,	  pharynx,	  oral	  cavity	  and	  larynx,	  whereas	  the	  metastases	  can	  occur	  in	  the	  neck	  lymph	  nodes,	  lungs	  and	  liver	  (reviewed	  by	  Lin	  and	  Rocco,	  2011).	  	  
1.3.	  Genetic	  background	  of	  skin	  SCCs.	  Genetic	   analyses	   of	   the	   squamous	   tumours	   revealed	   common	  mutations	   such	   as	   inactivation	   of	  p53,	   inactivation	   of	   cell	   cycle	   inhibitors,	   upregulation	   of	   cell	   cycle	   enhancers,	   mutational	   up-­‐regulation	  of	  epidermal	  growth	  factor	  receptor	  (EGFR),	  reduction	   in	  transforming	  growth	  factor	  (TGF)-­‐β	  signalling	  and	  activating	  mutations	  of	  Ras	  proteins	  (Cataisson	  and	  Yuspa,	  2011).	  Aberrant	  signalling	  of	  Ras-­‐dependent	  pathways	  has	  been	  linked	  to	  a	  range	  of	  human	  neoplasms,	  including	  skin.	  Activating	  mutations	  of	  RAS	  are	  found	  in	  approximately	  15%	  of	  human	  cancers	  (Bos,	  1989).	  The	   clinical	   observations	   and	   experimental	   data	   reveal	   that	   mutations	   of	   the	   proto-­‐oncogene	  
Harvey	  RAS	  (H-­‐RAS)	  belong	  to	  the	  most	  frequent	  genetic	  alterations	  found	  in	  human	  skin	  tumours	  (Ananthaswamy	  and	  Pierceall,	  1992).	  For	  instance,	  in	  the	  case	  of	  SCCs	  the	  majority	  of	  the	  tumours	  display	   elevated	   levels	   of	   guanosine	   triphosphate	   (GTP)-­‐bound	   active	   RAS	   (Ridky	   and	   Khavari,	  2004).	   Also,	   animal	  model	   studies	   show	   that	   heterozygous	   activation	   of	   Ras	   in	   keratinocytes	   is	  sufficient	   to	   induce	   benign	   squamous	   lesions.	   Among	  Ras	   gene	   alterations	   observed	   in	  murine	  skin	  carcinogenesis,	  H-­‐Ras	  mutations	  are	  predominant	  as	  well	  (Balmain	  and	  Brown,	  1988).	  	  A	   number	   of	   carcinogens	   can	   provoke	  Ras	   mutations	   in	   the	   skin.	   The	  most	   commonly	   used	   in	  murine	   skin	   carcinogenesis	   studies	   is	   7,12-­‐dimethylbenz[α]anthracene	   (DMBA)	   (Hennings	   and	  Boutwell,	  1970).	  The	  majority	  of	  DMBA-­‐induced	  skin	  cancers	  contain	  mutational	  activation	  of	  H-­‐Ras,	  which	  results	  from	  adenine	  transversion	  to	  thymidine	  (A>T)	  at	  the	  second	  base	  in	  codon	  61	  (Balmain	   et	   al.,	   1984).	   The	   mechanism	   underlying	   this	   mutation	   depends	   on	   T>A	   substitution	  during	   the	   first	   round	   of	   replication	   provoked	   by	   carcinogen-­‐diol-­‐epoxide	   binding	   to	   DNA,	  followed	  by	  a	  fixed	  transversion	  A:T>T:A	  after	  the	  second	  round	  of	  replication.	  This	  results	  in	  the	  replacement	  of	  glutamine	  by	   leucine	   in	   the	  protein,	  which,	   in	   turn,	   impairs	   the	   intrinsic	  GTPase	  activity.	  As	  a	  result	  mutant	  Ras	  is	  accumulated	  in	  its	  GTP-­‐bound	  active	  form	  and,	  thereby,	  causes	  the	  cancerous	  skin	  phenotype.	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In	  order	  to	  identify	  exact	  mechanisms	  by	  which	  the	  gene	  mutations	  lead	  to	  cancer,	  including	  skin	  cancer,	   molecular	   information	   obtained	   from	   human	   tumour	   studies	   is	   linked	   with	   biological	  processes	   also	   observed	   in	   animal	   experimentation.	   This	   is	   achieved	   by	   using	   an	   appropriate	  animal	   model	   that	   at	   least	   partially	   mimics	   the	   phenotypic	   changes	   along	   with	   genetic	   and	  epigenetic	  events	  (Cataisson	  and	  Yuspa,	  2011).	  	  	  Since	   H-­‐Ras	   is	   a	   common	   signal	   transducer	   in	   epithelial	   cells,	   multiple	   changes	   in	   signalling	  pathways	   controlled	   by	   H-­‐Ras	   (described	   in	   section	   2.1.1)	   are	   observed	   in	   skin	   papillomas	  developed	   in	   the	  most	   studied	  mouse	   skin	   carcinogenesis	  model	   –	   the	   chemically	   induced	   two-­‐stage	  DMBA/TPA	  model.	  
	  
1.4.	  Mouse	  model	  of	  chemically	  induced	  two-­‐stage	  skin	  tumorigenesis.	  Cancer	   development,	   including	   skin	   cancer,	   is	   a	   multiple	   step	   process	   during	   which	   originally	  normal	   cells	   undergo	   a	   number	   of	   progressive	   changes,	   leading	   to	   increased	   proliferation	  phenotype.	  Varied	  physicochemical	  and	  biological	  factors	  are	  commonly	  recognised	  to	  be	  capable	  of	   initiation	  of	   tumorigenesis	   in	   skin	   (Evan	  and	  Vousden,	  2001).	   For	   example,	  UV	   radiation	   is	   a	  skin	   tumour-­‐initiating	   factor	   present	   in	   the	   sunlight.	   Another	   initiating	   agent	   in	   skin	  tumorigenesis	  is	  the	  mentioned	  carcinogen	  DMBA.	  However,	  single	  administration	  of	  DMBA	  onto	  shaved	   murine	   skin	   is	   not	   sufficient	   to	   induce	   skin	   tumorigenesis.	   A	   standard	   procedure	  established	  in	  the	  1940s	  (Boutwell,	  1964),	  namely	  the	  two-­‐stage	  skin	  carcinogenesis,	  consists	  of	  the	  DMBA	  initiation	  followed	  by	  repeated	  applications	  of	  promoting	  agent,	  typically	  phorbol	  ester,	  12-­‐O-­‐tetradecanoylphorbol-­‐13-­‐acetate	  (TPA),	  usually	  for	  20	  weeks	  (Fig.	  I-­‐4).	  	  
	  Figure	  I-­‐4.	  Multistage	  mouse	  skin	  carcinogenesis	  model	  (Rundhaug	  and	  Fischer,	  2010).	  	  	  At	  the	  molecular	  level,	  the	  initiation	  involves	  DNA	  damage	  that	  causes	  mutations	  in	  specific	  cells	  of	   the	   skin,	   which	   then	   are	   exposed	   to	   regular	   promotion.	   Specifically,	   over	   90%	   of	   tumours	  initiated	  with	  DMBA	  have	  a	  point	  mutation	  in	  the	  H-­‐Ras	  gene	  (see	  section	  1.3)	  (Quintanilla	  et	  al.,	  1986).	  During	   the	  promotion,	   enhanced	  proliferation	   and	   altered	   cell	   activity	   take	  place.	  As	   for	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specific	  target	  cells	  in	  skin	  during	  these	  events,	  it	  is	  believed	  that	  stem	  cells	  in	  the	  interfollicular	  epidermis	  acquire	  H-­‐Ras	  mutations	  and	  give	   rise	   to	  mutated	  progenitors	   (Schwarz	  et	  al.,	  2013).	  These,	   in	   turn,	   need	   tumour	   promoter	   (TPA),	   which	   stimulates	   cell	   divisions	   and	   leads	   to	   skin	  thickening,	  increasing	  the	  probability	  of	  survival	  and	  clonal	  expansion	  of	  initiated,	  H-­‐Ras	  mutated	  cells,	  as	  illustrated	  in	  Figure	  I-­‐5.	  	  
	  Figure	  I-­‐5.	  Clonal	  outgrowth/cell	  death	  balance	  of	  progeny	  cells	  of	  epithelial	  stem	  cells	  with	  DMBA-­‐induced	  mutations	  in	  the	  absence	  and	  presence	  of	  TPA	  treatment	  (Schwarz	  et	  al.,	  2013).	  	  	  Skin	  papillomas,	  developed	   in	   the	  DMBA/TPA	  protocol,	  arise	   from	  hyperproliferating	  epidermal	  cells	  as	  protuberances	  on	  the	  skin.	  They	  form	  keratinized	  lesions	  due	  to	  changes	  in	  epithelial	  cell	  physiology	   and	   morphology	   during	   the	   tumour	   growth	   (Fig.	   I-­‐6).	   They	   are	   characterised	   by	  certain	  features	  absent	  in	  normal	  skin	  epithelium.	  Tumour	  stroma,	  consisting	  of	  connective	  tissue	  and	  filling	  this	  protuberance	  from	  within,	   is	  separated	  from	  tumour-­‐forming	  epithelial	  cells	  by	  a	  basal	  membrane.	  The	  basal	  membrane	  is	  composed	  of	  a	  compact,	  normally	  intact	  layer	  of	  highly	  proliferating	  cells.	  In	  a	  standard	  haematoxylin-­‐eosin	  staining	  the	  basal	  cells	  are	  darker	  and	  have	  a	  dark	  nucleus.	   	  The	   tumour	  part	  above	   the	  basal	  membrane	   is	   formed	  by	  epithelial	   cells	  derived	  from	  basal	  cells.	  They	  are	  predominantly	  oval	  and	  contain	  a	  prominent	  pale	  nucleus	  with	  a	  large	  nucleolus.	   During	   the	   growth	   of	   tumour	   the	   cells	   differentiate	   and	   get	   keratinized,	   losing	   their	  vital	  functions.	  	  	  
	  	  Figure	   I-­‐6.	  Representative	  skin	  papilloma	  developed	   in	   the	   two-­‐stage	  skin	   tumorigenesis	  protocol	  stained	  with	  haematoxylin	  and	  eosin.	  A	  whole	  tumour	  image	  with	  three	  rising	  magnifications	  from	  left	  to	  right	  are	  shown.	  Characteristic	  epithelial	  cells	  with	  a	  large	  pale	  nucleus	  and	  a	  prominent	  nucleolus	  can	  be	  observed.	  E	  –	  tumour	  epithelium.	  S	  –	  tumour	  stroma.	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While	   skin	   papillomas	   are	   exophytic	   tumours	   that	   show	   no	   evidence	   of	   stromal	   invasion,	  squamous	  cell	  carcinomas	  have	  a	  more	  endophytic	  appearance,	  with	  stromal	  invasion	  evidenced	  by	   loss	   of	   basal	   membrane	   continuity	   and	   development	   of	   an	   inflammatory	   stromal	   response	  (Thomas-­‐Ahner	  et	  al.,	  2007).	  	  TPA	   is	  not	   the	  only	  chemical	   skin	   tumour	  promoter.	  The	  promotion	  stage	   in	  mouse	  skin	  can	  be	  accomplished	  by	  a	  wide	  variety	  of	  weak	  or	  noncarcinogenic	  agents,	  other	  than	  TPA,	  characterised	  by	  different	  potency	  (Table	  I-­‐1).	  TPA,	  however,	  is	  most	  commonly	  used	  in	  the	  skin	  research.	  	  
	  Table	  I-­‐1.	  Skin	  tumour	  promoters	  and	  their	  potency	  (adapted	  from	  Slaga,	  1983).	  	  	  It	  has	  been	  demonstrated,	  that	  in	  the	  late	  stages	  of	  the	  tumour	  promotion	  a	  certain	  percentage	  of	  benign	  papillomas	  progress	  to	  carcinomas,	  giving	  rise	  to	  SCCs.	  This	  occurs	  spontaneously	  at	  a	  low	  frequency	  (Quintanilla	  et	  al.,	  1986).	  This	  conversion	  is	  strain-­‐dependent	  and	  not	  all	  mouse	  strains	  are	   capable	   of	   developing	   malignant	   skin	   lesions	   (Woodworth	   et	   al.,	   2004).	   The	   mechanism	  underlying	  this	  process	  still	  needs	  a	  better	  understanding.	  An	  insight	  into	  a	  possible	  regulation	  of	  the	  progression	  was	  delivered	  by	  experiments	  with	   transgenic	  mice,	  selectively	  over-­‐expressing	  the	  H-­‐ras	   oncogene	  under	   different	   keratin	   promoters.	   It	   turned	   out	   that	   hair	   bulge	   stem	   cells-­‐derived	  papillomas	  are	  more	  prone	  to	  malignant	  transformation,	  while	  the	  ones	  developed	  from	  interfollicular	  stem	  cell	  population	  progress	  into	  carcinomas	  less	  frequently	  (Brown	  et	  al.,	  1998).	  	  While	  most	  human	  skin	  SCCs	  are	  associated	  with	  UV,	  rather	  than	  chemical	  carcinogenesis,	  10%	  of	  the	   skin	   SCCs	   do	   have	   RAS	   gene	   mutations	   (Lopez-­‐Pajares	   et	   al.,	   2013),	   and	   DMBA/TPA	  carcinogenesis	   has	   contributed	   substantially	   to	   the	   understanding	   of	   the	   steps	   of	   tumour	  development	  in	  the	  human	  skin	  (Hirst	  and	  Balmain,	  2004).	  	  
2.	  Molecular	  mechanisms	  of	  skin	  tumour	  promotion.	  Multiple	   molecular	   mechanisms	   are	   involved	   in	   the	   promotion	   stage	   in	   the	   two-­‐stage	   skin	  tumorigenesis	  protocol.	  Keratinocytes	  with	  DMBA-­‐induced	  mutations	  maintain	  an	  elevated	  level	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of	  proliferation	  by	  a	  direct,	  TPA-­‐induced	  activation	  of	  mitotic	  signalling	  pathways	  or,	  indirectly,	  as	  a	  response	  to	  inflammatory	  processes	  in	  skin,	  dependent	  on	  immunological	  tissue	  response.	  It	  has	  been	   observed	   that	   chronic	   wounding	   might	   also	   contribute	   to	   the	   skin	   tumour	   promotion	  (Rundhaug	  and	  Fischer,	  2010).	  Moreover,	  since	  epithelial	  tumour	  development	  is	  associated	  with	  impairment	   in	   tissue	   structure	   organization,	   especially	   during	   progression	   into	   malignant	   skin	  carcinomas,	  cell	  adhesion-­‐controlling	  molecular	  events	  may	  also	  be	  affected.	  	  
2.1.	  Signalling	  pathways	  in	  DMBA/TPA	  challenged	  skin	  and	  in	  epithelial	  tumours.	  As	  mentioned	  above,	   the	  Ras	  pathway	  is	  affected	  due	  to	  the	  mutational	  activity	  of	  DMBA	  during	  the	  tumour	  initiation	  stage.	  Noteworthy,	  Ras	  is	  also	  one	  of	  the	  downstream	  elements	  of	  the	  EGFR-­‐induced	  signalling	  pathway,	  activated	  in	  response	  to	  TPA	  challenge,	  occurring	  during	  skin	  tumour	  promotion	  (Laurent-­‐Puig	  et	  al.,	  2009).	  
	  
2.1.1.	  Ras	  signalling.	  H-­‐Ras	   forms	   with	   K-­‐	   and	   N-­‐Ras	   a	   family	   of	   small	   guanosine	   triphosphotases	   (GTPases)	   that	  transduce	  signal	   from	  bound	  receptors	   to	  downstream	  effector	  pathways	   (Cataisson	  and	  Yuspa,	  2011).	  	  	  
	  	  
	  Figure	   I-­‐7.	   (A)	   Ras-­‐dependent	   signalling	   pathways.	   (B)	   Negative	   turnover	   of	   β-­‐catenin	   by	   GSK3β	  degradation	   complex.	   Phosphorylation	   of	  β-­‐catenin	   by	   GSK3β	   signals	   for	   ubiquitylation	   and	   proteasomal	  degradation	  (Aberle	  et	  al.,	  1997).	  	  (C)	  Wnt	  pathway.	  LRP	  –	  low-­‐density	  lipoprotein	  receptor-­‐related	  protein.	  Not	  all	  known	  elements	  are	  shown.	  	  
                                                                               C 
      A                                                    B                             
                                                                   
 
	  	  
Introduction	   	  	   	  
32	  
Ras	   cycles	   between	   inactive,	   guanosine	   diphosphate	   (GDP)-­‐bound,	   and	   active,	   GTP-­‐bound	  conformations.	  Ras	  proteins	   signal	   through	   extracellular	   signal-­‐regulated	  kinase	   (ERK)	  1/2	   and	  phosphoinositide-­‐3-­‐kinase	   (PI3K),	   which	   are	   involved	   in	   the	   regulation	   of	   a	   variety	   of	   cellular	  responses	  including	  proliferation,	  survival,	  apoptosis	  and	  cell	  cycle	  (Schwarz	  et	  al.,	  2013).	  ERK1/2	  are	  activated	  by	  MEK	  (or	  MKK)	  1/2,	  whose	  phosphorylation	  depends	  on	  the	  upstream	  regulator,	  called	  Raf-­‐1	  (Fig.	  I-­‐7A).	  The	  Raf-­‐1	  family,	  which	  is	  composed	  of	  serine/threonine	  kinases	  A-­‐raf,	  B-­‐raf	  and	  C-­‐raf,	  directly	  interacts	  with	  the	  membrane	  anchored	  GTP-­‐complexed	  Ras	  (Ehrenreiter	  et	  al.,	  2009).	  	  The	   other	   target	   of	   Ras,	   PI3K,	   acts	   through	   serine/threonine	   protein	   kinase	   B	   (PKB/Akt)	  (Rodriguez-­‐Viciana	  et	  al.,	  1994).	  Akt	  inhibits	  glycogen	  synthase	  kinase	  (GSK)	  3β,	  which	  is	  involved	  in	  the	  turnover	  of	  a	  transcriptional	  factor,	  β-­‐catenin	  (Fig.	  I-­‐7B)	  (The	  GSK3β	  inactivation	  results	  in	  the	  accumulation	  of	  the	  unphosphorylated	  functional	  β-­‐catenin	  (Manoukian	  and	  Woodgett,	  2002).	  	  	  Apart	   from	   the	  direct	  Ras-­‐dependent	  pathways,	   there	   is	   a	   crosstalk	  between	  Ras	   signalling	   and	  protein	  kinase	  C	  (PKC)	  pathway	  activated	  by	  TPA.	  Specifically,	  activated	  PKC	  phosphorylates	  Raf	  kinase	   inhibitory	  protein,	   leading	  to	   its	   inactivation,	   thus	   inducing	  the	  signalling	  of	   the	  Ras/Raf-­‐1/ERK1/2	  (Nishizuka,	  1988).	  
	  
	  
2.1.2.	  β-­‐catenin	  signalling.	  Wnt	   proteins	   are	   secreted	   factors	   interacting	   with	   transmembrane	   receptors	   of	   the	   Frizzled	  family	  and	  are	  expressed	  in	  adult	  mouse	  epidermis	  (Fig.	  I-­‐7C),	  where	  they	  control	  mesenchymal-­‐epithelial	   communication	   (Saitoh	   et	   al.,	   1998).	   β-­‐catenin	   is	   a	   cytoplasmic	   transcription	   factor	  involved	   in	  Wnt-­‐mediated	  regulation	  of	  cell	  adhesion,	  which	   is	   important	   in	   the	  maintenance	  of	  epithelial	  structures,	  including	  skin	  (Liu	  and	  Millar,	  2010).	  Normal	  epithelium	  is	  characterised	  by	  membranous	   and	   cytoplasmic	   localization	   of	   β-­‐catenin.	   The	   translocation	   of	   E-­‐cadherin,	  interacting	  with	  β-­‐catenin	   (Adams	  et	   al.,	   1996),	  was	  observed	   in	  mouse	   epidermis	   treated	  with	  TPA,	  which	  negatively	  influenced	  gap	  junctional	  cell	  communication	  by	  decreasing	  the	  membrane	  localization	  of	  E-­‐cadherin	  (Jansen	  et	  al.,	  1996).	  	  The	   nuclear	   localisation	   of	   β-­‐catenin	   is	   the	   hallmark	   of	   constitutive	   signal	   activation	   and	   its	  elevated	  expression	  has	  been	  observed	  in	  epithelial	  tumours	  in	  mice	  and	  humans.	  It	  has	  been	  also	  correlated	  with	   the	   tumour	   size	   and	   its	   clinical	   stage	   (Lee	   at	   al.,	   2012).	   The	   upregulation	   of	  β-­‐catenin	   pathway	   has	   also	   been	   observed	   in	   many	   SCCs	   and	   associated	   with	   their	   malignant	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transformation	  (Malanchi	  et	  al.,	  2008).	  One	  of	  the	  targets	  of	  a	  β-­‐catenin-­‐mediated	  cascade	  encodes	  the	   oncogene	   c-­‐Myc,	   whose	   constitutive	   activation	   often	   leads	   to	   carcinogenesis,	   especially	   in	  colon	  (Giles	  et	  al.,	  2003).	  	  Apart	   from	   clinical	   observations,	   the	   importance	   of	   β-­‐catenin	   signalling	   in	   epithelial	  tumorigenesis	  has	  been	  demonstrated	  by	  in	  vivo	  experiments	  in	  animal	  models.	  Transgenic	  mice	  expressing	  an	  activated	  form	  of	  β-­‐catenin	  were	  more	  prone	  to	  skin	  tumours	  development	  (Chan	  et	  al.,	  1999).	  Moreover,	   it	  was	  reported	   that	  downregulation	  of	  β-­‐catenin	   in	  human	  SCC13	  cells	  by	  short	  hairpin	  RNA	  strongly	  decreased	  tumour	  growth	  of	  xenografts	  in	  nude	  mice.	  Moreover,	  the	  β-­‐catenin	  gene	  ablation	  in	  the	  chemically	  induced	  DMBA/TPA	  skin	  tumorigenesis	  led	  to	  a	  complete	  regression,	  whereas	  the	  growth	  of	  control	  skin	  tumours	  was	  unaffected	  (Malanchi	  et	  al.,	  2008).	  
	  
	  
2.1.3.	  EGFR	  signalling.	  Epidermal	  growth	  factor	  (EGF)	   is	  a	  potent	  mitogen	  for	  keratinocytes	  and	  is	  essential	   for	  normal	  skin	   epithelium.	   Since	   tumour	   promotion	   relies	   on	   cell	   proliferation,	   EGFR	   signalling	   plays	   an	  important	  role	  in	  skin	  carcinogenesis;	  it	  is	  one	  of	  the	  most	  frequently	  altered	  proteins	  in	  cancer.	  Alterations	   in	   its	   activity	   have	   been	   demonstrated	   in	   many	   human	   tumours	   (Harari,	   2004).	   In	  particular,	  EGFR	  overexpression,	   the	  main	  mechanism	  causing	   the	  EGFR	  upregulation,	  has	  been	  observed	   in	   colon,	   lung,	   breast,	   cervical,	   prostate	   and	  HNSCC.	   In	   the	   case	   of	   the	   head	   and	   neck	  tumours	  90%	  showed	  elevated	  EGFR	  expression	  (Grandis	  and	  Tweardy,	  1993).	  	  The	  EGFR	  activation	  is	  initiated	  upon	  binding	  to	  such	  ligands	  as	  EGF,	  TGF-­‐α,	  heparin-­‐binding	  EGF-­‐like	  growth	  factor,	  amphiregulin	  and	  betacellulin	  (Harris	  et	  al.,	  2003).	  EGFR	  receptors	  can	  also	  be	  activated	  through	  ligand-­‐independent	  mechanisms,	  including	  reactive	  oxygen	  species	  induced	  by	  UV,	   G	   protein-­‐coupled	   receptors,	   tyrosine	   kinase	   receptors	   and	   cell	   adhesion	   molecules	  (Repertinger	   et	   al.,	   2011).	   Upon	   activation	   the	   EGFR	   subunits	   are	   subject	   to	   conformational	  changes	   enabling	   homo-­‐	   and	   heterodimerization.	   This	   activation	   leads	   to	   the	   transcriptional	  activation	  of	  specific	  genes	  encoding	  proteins	  which	  control	  cell	  proliferation,	  survival,	  adhesion,	  migration	  and	  differentiation	  and	   this	  occurs	   through	  signalling	  pathways	  such	  as	  Ras/ERK1/2,	  PI3K/Akt,	   phospholipase	   C	   γ	   (PLCγ),	   PKC	   and	   STAT,	   summarised	   in	   Figure	   I-­‐8	   (Markovic	   and	  Chung,	  2012).	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  Figure	   I-­‐8.	   EGFR	   downstream	   signalling	   cascades.	   mTOR:	   mammalian	   target	   of	   rapamycin.	   DAG:	  diacyloglycerol.	  FAK:	  focal	  adhesion	  kinase.	  TPA	  mimics	  the	  stimulatory	  action	  of	  the	  secondary	  messenger	  DAG	   on	   PKC	   enzymes.	   PKC	   positively	   induces	   Raf1/MEK/ERK1/2	   pathway	   through	   inactivating	  phosphorylation	  of	  Raf	  kinase	  inhibitory	  protein.	  Not	  all	  known	  elements	  of	  the	  pathways	  are	  shown.	  	  	  The	  expression	  of	  the	  EGFR	  ligands	  is	  increased	  in	  neoplastic	  keratinocytes	  (Dlugosz	  et	  al.,	  1995).	  TPA	   can	   also	   activate	   downstream	   EGFR	   cascades	   in	   murine	   skin	   that	   is	   accompanied	   by	   the	  receptor	   phosphorylation,	   indicating	   a	   direct	   interaction	   between	   TPA	   and	   EGFR	   signalling	  (Cichocki	   et	   al.,	   2012).	   Moreover,	   the	   chemical	   inhibition	   of	   EGFR	   effectively	   reduces	   TPA-­‐stimulated	  EGFR	  tyrosine	  phosphorylation	  in	  a	  dose-­‐dependent	  manner	  (Lu	  et	  al.,	  2007).	  	  The	   implication	   of	   EGFR	   signalling	   in	   skin	   tumour	   promotion	   has	   been	   highlighted	   by	   in	   vivo	  experiments.	  For	  instance,	  transgenic	  mice	  overexpressing	  the	  ligand	  TGF-­‐α	  in	  the	  skin	  developed	  skin	  papillomas	  in	  response	  to	  TPA	  promotion	  without	  carcinogen	  initiation	  (in	  the	  absence	  of	  Ras	  mutations),	  which	   indicates	   that	  abundance	  of	  TGF-­‐α	   can	  act	  as	  an	   initiating	  agent	  and	  enhance	  tumour	  promotion	  (Wang	  et	  al.,	  1994).	  	  Also,	  studies	  on	  the	  impairment	  of	  downstream	  elements	  of	  EGFR	  signalling	  have	  established	  its	  critical	   contribution	   during	   initiation	   and	   promotion	   during	   skin	   carcinogenesis.	   It	   has	   been	  demonstrated	  that	  the	  epidermis	  of	  mice	  lacking	  signal	  transducer	  and	  activator	  of	  transcription	  (STAT)	  3,	  which	   is	   the	  Src-­‐mediated	  EGFR	  effector,	  were	  characterised	  by	   reduced	  proliferative	  response	   after	   treatment	  with	   TPA,	   due	   to	   a	   defect	   in	   G1/S	   cell	   cycle	   progression	   (Chan	   et	   al.,	  2004).	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2.1.4.	  TGF-­‐β 	  signalling.	  Members	  of	  the	  transforming	  growth	  factor-­‐β	  family	  (TGF-­‐β1,	  TGF-­‐β2,	  and	  TGF-­‐β3)	  form	  a	  group	  of	  highly	  conserved	  cytokines	  (Roberts	  and	  Sporn,	  1993).	  TGF-­‐β,	   in	  the	  classical	  pathway,	  exerts	  its	   functions	   through	   binding	   to	   the	   type	   II	   receptor	   TβR-­‐II,	   which	   then	   recruits	   the	   type	   I	  receptor,	   TβR-­‐I.	   The	   latter	   one	   phosphorylates	   Smad2	   and	   Smad3	   proteins.	   Phosphorylated	  Smad2/3	  are	  then	  able	  to	   form	  a	  complex	  with	  Smad4,	  which	  then	  translocate	  to	  the	  nucleus	  to	  modulate	  gene	  expressions	  as	  transcriptional	  factors	  (Konig	  et	  al.,	  2005).	  	  	  Cell	  responses	  provoked	  by	  TGF-­‐β	  are	  highly	  contextual	  throughout	  development,	  across	  different	  tissues,	  and	  also	  in	  cancer	  (Massague,	  2008).	  In	  the	  skin	  TGF-­‐β	  is	  required	  for	  epidermal	  dendritic	  cells	   (Langerhans	   cells)	   development	   (Kaplan	   et	   al.,	   2007).	   In	   skin	   keratinocytes,	   TGF-­‐β	   plays	   a	  dual	  role.	  On	  one	  hand,	   in	  the	  physiological	  state,	  TGF-­‐β	  controls	  skin	  homeostasis,	  on	  the	  other	  hand,	  it	  responds	  to	  tissue	  injury	  and	  inflammatory	  conditions,	  by	  local	  induction	  of	  epithelial-­‐to-­‐mesenchymal	  transition	  (EMT)	  (Roberts	  et	  al.,	  2001).	  Constitutively	   induced	  activation	  of	  TGF-­‐β	  in	   chronically	   inflamed	   epithelium	   brings	   about	   permanent	   conversion	   of	   keratinocytes	   to	  myofibroblasts	  followed	  by	  complete	  loss	  of	  epithelial	  phenotype	  and	  tissue	  fibrosis	  (Border	  and	  Noble,	   1994).	   This	   is	   in	   line	   with	   the	   observation	   that	   persistent	   induction	   of	   EMT	   via	   TGF-­‐β	  signalling	   is	   associated	   with	   metastatic	   character	   of	   many	   cancers,	   including	   skin	   cancers.	  Moreover,	   mutational	   inactivation	   of	   the	   receptor	   TβR-­‐II	   has	   been	   reported	   in	   colon,	   gastric,	  pulmonary	  and	  HNSC	  carcinomas	  (Levy	  and	  Hill,	  2006).	  	  
	  
2.2.	  Cytokines.	  Another	   event	   in	   the	   skin	   during	   TPA-­‐induced	   skin	   tumour	   promotion	   is	   the	   recruitment	   of	  inflammatory	   cells	   into	   the	   dermis.	   It	   is	   caused	   by	   secretion	   of	   proinflammatory	   molecules	   in	  epidermal	  keratinocytes.	  The	  activated	  macrophages,	  lymphocytes	  and	  leukocytes	  infiltrating	  the	  skin	   produce	   growth	   factors,	   cytokines	   and	   chemokines	   that	   promote	   cell	   proliferation,	   tissue	  matrix	  remodelling,	  impairment	  of	  adaptive	  immunity	  and	  angiogenesis	  (Yoshimura,	  2006).	  When	  it	  comes	  to	  the	  cytokines,	  they	  are	  small	  proteins,	   important	  in	  inflammation	  signalling,	  such	  as:	  tumour	   necrosis	   factors,	   interleukins,	   chemokines,	   colony	   forming	   factors,	   growth	   factors	   and	  interferons.	  They	  also	  perform	  pivotal	  roles	  during	  malignant	  progression	  and,	  on	  the	  one	  hand,	  they	   induce	  malignant	   transformation,	   tumour	   growth,	   invasion	   and	  metastasis.	   However,	   they	  are	   also	   capable	   of	   activation	   of	  mechanisms	   leading	   to	   the	   tumour-­‐limiting	   immune	   reactions.	  Host	  cells	  (stroma	  and	  immune	  cells)	  can	  produce	  cytokines	  as	  a	  response	  to	  other	  transforming	  factors	   or	   as	   an	   integral	   part	   of	   inflammation	   accompanying	   the	   tumour	   growth.	   Cytokines	   can	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also	   be	   secreted	   by	   malignant	   cells	   due	   to	   acquired	   genetic	   alterations	   in	   cytokine	   expression	  pathways	  or	  in	  response	  to	  host-­‐derived	  cytokines	  (Apte	  and	  Voronov,	  2002).	  	  	  
2.2.1.	  TNF-­‐α .	  Tumour	   necrosis	   factor-­‐α	   (TNF-­‐α)	   plays	   an	   important	   role	   in	   host	   defence	   and	   is	   a	   critical	  cytokine	  during	  inflammation,	  including	  inflammation	  of	  the	  skin	  induced	  by	  tumour	  promoters.	  It	   is	   synthesised	   as	   a	   transmembrane	   pro-­‐peptide	   and,	   following	   proteolytic	   conversion,	   is	  released	  in	  a	  soluble	  homotrimer	  (Balkwill,	  2006).	  Two	  TNF-­‐α	  receptors,	  TNFR1	  and	  TNFR2,	  have	  specific	   expression	   patterns	   and	   are	   activated	   differently.	   TNFR1	   is	   expressed	   constitutively	   in	  most	   cells	   and	   binds	   soluble	   TNF-­‐α,	   whereas	   TNFR2	   is	   specific	   mostly	   for	   hematopoietic	   and	  immune	   cells,	   and	   binds	   membrane-­‐bound	   TNF-­‐α.	   Activated	   TNFRs	   signal	   through	   multiple	  signalling	   pathways,	   e.g.	   IκB	   kinase	   (IKK)/nuclear	   factor	   (NF)-­‐κB	   and	  MAPKs/activator	   protein	  (AP)-­‐1	   (Wajant	  et	   al.,	   2003).	  The	  activation	  of	   the	   transcription	   factors	   leads	   to	  upregulation	  of	  genes	  involved	  in	  the	  differentiation	  and	  apoptosis	  (anti-­‐apoptotic	  factors	  in	  the	  case	  of	  NF-­‐κB	  or	  pro-­‐	  and	  anti-­‐apoptotic	  in	  the	  case	  of	  AP-­‐1).	  	  The	  data	  from	  murine	  cancer	  models	  suggest	  that	  the	  mechanism	  by	  which	  TNF-­‐α	  promotes	  the	  early	   stages	   of	   cancer	   involves	   both	   the	   initiated	   cancerous	   cells	   and	   inflammatory	   cells	   in	   the	  surrounding	  stroma.	   Indeed,	  TNF-­‐α	  produced	  chronically	   in	   the	   tumour	  microenvironment	  may	  contribute	  to	  malignant	  promotion	  and	  progression	  via	  the	  induction	  of	  expression	  of	  chemokines	  and	   their	   receptors	   	   (e.g.	   CXCR4,	  CXCL12,	  CCL8)	   and,	   therefore,	  has	   anti-­‐apoptotic	  or	  mitogenic	  roles	   (Balkwill,	   2006).	   When	   it	   comes	   to	   TNF-­‐α	   in	   skin	   tumorigenesis,	   its	   implication	   was	  highlighted	   by	  Moore	   et	   al.	   (1999)	  who	   demonstrated	   that	  mice	   deficient	   in	   TNF-­‐α	   during	   the	  two-­‐stage	   DMBA/TPA	   skin	   protocol	   developed	   5-­‐10%	   of	   the	   number	   of	   tumours	   in	   wild	   type	  mice.	  It	  has	  also	  been	  observed	  that	  TNFR1-­‐/-­‐	  mice	  were	  shown	  to	  confer	  a	  profound	  resistance	  in	  this	  protocol	  too	  (Arnott	  et	  al.,	  2004),	  and	  the	  tumour	  promoting	  activity	  of	  TNF-­‐α	  in	  the	  skin	  was	  linked	  with	  the	  regulation	  of	  B	  cells	  (Schioppa	  et	  al.,	  2011).	  	  	  
2.2.2.	  Interleukins.	  Although	   the	   interleukin	   (IL)	   family	   is	   large	   and	   its	   members	   have	   pleiotropic	   effects	   in	  inflammation	   and	   immune	   responses,	   only	   some	   of	   them	   play	   roles	   in	   the	   skin	   and	   are	  undoubtedly	   linked	  with	  skin	   tumour	  promotion	  and	  skin	  cancer	   (Rundhaug	  and	  Fisher,	  2010).	  The	  predominant	  interleukins	  in	  skin	  are	  IL-­‐1,	  IL-­‐6	  and	  IL-­‐17.	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IL-­‐1α	  and	  IL-­‐1β,	  constitutively	  expressed	  in	  cultured	  keratinocytes,	  are	  upregulated	  by	  exposure	  to	  TPA	  (Kupper	  et	  al.,	  1987;	  Oberyszyn	  et	  al.,	  1993).	  Another	  example	  is	  NF-­‐κB-­‐inducible	  cytokine,	  IL-­‐6,	   which	   promotes	   STAT3	   activation	   and	   promotes	   tumorigenic	   phenotype	   of	   HNSCC	   in	  humans	   (Lee	   et	   al.,	   2006).	   The	   transcription	   factor	   STAT3	   is	   constitutively	   activated	   in	   many	  human	  malignancies	  and	  has	  been	  suggested	  to	  play	  an	  important	  role	  in	  carcinogenesis	  (Al	  Zaid	  and	  Turkson,	  2008;	  Kim	  et	  al.,	  2007).	  Tumour	  promoters,	  including	  TPA,	  activate	  STAT3	  in	  mouse	  epidermis	   and	   STAT3	   is	   maintained	   	   in	   an	   activated	   state	   in	   DMBA/TPA-­‐induced	   papillomas	  (Chan	  et	  al.,	  2004).	  In	  line	  with	  these	  observations	  are	  studies	  showing	  that	  increased	  levels	  of	  IL-­‐6	   are	   considered	   a	   bad	   prognostic	   factor	   in	   oral	   SCC	   (OSCC)	   (Culig,	   2013).	   IL-­‐6-­‐dependent	  tumorigenic	  effects	  can	  be	  also	  mediated	  at	  the	  epigenetic	  level.	  Specifically,	  OSCC	  cells	  induced	  by	  IL-­‐6	  have	  been	  shown	  to	  promote	  gene	  expression	  alterations	  through	  DNA	  hypomethylation	  and	  abberant	  promoters	  hypermethylation	  (Gasche	  et	  al.,	  2011).	  	  IL-­‐17	   is	  produced	   in	  skin	  by	  dermal	  and	  epidermal	  γδ	  T	  cells	   (the	   latter	  are	  called	  DETC)	  and	  T	  helper	  17	  (Th17)	  cells.	  γδ	  T	  cells	  are	  an	  innate	  source	  of	  IL-­‐17,	  preceding	  the	  development	  of	  the	  adaptive	  Th17	  cell	  response	  (Martin	  et	  al.,	  2009).	  IL-­‐17	  has	  been	  linked	  with	  pro-­‐oncogenic	  roles	  in	  DMBA-­‐induced	  skin	  carcinogenesis,	  through	  IL-­‐6-­‐mediated	  STAT3	  signalling	  regulation	  (Wang	  et	  al.,	  2010).	  Also,	  the	  pathogenesis	  of	  psoriatic	  disease	  has	  been	  associated	  with	  IL-­‐17	  functions	  (Raychaudhuri,	  2013).	  	  
2.3.	  Post-­‐transcriptional	  regulation.	  TPA-­‐dependent	   signalling	   alterations	   in	   post-­‐transcriptional	   regulation	   of	   protein	   expression	  have	  been	  linked	  with	  skin	  cancer	  development	  as	  well.	  One	  of	  the	  processes	  affected	  by	  TPA	  in	  epithelial	  cells	  is	  the	  proteasomal	  degradation	  of	  proteins.	  	  The	  translation	  inhibitor,	  programmed	  cell	  death	  protein	  4	  (Pdcd4)	  is	  the	  first	  tumour	  suppressor	  found	   to	   regulate	   protein	   translation.	   The	   decrease	   in	   Pdcd4	   levels,	   upon	   TPA	   treatment,	   was	  attributed	   to	   increased	   proteasomal	   degradation	   through	   ubiquitylation,	   catalysed	   by	   the	   E3-­‐ubiquitin	   ligase	  β-­‐TrCP1	   (Schmid	   et	   al.,	   2008).	   The	  negative	   regulation	  of	   Pdcd4	   in	   response	   to	  TPA	  has	  been	  reported	  in	  murine	  skin	  and	  in	  vitro	  in	  keratinocytes	  and	  the	  deregulated	  protein	  translation	  has	  been	  associated	  with	   carcinogenesis,	   including	   skin	   carcinogenesis.	  Also,	  Pdcd4-­‐haploinsufficient	   and	   Pdcd4-­‐deficient	   mice	   have	   increased	   papilloma	   incidence	   in	   a	   chemically	  induced	   DMBA/TPA	   skin	   carcinogenesis	   protocol,	   suggesting	   that	   Pdcd4	   protects	   against	   skin	  tumour	  formation.	  Interestingly,	  the	  negative	  regulator	  of	  Pdcd4,	  β-­‐TrCP1,	  has	  been	  biochemically	  and	  genetically	  shown	  to	  control	  the	  stability	  of	  β-­‐catenin	  (Latres	  et	  al.,	  1999).	  On	  the	  other	  hand,	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the	  data	  on	   the	  natural	   compound,	   erioflorin,	   have	   revealed	   its	   stabilizing	   effect	   on	  both	  Pdcd4	  and	  β-­‐catenin,	  thanks	  to	  the	  inhibition	  of	  TPA-­‐induced	  β-­‐TrCP1/target-­‐protein	  interactions	  (Blees	  et	  al.,	  2012).	  Moreover,	  it	  has	  been	  reported	  that	  expression	  patterns	  of	  PDCD4	  correlated	  with	  β-­‐catenin	  protein	  levels	  in	  gastric	  cancers	  in	  humans	  (Kakimoto	  et	  al.,	  2011).	  	  Taken	  together,	  the	  data	  on	  the	  TPA-­‐induced	  proteasomal	  regulation	  indicate,	  that	  tumorigenesis,	  including	   skin	   tumorigenesis,	   can	   be	   controlled	   at	   the	   level	   of	   ubiquitylation	   and	   that	   tumour	  promoters	  might	  target	  tumour	  suppressors	  functioning	  at	  the	  post-­‐transcriptional	  level.	  
	  
	  
3.	  p38γ 	  and	  p38δ 	  MAPKs.	  
	  
3.1.	  MAPKs.	  Mitogen-­‐activated	   protein	   kinase	   (MAPK)	   signalling	   plays	   a	   pivotal	   role	   in	   eukaryotic	   cell	  physiology.	  Its	  deregulation	  may	  lead	  to	  diseases	  and	  cancer	  development.	  Through	  multiple	  co-­‐ordinated	  pathways,	  MAPKs	  control	  a	  wide	  range	  of	  cell	  responses,	  such	  as	  growth,	  proliferation,	  differentiation,	  migration	  and	  apoptosis,	  depending	  on	  cell	  type	  and	  stimulus	  (Chen	  et	  al.,	  2001).	  The	  MAPK	  pathways	  are	  activated	  by	  a	  range	  of	  external	  stimuli	  resulting	  from	  physicochemical	  changes	   of	   the	   cell	   microenvironment.	   This	   activation	   requires	   ligand	   binding	   to	   different	  receptors	  such	  as	  tyrosine	  kinase	  receptors	  (hormones	  and	  growth	  factors),	  cytokine	  receptors	  or	  serine-­‐threonine	   kinase	   receptors	   (TGF-­‐β-­‐related	   polypeptides).	   Besides,	   the	   exposure	   to	  environmental	   stresses	   (osmotic	   shock,	   ionizing	   radiation	   and	   ischemic	   injury)	   can	   also	   bring	  about	  MAPKs-­‐dependent	  reactions	  in	  a	  cell	  (Kyriakis	  and	  Avruch,	  2012).	  	  There	  are	  four	  well-­‐characterised	  conventional	  MAPK	  subfamilies:	  ERK1/2,	  ERK5,	  Jun	  N-­‐terminal	  kinases	   (JNK)	   1/2	   and	   p38	   kinases	   (designated	   as	   p38	   MAPK).	   In	   the	   basal	   state	   they	   are	  catalytically	  inactive	  and	  require	  activating	  phosphorylation	  by	  upstream	  kinases,	  whose	  activity	  is	   also	   regulated	   by	   phosphorylation,	   so	   that	   signal	   transduction	   occurs	   by	   sequential	  phosphorylation	   of	   the	   following	   protein	   kinase	   families:	   MAPK	   kinase	   kinases	   (MKKKs	   or	  MAP3Ks),	  MAPK	  kinases	  (MKKs	  or	  MEKs	  or	  MAP2Ks)	  and	  MAPKs	  (Cuenda	  and	  Rousseau,	  2007;	  Keshet	  and	  Seger,	  2010)	  (Fig.	  I-­‐9).	  	  The	  activation	  of	  the	  MAPKs	  relies	  on	  dual	  phosphorylation	  of	  threonine	  (T)	  and	  tyrosine	  (Y)	  in	  a	  conserved	   T-­‐X-­‐Y	   motif	   (where	   X	   are	   different	   amino	   acids	   depending	   on	   the	   MAPK)	   in	   an	  activation	  loop	  of	  the	  subdomain	  VIII.	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  Figure	  I-­‐9.	  Canonical	  mammalian	  MAPK	  signalling	  pathways	  (Arthur	  and	  Ley,	  2013).	  p38γ	  and	  p38δ	  are	  highlighted	  in	  a	  red	  frame.	  	  These	  phosphorylations	  lead	  to	  conformational	  reorganizations	  that	  stabilize	  the	  activation	  loop	  in	   an	   open	   and	   extended	   conformation,	   enabling	   substrate	   binding	   and	   its	   phosphorylation	  (Cuenda	  and	  Rousseau,	  2007).	  MAPKs’	  targets	  (substrates)	  include	  another	  protein	  kinases	  (such	  as	  MAP	  kinase	  activated	  proteins	  kinase,	  MAPKAPK),	  transcription	  factors	  and	  other	  cytoplasmic	  targets	  (Risco	  and	  Cuenda,	  2012).	  	  
3.2.	  p38	  MAPKs.	  The	  mammalian	  p38	  subfamily	  of	  MAPK	  has	  four	  members	  (p38α,	  p38β,	  p38γ,	  p38δ)	  encoded	  by	  different	  genes,	  which	  share	  high	  homology	  reaching	  approximately	  60%	  of	  the	  sequence.	  Among	  p38	  MAPK	   isoforms,	   p38α,	   often	   referred	   to	   as	   stress-­‐activated	   protein	   kinase	   (SAPK)	   2a	   was	  identified	  at	  first	  by	  four	  independent	  groups	  (Han	  et	  al.,	  1994;	  Rouse	  et	  al.,	  1994;	  Freshney	  et	  al.,	  1994;	  Lee	  et	  al.,	  1994)	  and	  is	  the	  best-­‐described	  isoform	  so	  far.	  	  	  It	   has	   been	  widely	   described	   that	   p38α	   contributes	   to	   the	   regulation	   of	   pro-­‐inflammatory	   and	  anti-­‐inflammatory	  cytokines	  production	  during	  inflammation	  (Cuenda	  and	  Rousseau,	  2007),	  both	  at	   transcriptional	   and	   post-­‐transcriptional	   levels	   (Wagner	   and	   Nebreda,	   2009).	   Of	   note,	   the	  production	  of	  inflammatory	  agents,	  such	  as	  TNF-­‐α,	  IL-­‐1β	  and	  IL-­‐6	  is	  a	  crucial	  factor	  involved	  in	  a	  
	  	  
Introduction	   	  	   	  
40	  
number	   of	   human	   pathologies	   (Crohn	   disease,	   rheumatoid	   arthritis,	   psoriasis)	   (Cuenda	   and	  Rousseau,	   2007).	   Besides,	   p38α	   has	   been	   associated	  with	   proliferation	   (Halawani	   et	   al.,	   2004),	  survival	   (Aguirre-­‐Ghiso,	   2007),	   differentiation	   (Ventura	   et	   al.,	   2007;	   Cuadrado	   and	   Nebreda,	  2010),	   cell	   migration	   and	   metastasis	   (Rousseau	   et	   al.,	   2006),	   all	   hallmarks	   of	   carcinogenesis	  (Hanahan	  and	  Weinberg,	  2011).	  Moreover,	  p38α	  knock-­‐out	  mice	  are	  embryonically	  lethal	  (Allen	  et	  al.,	  2000).	  	  Since	  the	  identification	  of	  p38α,	  three	  additional	  isoforms	  have	  been	  identified:	  p38β	  (or	  SAPK2b)	  (Jiang	  et	  al.,	  1996),	  p38γ	  (or	  SAPK3)	  (Lechner	  et	  al.,	  1996;	  Li	  et	  al.,	  1996;	  Mertens	  et	  al.,	  1996)	  and	  p38δ	  (or	  SAPK4)	  (Goedert	  et	  al.,	  1997;	  Jiang	  et	  al.,	  1997).	  The	  four	  isoforms	  are	  characterised	  by	  different	   tissue	   expression	   patterns,	  with	   p38α	   being	   ubiquitously	   expressed	   at	   a	   high	   level	   in	  most	  cells	  and	  with	  the	  remaining	  three	  p38s	  distributed	  in	  a	  more	  tissue-­‐specific	  manner.	  p38β	  is	  specific	  for	  brain	  tissue,	  p38γ	  is	  abundantly	  expressed	  in	  skeletal	  muscle	  and	  p38δ	  in	  endocrine	  glands	  and	  small	   intestine	  (Cuadrado	  and	  Nebreda,	  2010;	  Risco	  and	  Cuenda,	  2012).	  Contrary	   to	  p38α	  knock-­‐out	  mice,	  p38β,	  p38γ	   and	  p38δ-­‐deficient	  mice	  develop	  normally	   (Sabio	  et	  al.,	  2005;	  Beardmore	  et	  al.,	  2005).	  	  Although	  all	  p38	  isoforms	  share	  some	  substrate	  specificities,	  there	  is	  similarity	  between	  p38α	  and	  p38β	   kinases	   and	   between	   p38γ	   and	   p38δ,	   due	   to	   the	   existence	   of	   particular	   substrates	   being	  better	  phosphorylated	  by	  the	  former	  ones	  than	  the	  latter	  ones	  and	  the	  other	  way	  around	  (Cuenda	  and	  Rousseau,	  2007;	  Risco	  and	  Cuenda,	  2012).	  For	  example	  all	  p38α,	  p38β	   (p38α/β),	  p38γ	   and	  p38δ	   (p38γ/δ)	  phosphorylate	   the	   transcription	   factors	  ATF2,	  Elk-­‐1	  and	  SAP1	  at	  similar	  rate	  but	  p38γ/δ	  are	  much	  less	  effective	  than	  p38α/β	  in	  activating	  MAPKAP	  kinase-­‐2	  and	  MAPKAP	  kinase-­‐3	  (Cuenda	  et	  al.,	  1997;	  Goedert	  et	  al.,	  1997).	  Another	  reason	   for	   the	  division	  of	  p38s	   into	  p38α/β	  and	  p38γ/δ	  is	  the	  amino	  acid	  sequence	  similarities:	  p38β	  is	  75%	  identical	  to	  p38α,	  whereas	  p38γ	  and	  p38δ	   -­‐	   only	  62%	  and	  61%,	   respectively.	  Of	  note,	  p38γ	   and	  p38δ	   are	  more	   identical	   to	  each	  other	  and	  share	  ∼70%	  of	  the	  amino	  acid	  sequence.	  Moreover,	  they	  differ	  in	  response	  to	  chemical	  inhibition,	   namely	   to	   the	   compounds	   SB203580	   and	   SB202190.	   It	   has	   been	   demonstrated	   that	  only	   p38α	   and	   p38β	   are	   inhibited	   by	   these	   compounds,	   whereas	   p38γ/δ	   were	   completely	  unaffected	  by	  the	  inhibitors.	  	  The	  activation	  of	  distinct	  p38	  MAPK	  isoforms	  is	  regulated	  by	  selective	  and	  synchronized	  action	  of	  the	  MKKs,	   in	   response	   to	   cell	   stress	   (Risco	   and	   Cuenda,	   2012).	   p38α	   activation	   in	   response	   to	  TNF-­‐α	   is	   severely	   impaired	   in	   cells	   lacking	  MKK3	   and	  MKK6,	   suggesting	   that	   both	   kinases	   are	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necessary	   for	   full	   p38α	   activity	   in	   response	   to	   this	   cytokine	   (Brancho	   et	   al.,	   2003).	   MKK3	   and	  MKK6	  are	  also	  essential	  for	  the	  activation	  of	  p38γ	  and	  p38β	  induced	  by	  environmental	  stress	  (Fig.	  I-­‐10).	  
	  	  Fig.	  I-­‐10.	  	  Activation	  of	  p38β,	  p38γ	  and	  p38δ	  by	  MKK3	  and	  MKK6.	  MKK6	  phosphorylates	  and	  activates	  p38β	  and	  p38γ,	  and	  also	  p38δ	  only	  in	  the	  absence	  of	  MKK3.	  MKK3	  phosphorylates	  and	  activates	  p38β	  and	  p38γ,	  and	   is	   the	   principal	   p38δ	   activator.	   MKK3	   and	   MKK6	   are	   activated	   by	   different	   MKKK,	   and	   p38MAPK	  phosphorylates	  several	  substrates	  following	  activation	  (Remy	  et	  al.,	  2010).	  
	  	  	  MKK6	   is	  besides	   the	  major	   activator	  of	  p38γ	   in	   response	   to	  TNF-­‐α,	  whereas	  p38δ	  activation	  by	  ultraviolet	  radiation,	  hyperosmotic	  shock,	  anisomycin	  or	  TNF-­‐α	  is	  mediated	  by	  MKK3.	  Moreover,	  in	  response	   to	  osmotic	  stress,	  MKK3	  and	  MKK6	  are	  crucial	   in	  regulating	   the	  phosphorylation	  of	  the	  p38γ	  substrate	  SAP97/hDlg	  and	  its	  activity	  as	  scaffold	  protein	  (Remy	  et	  al.,	  2010).	  	  
3.3.	  p38γ 	  and	  p38δ .	  A	   growing	   number	   of	   evidences	   reveal	   important	   roles	   of	   the	   alternative	   p38	   MAPKs	   in	  pathological	   processes.	   Altered	   expression	   of	   p38γ/δ	   has	   been	   correlated	   with	   some	  pathophysiological	  conditions	  in	  animals	  and	  humans.	  For	  example,	  elevated	  level	  of	  p38γ	  protein	  has	   been	   reported	   in	   gliomas	   (Yang	   et	   al.,	   2013).	   An	   important	   step	   in	   understanding	   the	  functions	  of	  p38γ	  and	  p38δ	  was	  the	  generation	  of	  mice	  deficient	   in	  p38γ,	  p38δ	  and	  both	  p38γ/δ	  (Sabio	   et	   al.,	   2005),	  which	   delivered	   a	   potent	   tool	   in	   animal	   based-­‐research.	   Indeed,	   a	   growing	  number	  of	  experiments	  with	  knock-­‐out	  mice	  in	  the	  last	  5	  years	  demonstrate	  an	  increasing	  interest	  in	  p38γ	  and	  p38δ	  as	  shown	  in	  Table	  I-­‐2.	  	  Nonetheless	   and	   contrary	   to	   p38α,	   little	   is	   known	   about	   the	   exact	   mechanisms	   of	   p38γ/δ	  functions	  and	  the	  contribution	  of	  p38γ/δ	  to	  human	  pathologies	  remains	  largely	  unknown.	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Model	   Observations	   Reference	  Knock-­‐out	   p38γ/δ-­‐/-­‐	  mice	  have	  decreased	  tumour	  number	  comparing	  with	  WT	  in	  colitis-­‐associated	  colon	  cancer	  model.	   del	  Reino	  et	  al.,	  2014	  Knock-­‐out	   p38γ-­‐/-­‐	  mice	  are	  resistant	  to	  cardiac	  hypertrophy.	   Thomas	  et	  al.,	  2014	  
Knock-­‐out	   p38γ/δ	  deficiency	  reduces	  arthritis	  severity	  and	  inflammatory	  response	  in	  collagen-­‐induced	  arthritis	  model.	   Criado	  et	  al.,	  2014	  Knock-­‐out	   p38γ/δ	  deficiency	  reduces	  cytokine	  production	  in	  response	  to	  lipopolysaccharide.	   Risco	  et	  al.,	  2012	  Knock-­‐out	   p38γ	  is	  activated	  in	  slow	  skeletal	  muscle	  and	  is	  involved	  in	  the	  normal	  growth	  and	  their	  development.	   Foster	  et	  al.,	  2012	  Conditional	  knock-­‐out	   Global	  and	  myeloid	  cell-­‐targeted	  p38δ	  loss	  decreases	  alveolar	  neutrophil	  accumulation	  and	  attenuates	  ALI*.	   Ittner	  et	  al.,	  2012	  Xenograft	   p38γ-­‐deficiency	  in	  Ras-­‐transformed	  fibroblasts	  increases	  tumorigenesis.	   Cerezo-­‐Guisado	  et	  al.,	  2011	  Xenograft	   p38γ	  knocking-­‐down	  delays	  tumorigenesis	  in	  breast	  cancer	  cells	  and	  long-­‐distance	  metastasis	  to	  the	  lungs.	   Meng	  et	  al.,	  2011	  Xenograft	   p38γ	  and	  its	  specific	  phosphatase	  PTPH1	  exert	  oncogenic	  activities	  in	  Ras-­‐activated	  colon	  cancer	  cells.	   Hou	  et	  al.,	  2010	  Knock-­‐out	   p38δ-­‐/-­‐	  mice	  display	  improved	  glucose	  tolerance	  due	  to	  enhanced	  insulin	  secretion	  from	  pancreatic	  β	  cells.	   Sumara	  et	  al.,	  2009	  Knock-­‐out	   p38δ-­‐/-­‐	  mice	  exhibit	  marked	  resistance	  to	  chemically	  induced	  two-­‐stage	  skin	  carcinogenesis.	   Schindler	  et	  al.,	  2009	  	  Table	  I-­‐2.	  Selected	  data	  from	  mouse	  model	  research	  on	  the	  involvement	  of	  p38γ/δ	  in	  different	  pathologies.	  (*)	  inflammation	  induced	  acute	  lung	  injury.	  	  	  They	  have	  been	  described	  to	  be	  involved	  in	  such	  processes	  as	  proliferation,	  apoptosis,	  cell	  cycle	  regulation,	   regulating	   tumorigenesis,	   as	   well	   as	   in	   metabolic	   disease	   and	   tissue	   regeneration	  (Risco	  and	  Cuenda,	  2012;	  Cuadrado	  and	  Nebreda,	  2010;	  Cuenda	  and	  Rousseau,	  2007).	  Moreover,	  apoptosis	   in	   keratinocytes	   treated	   with	   okadaic	   acid	   has	   been	   linked	   with	   p38δ-­‐dependent	  regulation	  (Kraft	  et	  al.,	  2007).	  	  
3.3.1.	  p38γ 	  and	  p38δ 	  in	  tumorigenesis	  and	  inflammation.	  Evidences	   from	   cell	   base	   assays	   support	   p38γ	   and	   p38δ	   tumorigenic	   functions	   by	   modulating	  processes	   implicated	   in	   cellular	  malignant	   transformation	   (Risco	   and	  Cuenda	   2012;	   Yang	   et	   al.,	  2013;	  Faraone	  et	  al.,	  2009).	  	  It	  has	  been	  described	  that	  p38δ	  promotes	  the	  malignant	  phenotype	  of	  squamous	  cell	  carcinoma	  by	  regulating	  cell	  proliferation	  and	  invasion	  (Junttila	  et	  al.,	  2007).	  In	  rat	  intestinal	  epithelial	  cells	  (IEC)	   and	   in	   human	   breast	   cancer,	   p38γ	   RNA	   and	   protein	   expression	   increases	   during	   RAS-­‐
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induced	   transformation	   (Loesch	   and	   Chen,	   2008;	   Tang	   et	   al.,	   2005).	   p38γ	   knock-­‐down	   in	   IEC	  blocks	  the	  Ras	  transformation	  activity	  and	  results	   in	   the	  significant	  diminution	  of	   the	  oncogenic	  characteristics	  of	  breast	  cancer	  cells	  (Meng	  et	  al.,	  2011).	  Additionally,	  one	  recent	  study	  shows	  that	  p38γ	  mediates	  Ras-­‐induced	  senescence	  at	   least	  partly	  by	  stimulating	  the	  transcriptional	  activity	  of	  p53	  through	  direct	  phosphorylation;	  in	  contrast	  p38α	  appears	  to	  regulate	  senescence	  in	  a	  p53-­‐independent	   manner	   (Kwong	   et	   al.,	   2009).	   These	   results	   indicate	   that	   increased	   p38γ	   gene	  expression	  is	  required	  for	  Ras	  oncogene	  activity	  but	  the	  mechanism	  by	  which	  p38γ	  may	  promote	  Ras	  transformation	  is	  not	  clear.	  Interestingly,	  p38δ	  was	  recently	  shown	  to	  mediate	  TPA-­‐induced	  epidermal	   cell	   proliferation	   in	  mice,	   and	  mice	   lacking	   p38δ	   show	   reduced	   susceptibility	   to	   the	  development	   of	   TPA-­‐induced	   skin	   carcinomas	   (Schindler	   et	   al.,	   2009).	  All	   these	   results	   indicate	  the	  oncogenic	  function	  of	  p38γ	  and	  p38δ.	  	  	  Contrary,	  there	  is	  one	  study	  that	  shows	  pieces	  of	  evidence	  indicating	  that	  p38γ	  and	  p38δ	  have	  a	  role	   in	   the	   suppression	   of	   tumour	   development	   using	   mouse	   embryonic	   fibroblasts	   (MEFs)	  derived	  from	  mice	  lacking	  p38γ	  or	  p38δ	  (Cerezo-­‐Guisado	  et	  al.,	  2011).	  Lack	  of	  either	  p38γ	  or	  p38δ	  increases	  cell	  migration	  and	  metalloproteinase-­‐2	  secretion,	  whereas	  only	  p38δ	  deficiency	  impairs	  cell	   contact	   inhibition.	   In	   addition,	   lack	   of	   p38γ	   in	   K-­‐Ras-­‐transformed	   fibroblasts	   leads	   to	  increased	  cell	  proliferation	  as	  well	  as	  tumorigenesis	  both	   in	  vitro	  and	   in	  vivo	   (Cerezo-­‐Guisado	  et	  al.,	   2011).	   Moreover,	   it	   has	   been	   shown	   that	   p38δ	   regulates	   the	   expression	   of	   the	   zonula	  occludens	   (ZO)-­‐1	   protein,	   an	   integral	   component	   of	   functional	   tight	   junctions	   in	   differentiating	  human	  epidermal	  keratinocytes	  and	  in	  human	  SCC	  cell	   lines	  (Siljamäki	  et	  al.,	  2014).	  Considering	  the	   fact	   that	   ZO-­‐1	   is	   associated	   with	   the	   motility	   of	   malignant	   cells	   (Tuomi	   et	   al.,	   2009),	   this	  observation	   is	   in	   agreement	  with	   the	   increased	   cell	  migration	   of	   p38δ-­‐deficient	  MEFs	   (Cerezo-­‐Guisado	  et	  al.,	  2011).	  Nonetheless,	   the	  discrepancies	  between	  different	  studies	  could	  be	  due	  not	  only	   to	   the	   difference	   in	   the	   experimental	  model	   and	   approaches	   used,	   but	   also	   to	   the	   distinct	  nature	  of	  cells	  and	  processes	  that	  are	  involved	  in	  each	  study.	  	  In	   addition	   to	   the	  potential	   role	   of	   p38γ	   and	  p38δ	   in	   tumorigenesis,	   they	  have	   a	   critical	   role	   in	  inflammation,	   which	   is	   an	   important	   process	   in	   tumour	   promotion	   (Hanahan	   and	   Weinberg,	  2011).	  Recent	  studies	  in	  mice	  deficient	  in	  p38γ,	  p38δ,	  or	  both	  showed	  that	  they	  are	  essential	  for	  the	   innate	   immune	   response	   (Arthur	   and	   Ley,	   2013;	   Risco	   et	   al.,	   2012;	   Criado	   et	   al.,	   2014).	  	  Combined	   deletion	   of	   p38γ	   and	   p38δ	   impairs	   proinflammatory	   cytokine	   production	   in	  macrophages	  and	  dendritic	  cells	  in	  response	  to	  the	  bacterial	  lipopolysaccharide	  (LPS)	  (Risco	  et	  al.,	  2012).	  	  p38γ/δ	  deficient	  mice	  are	  less	  sensitive	  than	  controls	  to	  LPS-­‐induced	  septic	  shock	  and,	  in	  a	  mouse	  collagen-­‐induced	  arthritis	  model,	  p38γ/δ	  deficiency	  greatly	  reduced	  symptom	  severity	  and	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joint	   damage	   compared	   to	  WT	  mice	   (Criado	   et	   al.,	   2014).	   In	   both	   experimental	  models,	   p38γ/δ	  deficient	  mice	  produced	  lower	  levels	  of	  cytokines	  such	  as	  IL-­‐1β,	  TNF-­‐α,	  INF-­‐γ	  and	  IL-­‐17	  (Risco	  et	  al.,	  2012;	  Criado	  et	  al.,	  2014).	  These	  findings	  strongly	  suggest	  that	  p38γ	  and	  p38δ	  are	  implicated	  in	  linking	  inflammation	  and	  tumour	  promotion	  and/or	  progression.	  	  
3.3.2.	  p38γ 	  and	  p38δ 	  in	  keratinocytes	  and	  skin.	  p38δ	  has	  been	  also	  suggested	  to	  play	  an	  important	  role	  in	  inducing	  keratinocyte	  differentiation	  by	  regulating	   the	   expression	   of	   involucrin,	   which	   is	   a	   protein	   expressed	   during	   keratinocyte	  differentiation	  (Eckert	  et	  al.,	  2003).	   It	  has	  been	  shown	  that	  activation	  of	  exogenously	  expressed	  p38δ	  by	  differentiation-­‐inducing	  agents	  correlates	  with	  increased	  involucrin	  promoter	  activity	  in	  keratinocytes	   (Efimova	  et	   al.,	   2003).	  This	  occurs	   in	  a	  p38α/β-­‐independent	  manner,	   and	  what	   is	  more,	  p38γ	   is	  poorly	  expressed	   in	  keratinocytes	   (Dashti	  et	  al.,	  2001).	  More	  data	   supporting	   the	  idea	   that	  p38δ	  may	  play	  a	   role	   in	  keratinocyte	  differentiation	   come	   from	  a	   study	  carried	  out	   in	  lesional	   psoriasis	   skin.	   Psoriasis	   is	   a	   chronic	   inflammatory	   skin	   disorder	   characterised	   by	  keratinocytes	  hyperproliferation	  and	  differentiation.	  It	  has	  been	  shown	  that	  the	  activity	  of	  p38α,	  p38β,	  and	  p38δ	  is	  augmented	  in	  lesional	  psoriasis	  skin	  compared	  with	  nonlesional	  psoriasis	  skin	  (Johansen	  et	  al.,	  2005).	  Additionally,	  p38δ	  may	  have	  a	  dual	  role	  in	  keratinocytes	  contributing	  not	  only	   to	   the	   differentiation	   process,	   but	   also	   to	   their	   apoptosis	   in	   a	   PKCδ-­‐dependent	   manner,	  though	   the	   exact	   mechanisms	   by	   which	   p38δ	   may	   regulate	   keratinocyte	   differentiation	   or	  apoptosis	  are	  still	  unknown	  (Kraft	  et	  al.,	  2007;	  Adhikary	  et	  al.,	  2010).	  It	  is	  important	  to	  notice	  that	  most	   of	   the	   pieces	   of	   evidence	   involving	   p38δ	   in	   regulating	   keratinocyte	   differentiation	   or	  apoptosis	  are	  based	   in	  overexpression	  experiments	  and	  require	  verification	  using	  other	   tools	   to	  both	  inhibit	  the	  activity	  or	  the	  expression	  of	  different	  p38	  MAPKs.	  	  	  It	   had	   been	   claimed	   that	   p38δ	   deletion	   in	   mice	   brings	   about	   a	   higher	   resistance	   to	   skin	  carcinogenesis	   induced	   chemically	   by	   a	   two-­‐stage	  DMBA/TPA	   protocol	   (Schindler	   et	   al.,	   2009).	  However,	  so	  far	  there	  have	  been	  no	  published	  data	  on	  the	  importance	  of	  the	  other	  alternative	  p38	  isoform,	  p38γ,	  in	  skin	  tumour	  development.	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  The	  principal	  objective	  of	  this	  thesis	  has	  been	  to	  gain	  an	  insight	  into	  an	  involvement	  of	  p38γ	  and	  p38δ	  MAPKs	   in	   the	   inflammation-­‐associated	   skin	   tumorigenesis	   using	  wild	   type,	   p38γ-­‐/-­‐,	   p38δ-­‐/-­‐	  and	  p38γ/δ-­‐/-­‐	  mice.	  	  	  In	  order	  to	  achieve	  this	  goal	  we	  had	  the	  following	  partial	  aims:	  	  1. To	  examine	  the	   in	  vivo	  contribution	  of	  p38γ	  and	  p38δ	   in	  skin	  tumour	  development	  by	  performing	  the	  chemically	  induced	  two-­‐stage	  DMBA/TPA	  skin	  tumorigenesis	  protocol,	  describing	   the	   expression	   and	   activation	   of	   oncogenic	   proteins,	   measuring	   the	  infiltration	  of	  immune	  cells	  and	  the	  proliferation	  of	  epithelial	  cells	  in	  the	  tumours.	  	  2. To	  analyse	  the	  p38γ	  and	  p38δ	  involvement	  in	  the	  DMBA-­‐induced	  apoptosis	  in	  the	  skin.	  	   3. To	  investigate	  the	  implication	  of	  p38γ	  and	  p38δ	  in	  the	  skin	  inflammation	  by	  measuring	  epithelial	   cell	   proliferation	   and	   analysing	   immune	   cells	   infiltration,	   cytokines	  production	  and	  cell	  signalling	  in	  the	  TPA-­‐treated	  skin.	  	  4. To	   generate	   stable	   p38γ,	   p38δ	   and	   p38γ/δ	   knock-­‐down	   clones	   of	   the	   human	  epidermoid	  cancer	  (squamous	  cell	  carcinoma)	  A-­‐431	  cells	  and	  to	  examine	  their	  role	  in	  cell	  proliferation	  and	  tumorigenesis	  by	  xenograft	  assay.	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1.	  Animal-­‐based	  experiments.	  	  
1.1.	  Mice.	  Mice,	   lacking	   p38γ	   (p38γ-­‐/-­‐),	   p38δ	   (p38δ-­‐/-­‐)	   and	   p38γ/δ	   (p38γ/δ-­‐/-­‐),	   used	   in	   most	   of	   the	  experiments,	  have	  been	  described	  (Risco	  et	  al.,	  2012).	  All	  strains	  were	  backcrossed	  onto	  C57BL/6	  background	   for	   at	   least	   nine	   generations.	   For	   xenograft	   experiments	   we	   used	   Crl:NU(Ico)-­‐Foxn1nu	  nude	  mice	  purchased	  from	  Charles	  River.	  They	  had	  been	  developed	  from	  the	  transfer	  of	  the	  nude	  gene	  to	  a	  CD-­‐1	  mouse	  through	  a	  series	  of	  crosses	  and	  back-­‐crosses.	  The	  animals	  do	  not	  have	   a	   thymus	   and	   are	   therefore	   unable	   to	   produce	   T-­‐cells	   and	   are	   consequently	  immunodeficient.	  Mice	  used	   in	  experiments	  were	  housed	   in	  specific	  pathogen-­‐free	  conditions	   in	  accordance	  with	  the	  European	  Union	  regulations	  and	  the	  work	  was	  approved	  by	  a	  local	  CNB-­‐CSIC	  ethical	  review.	  	  
1.2.	  Two-­‐stage	  skin	  tumorigenesis	  protocol.	  Chemically	   induced	   two-­‐stage	   skin	   tumorigenesis	   is	   a	   widely	   used	   protocol,	   which	   enables	   an	  induction	   of	   benign	   skin	   papillomas	   (skin	   tumours)	   and	   malignant	   squamous	   cell	   carcinomas	  (SCC)	   in	  murine	  dorsal	   skin.	   It	   consists	  of	   topical	   treatment	  with	  an	   inducing	  agent,	   carcinogen,	  called	   7,12-­‐dimethylbenz[α]anthracene	   (DMBA)	   followed	   by	   repeated	   treatments	   with	   an	  inflammatory	   and	   mitogenic,	   promoting	   agent	   –	   12-­‐O-­‐tetradecanoylphorbol-­‐13-­‐acetate	   (TPA).	  This	  protocol	  relies	  on	  clonal	  expansion	  of	  initiated	  epidermal	  cells	  (keratinocytes)	  in	  response	  to	  continuous	  TPA	  treatments	  leading	  to	  tumorigenic	  changes	  in	  skin	  (Fig.	  M-­‐1).	  	  
	  	  Figure	  M-­‐1.	   Schematic	   representation	   of	   chemically	   induced	   two-­‐stage	   skin	   tumorigenesis	   protocol.	   Only	  some	  benign	  papillomas	  progress	  to	  an	  advanced	  stage	  of	  squamous	  cell	  carcinoma	  in	  this	  protocol.	  	  	  WT,	   p38γ-­‐/-­‐,	   p38δ-­‐/-­‐	   and	   p38γ/δ-­‐/-­‐	   mice	   at	   the	   age	   of	   6	   –	   8	   weeks	   were	   subject	   to	   a	   two-­‐stage	  induced	   skin	   tumorigenesis	   protocol.	   Dorsal	   skin	   was	   shaved	  with	   a	   clipper	   24	   hours	   prior	   to	  initiation.	   On	   day	   1	   the	  mice	  were	   topically	   treated	  with	  DMBA	  dissolved	   in	   acetone.	   On	   day	   2	  topical	   treatments	  with	  TPA,	  dissolved	   in	  acetone	  were	  carried	  out	  continually	  every	  3	  –	  4	  days	  (two	   treatments	  weekly)	   for	   19	  weeks.	  Mice	  were	   regularly	   examined	   for	   tumours	   appearance	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and,	   from	  week	  15,	   the	  growth	  of	   tumours	  was	  measured	  with	  a	  calliper	  every	   fortnight.	  At	   the	  end	  of	  the	  experiment	  (week	  29)	  mice	  were	  sacrificed	  and	  samples	  derived	  from	  the	  tumours	  and	  healthy	  skin	  were	  processed	   for	   further	  analysis.	  Control	  mice	  were	  treated	  with	  acetone	  alone.	  Details	  of	  the	  compounds	  used	  are	  summarised	  in	  Table	  M-­‐1.	  	  
 
Agent Full Name Amount Utility 
DMBA 7,12-dimethylbenz[α]anthracene 100 µg [390 nmol] Inducer 
TPA 12-O-tetradecanoylphorbol-13-acetate 10 µg  [16 nmol] Promoter 
 Table	  M-­‐1.	  Chemical	  compounds	  used	  in	  the	  two-­‐stage	  skin	  carcinogenesis	  protocol.	  
	  
	  
1.3.	  Acute	  skin	  inflammation	  model.	  Acute	  skin	  inflammation	  experiments	  were	  carried	  out	  using	  single	  topical	  applications	  of	  either	  TPA	  (10	  µg	   in	  200	  µl	  acetone,	  16	  nmol)	  or	  acetone	  (control)	  onto	  shaved	  dorsal	  skin.	  Following	  mice	  sacrifice,	  at	  different	  times	  post-­‐treatment	  (30	  min,	  1,	  2,	  4,	  8,	  12,	  24	  and	  48	  hours),	  samples	  were	  excised	  and	  analysed.	  	  
1.4.	  Xenograft	  model.	  Xenograft	   tumour	   growth	   experiment	  were	   carried	   out	   using	   athymic	   nude	  mice	   (described	   in	  paragraph	   1.1)	   and	   genetically	   modified	   clones	   of	   human	   epidermoid	   cancer	   cells,	   A-­‐431	  (described	  in	  paragraphs	  2.3	  and	  2.4).	  The	  clones	  were	  stable	  knock-­‐down	  for	  p38γ	  and/or	  p38δ	  and	  their	  establishment	  has	  been	  described	  in	  more	  detail	  in	  section	  4.1	  of	  Results.	  	  	  Mice,	   at	   the	   age	   of	   6	   –	   8	  weeks,	   received	   subcutaneous	   injections	   of	   106	   A-­‐431	   cells	   diluted	   in	  sterile	   DMEM	   and	   the	   growth	   of	   tumours	  was	  monitored	   every	   2	   –	   4	   days	   for	   about	   3	  weeks.	  Tumour	  volume	  was	  calculated	  by	  the	  formula:	  V	  =	  (Dxd2)/2,	  where	  D	  and	  d	  are	  the	  longest	  and	  shortest	  diameter	  in	  mm,	  respectively.	  
	  
1.5.	  Assessment	  of	  cell	  proliferation.	  We	   used	   the	   5-­‐bromo-­‐2´-­‐deoxyuridine	   (BrdU)-­‐based	   immunofluorescence	   staining	   protocol	   in	  order	   to	   establish	   the	   proliferation	   rates	   in	   skin	   and	   tumour	   samples.	   Mice	   were	   given	   intra-­‐peritoneal	  injections	  of	  BrdU	  (100	  mg/kg	  body	  weight),	  dissolved	  in	  sterile	  PBS,	  2	  hours	  prior	  to	  sacrifice.	  Excised	  skin	  and	  tumour	  samples	  were	  fixed	  in	  70%	  ethanol	  or	  in	  10%	  neutral	  buffered	  formalin	   solution	   (NBF)	   for	   up	   to	   48	   hours	   at	   room	   temperature	   (RT)	   and	   then	   processed	   for	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dehydration	   and	   paraffin	   embedded	   blocks	   preparation.	   Tissue	   sections	   (of	   5	   μm	   of	   thickness)	  were	   immunostained	  with	  anti-­‐BrdU	  antibody	  (Table	  M-­‐2),	  according	  to	  a	  protocol	  described	   in	  section	  3.6,	  and	   the	  numbers	  of	  BrdU-­‐positive	  epithelial	   cells,	   found	   in	  skin	   interfollicular	  areas	  (acute	  skin	  inflammation	  experiments)	  or	  in	  tumours	  (DMBA/TPA	  protocol),	  were	  counted	  in	  at	  least	  8	  fields	  per	  sample.	  	  
Antibody Company and Reference No. Dilution   Type 
BrdU [BU1/75 (ICR1)] (Rat) Abcam, ab6326 1:100 Primary 
Alexa Fluor 647 Goat Anti-Rat Molecular Probes, A-21247 1:200 Secondary 
 Table	  M-­‐2.	  Antibodies	  used	  in	  cell	  proliferation	  protocol.	  
 	  
2.	  Cell	  culture	  methods.	  
	  
2.1.	  General	  cell	  culturing.	  Human	  Embryonic	  Kidney	  (HEK)	  293T	  and	  epidermoid	  carcinoma	  (A-­‐431)	  cells	  were	  cultured	  in	  Dulbecco´s	   Modified	   Eagle´s	   Medium	   (DMEM)	   (Lonza,	   Belgium)	   routinely	   supplemented	   with	  10%	   foetal	   bovine	   serum	   (FBS),	   4	   mM	   L-­‐glutamine	   and	   1%	   antibiotics	   (penicillin	   and	  streptomycin)	  in	  10	  cm	  (P10)	  cell	  culture	  plates	  at	  37°C,	  5%	  CO2	  and	  90%	  relative	  humidity	  in	  an	  incubator.	   Cells	   were	   split	   1:8	   every	   3-­‐4	   days	   (after	   reaching	   80-­‐90%	   confluence).	   Cells	   were	  washed	   once	  with	   PBS	   and	   disaggregated	   by	   incubation	  with	   0.05%	   trypsin/0.02%	   EDTA/PBS	  (1.5	   ml	   per	   plate)	   at	   37°C	   for	   5-­‐10	   min	   until	   cells	   detached.	   Trypsin	   was	   then	   inactivated	   by	  adding	  3.5	  ml	  medium	  with	  10%	  FBS	  and	  cells	  were	  diluted	  in	  fresh	  medium.	  
	  
2.2.	  Cell	  freezing	  and	  thawing.	  For	   long-­‐term	   storage	   of	   cells	   they	  were	   frozen	   in	   freezing	  medium	   and	   stored	   in	   cryovials	   in	  liquid	   nitrogen.	   Briefly,	   the	   cells	  were	   cultured	   on	   P10	   plates	   to	   70-­‐80%	   confluency.	   Following	  removal	   of	   the	   medium	   and	   washing	   with	   PBS,	   the	   cells	   were	   harvested	   using	   trypsin/EDTA	  solution	   (750	   µl)	   to	   detach	   them.	   Cells	   suspended	   in	   trypsin	   were	   then	   mixed	   with	   750	   µl	   of	  freezing	  medium	  composed	  of	  80%	  of	  FBS	  and	  20%	  DMSO	  (to	  get	  a	   final	  DMSO	  concentration	  –	  10%)	  and	  transferred	  into	  a	  2	  ml	  cryovial.	  To	  allow	  gradual	  freezing,	  the	  cryovials	  were	  covered	  abundantly	   with	   paper	   towel	   and	   placed	   at	   -­‐80°C	   for	   three	   days.	   Subsequently,	   the	   cryovials	  transferred	  to	  liquid	  nitrogen	  (-­‐180°C).	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To	  start	  a	  new	  cell	  culture	  from	  frozen	  cells,	  the	  cryovials	  were	  rapidly	  thawed	  using	  a	  bath	  (37°C)	  and	   diluted	   in	   fresh	  medium	   in	   P10	   plates.	   To	   facilitate	   the	   recovery,	  medium	  was	   changed	   on	  next	  day.	  
	  
2.3.	  Lentivirus	  short	  hairpin	  RNA	  production	  in	  HEK293T	  cells.	  Short	  hairpin	  RNA	  (shRNA)	  constructs	  in	  the	  pLKO.1	  lentiviral	  expressing	  vectors	  were	  purchased	  from	  Open	  Biosystems	  Thermo	  Scientific	  (Table	  M-­‐3)	  to	  knock-­‐down	  endogenous	  p38γ	  and	  p38δ	  in	   A-­‐431	   cells.	   HEK293T	   packaging	   cell	   line	  was	   used	   for	   lentivirus	   production	   in	   so-­‐called	   3rd	  generation	  packaging	  system.	  	  	  
Gene Silenced   Clone ID   Catalog No. Antisense Sequence (5’ à 3’) shRNA Name * 
p38γ TRCN0000006145 RHS3979-9575012 AAAGTCCGTGAAGTCATCCAG 145 
p38γ TRCN0000006147 RHS3979-9575014 ATCAGGAGTGAATACGTCCAG 147 
p38γ TRCN0000006148 RHS3979-9575015 TCATCATACTTCTGGACCTGG 148 
p38γ TRCN0000006149 RHS3979-9575016 AACAGCTCGGACTGGAAGGGC 149 
p38δ TRCN0000055428 RHS3979-9569233 TAGAAGTCATAGAAGTTGCGC 428 
p38δ TRCN0000000827 RHS3979-9569234 TTCTAAGGAATCATCAAACGG 827 
p38δ TRCN0000000828 RHS3979-9569235 ATTTGGCCGCTTTGTCGTTCA 828 
p38δ TRCN0000009973 RHS3979-9631088 TTTGGCCGCTTTGTCGTTCAG 973 
p38δ TRCN0000009978 RHS3979-9631084 GAAGATCTCGGACTGAAAGGG 978 
p38δ TRCN0000009979 RHS3979-9631085 TAGAAGTCATAGAAGTTGCGC 979 
 Table	  M-­‐3.	  shRNAs	  used	  for	  lentiviral	  particles	  production.	  (*)	  shRNA	  names	  used	  in	  Results.	  	  Briefly,	  2.5	  x	  106	  cells	  were	  seeded	  on	  a	  six-­‐well	  culture	  plate	  (P6)	  and	  incubated	  overnight	  (day	  1).	  On	  day	  2	  the	  medium	  was	  removed	  and	  fresh	  medium	  was	  added.	  Four	  hours	  later	  a	  mixture	  of	   plasmids	   encoding	   shRNA	   and	   viral	   components,	   diluted	   in	   150	   mM	   NaCl	   solution	   and	  containing	   5%	   JetPei,	  was	   added	   drop-­‐wisely	   onto	   the	  medium	   for	   transient	   transfection.	   Each	  shRNA	  lentivirus-­‐containing	  medium	  was	  produced	  in	  two	  wells.	  The	  transfection	  was	  performed,	  introducing	  simultaneously	  four	  different	  plasmids	  into	  the	  cells.	  The	  plasmids	  were	  suspended	  in	  1	  ml	   of	  medium	   per	  well	   (Table	  M-­‐4):	   shRNA-­‐pLKO.1	   (plasmid	  with	   puromycin	   resistance	   and	  encoding	  either	  p38γ	  shRNA	  or	  p38δ	  shRNA)	  and	  three	  plasmids	  belonging	  to	  a	  packaging	  system,	  i.e.	  pRSV-­‐Rev	  (plasmid	  encoding	  Rev,	  responsible	  for	  the	  RNA	  transport),	  pMDLg/pRRE	  (plasmid	  containing	   [1]	   Gag,	   coding	   for	   the	   virion	   main	   structural	   proteins;	   [2]	   Pol,	   responsible	   for	   the	  lentivirus-­‐specific	   enzymes;	   and	   [3]	   Rev-­‐responsive	   element	   RRE,	   a	   binding	   site	   for	   the	   Rev	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protein)	  and	  pMD2.G	  (plasmid	  encoding	  VSV-­‐G,	  a	  lentivirus	  envelope	  protein).	  An	  empty	  pLKO.1	  vector	  (without	  any	  shRNA	  gene)	  was	  used	  to	  produce	  viral	  particles	  as	  well.	  After	  6	  hours	  of	  the	  transfection	   the	   medium	   was	   removed	   and	   fresh	   medium	   was	   added.	   On	   day	   4	   the	   virus-­‐containing	  medium	  was	  collected	   from	  each	  well,	   filtered	  with	  0.45	  µm-­‐pore	  syringe	   filters	  and	  stored	  at	  -­‐80°C.	  In	  order	  to	  produce	  more	  lentivirus	  with	  the	  same	  cells,	  fresh	  medium	  was	  added	  and	   viral	   particles	   were	   produced	   for	   another	   24	   hours.	   Collection	   and	   filtration	   of	   the	   viral-­‐containing	  supernatants	  was	  repeated	  on	  day	  5	  and	  the	  plates	  were	  discarded	  in	  the	  end.	  	  	  
Vector Utility Amount  
pLKO.1 HIV-1-derived transfer plasmid, expressing puromycin resistance proteins (and shRNA) 3.00 µg 
pMD2.G Envelope plasmid, encoding VSV-G-derived heterologous envelope protein for pseudotyping 0.70 µg 
pRSV-Rev Packaging plasmid, producing viral particles, includes Rev (export of RNA from the nucleus) 0.35 µg 
pMDLg/pRRE Packaging plasmid, producing viral particles, includes RRE, Gag and Pol 1.80 µg 
 Table	  M-­‐4.	  Vectors	  used	  to	  produce	  lentivirus	  particles	  in	  HEK293T.	  Amounts	  are	  given	  per	  2	  ml.	  
	  
	  
2.4.	  Infection	  of	  A-­‐431	  cells	  with	  lentivirus.	  For	   A-­‐431	   infection	   with	   shRNA-­‐containing	   lentivirus,	   the	   cells	   were	   grown	   on	   P6	   plates	   in	  standard	  conditions.	  Once	  80-­‐90%	  of	  cell	  confluency	  was	  achieved	  the	  medium	  was	  removed	  and	  1	   ml	   of	   defrost	   lentivirus-­‐containing	   medium	   (supplemented	   with	   10	   mM	   Hepes	   and	   8	   µg/ml	  hexadimethrine	  bromide	  –	  Polybrene®)	  was	  added	  to	  each	  well	  (two	  wells	  in	  a	  P6	  per	  one	  shRNA,	  in	   duplicates)	   and	   incubated	   overnight.	   On	   next	   day,	   0.4	   ml	   of	   the	   same	   lentivirus-­‐containing	  medium	   (with	   10	   mM	   Hepes	   and	   8	   µg/ml	   Polybrene®)	   was	   added	   into	   the	   wells	   in	   order	   to	  increase	   the	  efficiency	  of	   the	   infection.	  48	  hours	  after	   the	   initiation	  of	   the	   infection	   the	  medium	  was	   removed	   and	   fresh	   medium	   was	   added.	   Six	   hours	   later	   selection	   of	   antibiotic	   resistance-­‐bearing	   cells	   was	   started	   by	   adding	   0.5	   µg/ml	   of	   puromycin	   into	   the	   medium.	   The	   cells	   were	  carefully	  observed	  and	  the	  infection	  was	  considered	  successful	  when	  non-­‐infected	  cells	  were	  dead	  (after	  4	  -­‐	  5	  days	  of	  selection).	  To	  assure	  that	  the	  resistance	  is	  not	  lost	  and	  to	  grow	  stable	  clones,	  the	  cells	  were	  diluted	  1:8	  and	  they	  continued	  their	  growth	  in	  puromycin-­‐containing	  medium	  for	  at	  least	  one	  week	  more	  (two	  weeks	  of	  selection	   in	   total).	  The	  efficiency	  of	  shRNA-­‐mediated	  down-­‐regulation	  was	  addressed	  by	  immunoblotting	  and	  bands	  density	  quantification.	  	  
	  
3.	  General	  methods.	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3.1.	  Protein	  and	  RNA	  samples	  preparation.	  In	  order	  to	  extract	  protein	  and	  RNA	  from	  murine	  tissue,	  mice	  were	  sacrificed	  and	  skin	  and	  tumour	  samples	   were	   collected	   and	   mechanically	   disrupted	   in	   liquid	   nitrogen.	   Tissue	   powder	   was	  processed	  for	  protein	  and	  RNA	  extractions.	  Proteins	  were	  extracted	  using	  a	  lysis	  buffer	  containing	  1%	  Triton	  X-­‐100,	  50	  mM	  Tris-­‐HCl	  pH	  7.5,	  1	  mM	  EDTA,	  1	  mM	  EGTA,	  50	  mM	  NaF,	  10	  mM	  sodium	  glicerophosphate,	   5	  mM	  sodium	  pyrophosphate,	   1	  mM	  sodium	  orthovanadate,	   270	  mM	  sucrose	  and	   0.1%	   β-­‐mercaptoethanol,	   supplemented	   with	   a	   mixture	   of	   proteinase	   inhibitors:	   1	   mM	  benzamidine	   and	   0.2	   mM	   phenylmethylsulfonyl	   fluoride	   (PMSF).	   Protein	   concentration	   in	   the	  lysates	  was	  measured	  with	   the	  Coomassie	  Plus	   (Bradford)	   reagent.	   For	  RNA	  preparation	   tissue	  powder	  was	  homogenised	  in	  TRI	  Reagent	  (Sigma	  Aldrich)	  and	  RNA-­‐containing	  fraction	  was	  mixed	  with	  isopropanol	  for	  RNA	  precipitation.	  After	  double	  precipitate	  washing	  (with	  70%	  ethanol)	  and	  dissolving	   in	   RNase-­‐free	   water,	   the	   RNA	   concentration	   was	   measured	   with	   Nanodrop	  spectrophotometer.	  	  	  For	   cell-­‐derived	   protein/RNA	   extractions	   the	   same	   buffers	   and	   procedures	   were	   applied.	  Detached	  cells	  were	  spinned	  down,	   supernatants	   removed	  and	  pellets	  washed	  once	  with	  sterile	  PBS.	  Then	  lysis	  buffer	  (for	  protein	  extraction)	  or	  in	  TRI	  Reagent	  (for	  RNA	  extraction)	  was	  added	  to	  the	  pellet	  and	  the	  same	  procedure	  was	  followed,	  as	  described	  above.	  In	  some	  cases,	  the	  protein	  extraction	   from	   adherent	   cells	   was	   done	   by	   adding	   cold	   lysis	   buffer	   onto	   the	   cells	   just	   after	  medium	  removal	  and	  detaching	  them	  off	  the	  plate	  with	  a	  cell	  scraper.	  	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Table	  M-­‐6.	  Running	  buffer	  (1X)	  components.	  Table	  M-­‐5.	  Loading	  buffer	  (1X)	  components.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
3.2.	  Immunoblotting.	  Proteins	   were	   denatured	   using	   standard	   loading	   buffer,	   containing	   5%	   of	   β-­‐mercaptoethanol	  (Table	  M-­‐5),	   for	  10	  minutes	  at	  99°C.	  Polyacrylamide	  gel	  electrophoresis	   (PAGE)	  was	  performed	  according	  to	  a	  common	  procedure.	  Denatured	  protein	  samples,	  at	  volumes	  corresponding	  to	  equal	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protein	  amounts,	  were	  loaded	  into	  12.5%	  polyacrylamide	  gel	  wells	  and	  proteins	  were	  separated	  in	  a	  running	  buffer	  (Table	  M-­‐6)	  connected	  to	  a	  source	  of	  electrical	  field	  (120	  V,	  for	  2	  hours,	  at	  RT).	  Separated	  proteins	  were	  electro-­‐blotted	  onto	  a	  nitrocellulose	  membrane	  using	  a	   transfer	  buffer	  (Table	  M-­‐7).	  The	  membrane	  was	  later	  incubated	  with	  a	  blocking	  solution,	  containing	  5%	  skimmed	  milk	  dissolved	  in	  a	  TBS	  buffer	  (Table	  M-­‐8)	  with	  0.1%	  of	  Tween	  20,	  at	  RT.	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Table	  M-­‐8.	  TBS	  buffer	  (10X)	  components.	  
	  Table	  M-­‐7.	  Transfer	  buffer	  (1X)	  components.	  	  	  
Antibody Company and Reference No. Dilution *  Specificity ** 
Akt Cell Signaling, #9272 1:1000 (WB) Rb 
BrdU [BU1/75 (ICR1)] Abcam, ab6326 1:100 (IF) Rt 
CD3 Dako, A 0452 1:50 (IF) Rb 
Myeloperoxidase (MPO) Abcam, ab9535 1:500 (WB), 1:25 (IHC) Rb 
P38α (C-20) Santa Cruz Biotechnology, sc-535 1:1000 (WB) Rb 
P38γ (GST-SAPK3) 0.25 mg/ml DSTT***, S524A 1st Bleed 0.5 µg/ml (1:500) (WB) Sh 
P38γ (GST-SAPK3) 0.86 mg/ml DSTT*** 1.5 µg/IP Sh 
P38δ 0.30 mg/ml DSTT***, S526A 3rd Bleed 0.2 µg/ml (1:1500) (WB) Sh 
P38δ 0.28 mg/ml DSTT*** 1.0 µg/IP Sh 
Phospho-Akt (Ser473) Cell Signaling, #9271 1:1000 (WB) Rb 
Phospho-Akt (Ser473) Cell Signaling, #9277 1:200 (IHC) Rb 
Phospho-ERK1 (Tyr204) Santa Cruz Biotechnology, sc-7383 1:200 (IHC) Rb 
Phospho-p38 MAP Kinase (Thr180/Tyr182) Cell Signaling, #9211 1:500 (WB) Rb 
Phospho-p44/42 (Erk1/2) (Thr202/Tyr204) Cell Signaling, #9101 1:1000 (WB) Rb 
Phospho-STAT3 (D3A7) (Tyr705)  Cell Signaling, #9145 1:1000 (WB), 1:200 (IHC) Rb 
STAT3 Santa Cruz Biotechnology, sc-482 1:1000 (WB) Rb 
α-Tubulin Invitrogen, 32-2500 1:1000 (WB) Ms 
β-Catenin Millipore, MAB2081 1:20000 (WB), 1:100 (IHC) Ms 	  Table	   M-­‐9.	   Primary	   antibodies	   used	   in	   the	   experiments.	   (*)	  WB	   -­‐	   western	   blot	   (immunoblotting);	   IHC	   -­‐	  immunohistochemistry;	  IF	  -­‐	  immunofluorescence;	  IP	  -­‐immunoprecipitation.	  (**)	  Rb	  -­‐	  rabbit;	  Sh	  -­‐	  sheep;	  Ms	  -­‐	  mouse;	  Rt	  -­‐	  rat.	  (***)	  Division	  of	  Signal	  Transduction	  Therapy,	  Dundee,	  UK.	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The	  blocked	  membrane	  was	  incubated	  overnight	  with	  a	  primary	  antibody	  (Table	  M-­‐9)	  diluted	  in	  a	  blocking	   solution	   at	   4°C.	   Protein	   expression	   was	   addressed	   using	   fluorescent	   secondary	  antibodies	  (Table	  M-­‐10)	  and	  LI-­‐COR	  Odyssey	  infrared	  scanning.	  	  If	  not	  stated	  otherwise,	   in	  the	  experiments	  with	  the	  mouse	  skin,	  total	  protein	  lysates	  from	  three	  mice	   were	   grouped	   (pooled)	   and	   run	   in	   gels	   in	   the	   same	   well	   at	   the	   amount	   of	   45	   µg,	   which	  corresponds	  to	  the	  sum	  of	  three	  equal	  amounts	  from	  each	  animal	  	  (15	  µg).	  
 
Antibody and Specificity Company and Reference No. Dilution * 
Alexa Fluor 647 Goat Anti-Rat Molecular Probes, A-21247 1:200 (IF) 
Alexa Fluor 680 Donkey Anti-Sheep Molecular Probes, A-21102 1:5000 (WB) 
Alexa Fluor 680 Goat Anti-Rabbit Molecular Probes, A-21109 1:5000 (WB) 
Alexa Fluor 700 Goat Anti-Mouse Molecular Probes, A-21036 1:5000 (WB) 
Alexa Fluor 790 Donkey Anti-Rabbit Molecular Probes, A-11374 1:20000 (WB) 
Biotin Goat Anti-Mouse Jackson Immunoresearch, 115-066-071 1:500 (IHC) 
Biotin Goat Anti-Rabbit Jackson Immunoresearch, 111-066-008 1:500 (IHC) 
CY3 Goat Anti-Rabbit Jackson Immunoresearch, 111-166-046 1:400 (IF) 
CY5 Goat Anti-Mouse Jackson Immunoresearch, 115-176-071 1:400 (IF) 
 Table	  M-­‐10.	  Secondary	  antibodies	  used	  in	  the	  experiments.	  (*)	  WB	  -­‐	  western	  blot	  (immunoblotting);	  IHC	  -­‐	  immunohistochemistry;	  IF	  -­‐	  immunofluorescence.	  
	  
	  
3.3.	  Real-­‐time	  quantitative	  PCR.	  cDNA	   for	   real-­‐time	   quantitative	   PCR	   (qPCR)	  was	   generated	   from	   0.5	   μg	   of	   total	   RNA	   using	   the	  High	  Capacity	   cDNA	  Reverse	  Transcription	  Kit	   (Applied	  Biosystems)	   in	   a	  10	  μl	   of	   final	   reaction	  volume.	  The	  qPCR	  reactions	  were	  performed	  in	  triplicate	  using	  5	  μl	  of	  each	  cDNA	  1/40	  dilutions,	  10	  μM	  of	  each	  oligonucleotide	  and	  HOT	  FIREPol	  qPCR	  mix	  (Solis	  Biodyne)	  in	  a	  total	  volume	  of	  8	  μl	  in	  MicroAmp	  Optical	  384-­‐well	  plates	  (Applied	  Biosystems).	  PCR	  reactions	  were	  carried	  out	  in	  an	  ABI	  PRISM	  7900HT	  (Applied	  Biosystems).	  The	  amount	  of	  amplified	  DNA	  was	  measured	  through	  the	  emission	  of	  light	  by	  the	  SYBR	  green	  dye,	  intercalating	  in	  synthesised	  double	  stranded	  DNA.	  All	  samples	   were	   measured	   in	   triplicates.	   SDS	   v2.2	   software	   was	   used	   to	   analyse	   results.	   Specific	  amplification	   was	   controlled	   by	   melting-­‐curve	   analysis.	   The	   data	   were	   exported,	   processed	   to	  Microsoft	   Excel	   and	   analysed	   by	   the	   Comparative	   Ct	   Method	   (DDCt).	   X-­‐fold	   change	   in	   mRNA	  expression	   was	   quantified	   relative	   to	   unstimulated	   WT	   samples	   from	   the	   same	   experiment.	  GAPDH	  mRNA	  was	  used	  as	  a	  housekeeping	  gene.	  The	  sequences	  of	   the	  oligonucleotides	  used	   in	  this	  thesis	  can	  be	  found	  in	  Table	  M-­‐11.	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Gene  Forward Sequence (5’ à  3’) Reverse Sequence (5’ à  3’) 
KC (CXCL1) CCTTGACCCTGAAGCTCCCT CGGTGCCATCAGAGCAGTCT 
MIP-2 (CXCL2) CCTGGTTCAGAAAATCATCCA CTTCCGTTGAGGGACAGC 
GAPDH CCCATCACCATCTTCCAGGA CGACATACTCAGCACCGGC 
IL-1β TGGTGTGTGACGTTCCCATT CAGCACGAGGCTTTTTTGTTG 
IL-6 GAGGATACCACTCCCAACAGACC AAGTGCATCATCGTTGTTCATACA 
p38α AACCAGACAGTGGATATTTGGTC TGAGCTTCAACTGATCAATATGGT 
p38γ ACCTGATGAGTCTCTGGACGA CCAGATCAGTGCCCATGAAT 
p38δ GGACCCTGAGGAGGAGACA GTTTGAGATCTCTTTGTAGATGTGTTG 
TNF-α CTGTAGCCCACGTCGTAGC TTGAGATCCATGCCGTTG 
TGF-β GGAACTCTACCAGAAATATAGCAACAATTC TGTAATCCGTCTCCTTGGTTCAG 
β-catenin GCAGCAGCAGTTTGTGGAG TGTGGAGAGCTCCAGTACACC 	  Table	  M-­‐11.	  Sequences	  of	  the	  oligonucleotides	  used	  in	  the	  experiments.	  
	  
	  
3.4.	  Immunoprecipitation.	  Specific	  anti-­‐p38γ	  (1.5	  μg)	  and	  anti-­‐p38δ	  (1	  μg)	  primary	  antibodies	  were	  first	  coupled	  to	  10	  µl	  of	  Protein	  G	  Sepharose	  beads	  (GE	  Healthcare)	  per	  one	  immunoprecipitation	  by	  incubating	  at	  4°C	  for	  30	  min	  in	  a	  mechanic	  shaker.	   In	  order	  to	  remove	  the	  excess	  of	  the	  uncoupled	  antibody	  PBS	  was	  added,	   the	   beads	   spinned	   down	   and	   supernatant	   removed.	   Then,	   skin	   protein	   lysates	   (1.6	  mg)	  were	  incubated	  with	  the	  beads	  (containing	  appropriate	  coupled	  antibody)	  for	  2	  hours	  at	  4°C.	  After	  the	   incubation	   the	   captured	  proteins	   on	   the	   beads	  were	   centrifuged	   (13.000	   x	   g),	   supernatants	  discarded	  and	  the	  beads	  washed	  twice	  in	  a	   lysis	  buffer	  containing	  0.5	  M	  NaCl,	  and	  then	  twice	  in	  lysis	   buffer	   alone.	   To	   visualise	   the	   immunoprecipitated	   proteins	   pellets	   were	   subjected	   to	  immunoblotting.	  	  	  
3.5.	  Immunohistochemistry.	  Formalin-­‐fixed,	  paraffin-­‐embedded	  skin	  and	  tumour	  sections	  were	  deparaffinised	  using	  xylene	  for	  20	  min	  and	  rehydrated	  with	  3-­‐min	  incubations	  in	  ethanol	  at	  decreasing	  concentrations	  (2x	  100%,	  1x	  90%	  and	  1x	  70%).	  The	  antigen	  retrieval	  was	  performed	  by	  heating	  up	  the	  sections	  in	  0.01	  M	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citrate	  buffer	  (pH	  6.0)	  for	  15	  min.	  The	  samples	  in	  hot	  citrate	  buffer	  were	  placed	  on	  ice	  for	  20	  min	  to	  cool	  down	  gradually.	  The	  activity	  of	  endogenous	  peroxidase	  was	  blocked	  by	  incubating	  for	  20-­‐min	   in	   3.3%	   of	   hydrogen	   peroxide	   (H2O2)	   in	  methanol	   at	   RT.	   To	   block	   unspecific	   proteins	   the	  sections	  were	  incubated,	  for	  1	  hour	  at	  37°C,	  in	  20%	  of	  goat	  serum	  in	  3%	  of	  bovine	  serum	  albumin	  (BSA)	  in	  distilled	  water.	  After	  the	  blocking	  step,	  incubations	  in	  different	  primary	  antibodies	  were	  performed	  in	  accordance	  with	  manufacturer’s	  recommendations.	  The	  antibodies	  were	  diluted	  in	  blocking	  solution	  and	  then	  added	  onto	  the	  tissue	  sections	  that	  were	  placed	   in	  a	  humid	  chamber	  for	  an	  overnight	  incubation	  at	  4°C.	  On	  next	  day,	  the	  sections	  were	  washed	  with	  PBS-­‐Tween	  0.1%	  (Table	  M-­‐12)	   three	   times	   for	  5	  min.	  Biotinylated	  secondary	  antibodies	  were	  used	  to	  bind	  to	   the	  primary	  antibodies	  in	  accordance	  with	  their	  specificity	  during	  1-­‐hour	  incubation	  at	  RT.	  	  	  
	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Table	  M-­‐12.	  PBS	  buffer	  (10X)	  components.	  	  Signal	   amplification	  was	   achieved	   incubating	   for	   40	  min	   at	   RT	   in	   a	   solution	   containing	   avidin–biotin-­‐peroxidase	   complexes	   from	  ABC	   kit	   (Vectastain).	   The	   oxidation	   of	   3,3’-­‐diaminobenzidine	  (DAB,	   Vector	   Laboratories),	   catalysed	   by	   the	   peroxidase	   attached	   to	   biotin	   in	   avidin-­‐biotin	  complex	  enabled	  visualisation	  of	  the	  protein	  of	  interest	  thanks	  to	  (1)	  the	  high	  affinity	  of	  avidin	  to	  the	   biotin	   attached	   to	   the	   secondary	   antibody	   and	   (2)	   to	   the	   brown	   coloured	   product	   of	   the	  reaction.	  The	  signal	  was	  observed	  by	  light	  microscopy.	  Final	  processing	  of	  the	  samples	  consisted	  in	   haematoxylin	   counterstaining	   and	   ethanol-­‐based	   dehydration	   followed	   by	   slides	   mounting,	  using	  VectaMount	  medium	  (Vector	  Laboratories).	  
	  
3.6.	  Immunofluorescence	  of	  BrdU-­‐positive	  cells.	  Sections	   were	   deparaffinised	   and	   rehydrated	   as	   described	   in	   3.5.	   Following	   the	   last	   ethanol	  incubation	  the	  sections	  were	  rinsed	  with	  MiliQ	  water	  and	  PBS	  and	  then	  treated	  with	  1	  N	  ice-­‐cold	  hydrochloric	  acid	  (HCl)	  for	  10	  min	  followed	  by	  incubation	  in	  2	  N	  HCl	  at	  RT	  to	  cause	  DNA	  breakage.	  PBS	   washings	   and	   borate	   buffer	   (0.1	   M)	   incubation	   for	   12	  min	   at	   RT	   served	   to	   neutralise	   the	  acidity.	  Incubation	  with	  5%	  goat	  serum	  in	  PBS,	  containing	  0.25%	  Triton	  X-­‐100,	  for	  1.5	  hours	  at	  RT	  was	  used	  to	  block	  unspecific	  bindings.	  The	  incubation	  with	  an	  anti-­‐BrdU	  primary	  antibody	  (Table	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M-­‐2)	  was	  performed	   in	   a	   humid	   chamber	  overnight	   at	  RT.	  After	   this	   the	   sections	  were	  washed	  three	   times	   with	   PBS.	   Finally,	   a	   secondary	   antibody	   (Table	   M-­‐10),	   labelled	   with	   a	   fluorescent	  marker,	   was	   added.	   Nuclei	   were	   stained	   with	   Hoechst33342	   and	   BrdU-­‐positive	   cells	   were	  observed	  using	  Leica	  MicroFluor	  microscope.	  	  
3.7.	  TUNEL.	  Apoptotic	  cells	  in	  skin	  epithelium	  were	  stained	  using	  terminal	  deoxynucleotidyltransferase	  (TdT)-­‐mediated	   dUTP	  nick-­‐end	   label	   (TUNEL)	   staining.	   Briefly,	   paraffin-­‐embedded	   skin	   sections	  were	  deparaffinised	   and	   rehydrated	   as	   described	   above.	   The	   cells	   were	   washed	   with	   PBS	   and	  permeabilized	  in	  PBS	  containing	  0.5%	  Triton	  X-­‐100.	  Next,	  the	  sections	  were	  pre-­‐incubated	  for	  15	  min	  at	  RT	   in	   freshly	  prepared	  TdT	  1X	  buffer	   (Table	  M-­‐13)	   containing	  1mM	  cobalt	   (II)	   chloride.	  The	  TdT-­‐based	  reaction	  was	  carried	  out	  in	  a	  humid	  chamber	  at	  37°C	  for	  1	  hour	  in	  the	  same	  buffer,	  containing	   besides	   3%	   TdT	   (v/v)	   (Roche,	   ref.	   03333574001)	   and	   2%	   biotin-­‐16-­‐dUTP	   (v/v)	  (Roche,	   11093070910).	   After	   this	   the	   sections	   were	   washed	   twice	   with	   PBS	   containing	   0.01%	  Tween	   20.	   Sections	   were	   then	   incubated	   with	   streptavidin	   conjugated	   with	   a	   cyanine	  fluorochrome	   (Cy5).	   Nuclei	   were	   stained	   with	   Hoechst33342.	   The	   slides	   were	   observed	   by	  fluorescent	  microscopy.	  	  
	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Table	  M-­‐13.	  TdT	  buffer	  (5X)	  components.	  	  
	  
4.	  Statistical	  analysis.	  
	  For	   statistical	   analyses	   GraphPad	   Prism	   5	   was	   used.	   Differences	   were	   considered	   statistically	  significant	   for	   P<0.05	   (*).	   If	   not	   stated	   otherwise,	   not	   significant	   differences	   between	   the	  corresponding	  groups	  from	  different	  genotypes	  have	  not	  been	  shown	  on	  the	  graphs.	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1.	  p38γ 	  and	  p38δ 	  are	  essential	  for	  skin	  tumorigenesis.	  	  Using	  a	  well	  established	  procedure,	  the	  two-­‐stage	  DMBA/TPA	  skin	  tumour	  induction,	  in	  C57BL/6	  mice	  deficient	  in	  p38γ	  (p38γ-­‐/-­‐),	  p38δ	  (p38δ-­‐/-­‐)	  and	  both	  (p38γ/δ-­‐/-­‐),	  we	  have	  addressed	  p38γ	  and	  p38δ	  role	  in	  skin	  tumour	  development.	  	  
1.1	  p38γ 	  and	  p38δ 	  are	  expressed	  in	  mouse	  skin.	  We	  first	  checked	  that	  both	  p38γ	  and	  p38δ	  were	  expressed	  in	  the	  skin	  of	  wild	  type	  (WT)	  mice.	  We	  also	  confirmed	  the	  lack	  of	  p38γ	  expression	  in	  skin	  from	  p38γ-­‐/-­‐	  mice,	  the	  lack	  of	  p38δ	  expression	  in	  p38δ-­‐/-­‐	  skin	  samples	  and	  the	  lack	  of	  both	  p38s	  in	  p38γ/δ-­‐/-­‐	  by	  immunoblotting,	  using	  anti-­‐p38γ	  and	  anti-­‐p38δ	  specific	  antibodies	  (Fig.	  R-­‐1A).	  	  	  
1.2.	  p38γ 	  and	  p38δ 	  deletion	  impairs	  chemically	  induced	  skin	  tumorigenesis.	  WT,	  p38γ-­‐/-­‐,	  p38δ-­‐/-­‐	  and	  p38γ/δ-­‐/-­‐	  mice	  were	  subjected	  to	  the	  complete	  DMBA/TPA	  protocol	  for	  19	  weeks	  and	  monitored	  for	  papillomas	  formation	  for	  another	  10	  weeks	  (Fig.	  R-­‐1B).	  29	  weeks	  after	  DMBA	  administration	  WT,	  p38γ-­‐/-­‐	   and	  p38δ-­‐/-­‐	  but	  not	  p38γ/δ-­‐/-­‐	  mice	  developed	  skin	  papillomas	  (Fig.	  R-­‐1C).	  First	  skin	  papillomas	  were	  developed	  in	  WT	  and	  p38γ-­‐/-­‐	  mice	  at	  week	  10.	  Some	  of	  the	  tumours	   in	   WT	   mice	   disappeared	   between	   weeks	   12	   and	   13.	   In	   the	   case	   of	   p38δ-­‐/-­‐	   mice,	   the	  development	   of	   the	   earliest	   papillomas	  was	   observed	   at	  week	   15	   (Fig.	   R-­‐1D,	   E).	   The	  maximum	  average	  tumour	  number	  in	  these	  three	  genotypes	  was	  observed	  between	  weeks	  19	  and	  21	  (Fig.	  R-­‐1E).	  Tumour	  incidence	  in	  that	  period	  reached	  90%	  in	  WT,	  80%	  in	  p38γ-­‐/-­‐and	  about	  60%	  in	  p38δ-­‐/-­‐	  mice	   and	   slightly	   decreased	   during	   the	   remaining	   time	   of	   the	   experiment,	   mostly	   due	   to	   the	  regression	   of	   the	   smallest	   papillomas	   (Fig.	   R-­‐1D,	   E,	   F),	   which	   is	   a	   phenomenon	   commonly	  observed	   in	   this	  protocol	   (Kopp-­‐Schneider	  and	  Portier,	  1992).	   	  Mice	  deficient	   in	  p38γ/δ,	  on	   the	  other	  hand,	  developed	  first	  small	  papillomas	  at	  week	  19	  and	  all	  of	  them	  disappeared	  after	  week	  20.	   Therefore,	   there	   were	   no	   p38γ/δ-­‐/-­‐	   tumours	   observed	   from	   week	   21	   until	   the	   end	   of	   the	  experiment	  (Fig.	  R-­‐1C,	  D,	  E).	  	  In	  addition,	  tumour	  size	  displayed	  different	  patterns	  in	  WT,	  p38γ-­‐/-­‐	  and	  p38δ-­‐/-­‐	  mice.	  Only	  WT	  and	  p38γ-­‐/-­‐	  mice	  developed	  large	  (above	  100	  mm3)	  and/or	  medium	  (21	  –	  100	  mm3)	  papillomas	  during	  the	  TPA	  promotion	  stage,	   i.e.	  until	  week	  19	  (Fig.	  R-­‐1F),	  while	  the	  p38δ	  deficiency	  seems	  to	  have	  slowed	   down	   the	   tumour	   growth.	   This	   observation	   might	   be	   due	   to	   a	   markedly	   delayed	  appearance	  of	  the	  papillomas	  in	  p38δ-­‐/-­‐	  mice.	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In	   conclusion,	   our	   results	   showed	   that	   the	   absence	   of	   the	   p38δ	   isoform	   led	   to	   a	   delayed	   skin	  tumour	  induction	  and	  to	  a	  more	  reduced	  tumour	  multiplicity.	  Notably,	  the	  deletion	  of	  both	  p38γ	  and	  p38δ	  resulted	  in	  a	  marked	  resistance	  to	  skin	  tumorigenesis,	   leading	  to	  no	  mice	  bearing	  skin	  papillomas	  at	  the	  end	  of	  the	  experiment.	  Besides,	  the	  p38γ	  deficiency	  reduced	  tumour	  incidence	  comparing	  with	  WT	   (Fig.	   R-­‐1D),	   although	   the	   differences	   in	   tumour	   numbers	   between	  WT	   and	  p38γ-­‐/-­‐	  mice	  were	  not	  signifficant	  (Fig.	  R-­‐1E).	  	  	  
	  	  	  	  	  	  	   	  
	  	  	  	  	  	  	   	  	  Figure	   R-­‐2.	   (A)	   HE	   staining	   of	   a	   skin	   papilloma	   progressed	   to	   carcinoma	   and	   three	   magnifications	  highlighting	   its	   characteristic	   features	  marked	  with	  black	   arrows:	   (x)	  pigment	  depositions,	   (y)	   squamous	  cell	  nests	  and	  (z)	  keratin	  pearls.	  Scale	  bars:	  100	  µm.	  (B)	  A	  progressed	  carcinoma	  and	  a	  benign	  papilloma.	  	  As	   for	   the	  phenotype	  of	   the	  developed	  skin	  papillomas	  we	  did	  not	   find	  differences	  between	   the	  genotypes.	  They	  were	  benign,	  non-­‐invasive,	  keratin-­‐producing	  skin	  growths	  which	  were	   formed	  within	  overgrown	  epidermis	  and	  contained	  a	  conserved,	  intact	  basal	  membrane	  that	  surrounded	  the	   tumour	  stroma	  (Fig.	  R-­‐1G).	   In	  most	  of	   the	  cases	   the	  progresssion	   to	  malignant	  state	  did	  not	  take	   place.	  We	   only	   found	   one	   p38γ-­‐/-­‐	   tumour	   that	   displayed	   features	   of	  malignancy	   typical	   for	  squamous	   cell	   carcinomas,	   such	   as:	   numerous	   keratin	   pearls,	   squamous	   cell	   nests,	   pigment	  depositions	   and,	   importantly,	   stromal	   invasion	  evidenced	  by	  decomposition	  of	   basal	  membrane	  continuity	   (lack	   of	   clear	   border	   between	   tumour	   epithelium	   and	   tumour	   stroma)	   (Fig.	   R-­‐2A).	  Besides	   this	   tumour	  was	   less	  keratinized	  at	   first	  glance	  and	   less	  exposed	  outside	   the	  skin	  when	  compared	  with	  the	  remaining	  skin	  tumours	  (Fig.	  R-­‐2B).	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Mutational	   activation	   of	   a	   signal	   transducer	   H-­‐Ras	   is	   very	   common	   in	   DMBA-­‐induced	   skin	  papillomas.	  It	  provokes	  changes	  in	  a	  number	  of	  signalling	  pathways	  -­‐	  effectors	  of	  Ras	  oncoprotein,	  which	   are	   involved	   in	   cell	   cycle	   and	   apoptosis	   regulations	   (Schwarz	   et	   al.,	   2013).	  Among	  direct	  and	  indirect	  targets	  of	  Ras	  there	  are	  MAPKs	  such	  as	  p38	  MAPK	  and	  Akt,	  β-­‐catenin	  and	  STAT3.	  	  To	   gain	   an	   insight	   into	   a	   possible	   mechanism,	   by	   which	   p38γ	   and	   p38δ	   affect	   skin	   tumour	  development	   and	   tumour	   growth,	   we	   analysed	   the	   expression	   and	   phosphorylation	   of	   the	   p38	  isoforms,	  as	  well	  as	  expression	  of	  STAT3,	  Akt	  and	  β-­‐catenin	  in	  the	  papillomas.	  The	  proteins	  were	  analysed	   by	   immunoblotting	   from	   tissue	   lysates	   and	   by	   immunohistochemistry	   in	   paraffin-­‐embedded	  tissue	  sections	  from	  DMBA/TPA	  treated	  WT,	  p38γ-­‐/-­‐	  and	  p38δ-­‐/-­‐	  mice	  at	  the	  end	  of	  the	  protocol	  at	  week	  29.	  	  
1.3.1.	  p38.	  Immunoblotting	   analysis	   of	   p38s	   showed	   that	   both	   p38γ	   and	   p38δ	   are	   expressed	   in	   skin	  papillomas	   (Fig.	   R-­‐3A).	   However,	   in	   comparison	   with	   the	   healthy	   skin,	   p38δ	   in	   papillomas	  displayed	  very	  augmented	  levels,	  whereas	  p38γ	  was	  much	  less	  expressed.	  The	  difference	  was	  then	  confirmed	  by	  qPCR	  of	  the	  p38γ/δ	  genes	  in	  healthy	  skin	  and	  papilloma	  samples	  (Fig.	  R-­‐3B).	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Interestingly,	  primary	  keratinocytes	  from	  WT	  mice,	  used	  as	  control,	  were	  characterised	  by	  p38γ/δ	  expression.	  p38γ/δ	  mRNA	  and	  proteins	   levels	  were	  more	   similar	   to	   those	   in	  papilloma	  samples	  than	  to	  the	  healthy	  skin.	  This	  finding	  correlates	  with	  the	  predominant	  presence	  of	  (transformed)	  keratinocytes	   in	   skin	   tumours.	   p38γ	   was	   also	   expressed	   in	   p38δ-­‐/-­‐	   papillomas	   and	   p38δ	   was	  expressed	   in	   p38γ-­‐/-­‐	   (Fig.	   R-­‐3A,	   B).	   Contrary	   to	   p38γ	   and	   p38δ	   expression	   in	   the	   skin	   and	  papillomas,	   the	   levels	   of	   p38α	   expression	   did	   not	   vary	   between	   the	   three	   genotypes	   and	  were	  similar	  in	  tumours	  and	  healthy	  skin	  samples	  (Fig.	  R-­‐3A,	  B).	  	  
	  	   	  	  	  	  	  	   	  	  Figure	  R-­‐4.	  Immunoblot	  of	  p38δ	  and	  phospho-­‐p38	  in	  skin	  papillomas	  (P)	  and	  healthy	  skin	  from	  two	  WT	  (A),	  two	   p38γ-­‐	   and	   two	   p38δ-­‐deficient	  mice	   (B):	   The	   upper	   band	   in	   the	   p38δ	   blot	   (red	   colour	   in	   panel	   A)	   is	  phosphorylated	   p38δ,	   as	   confirmed	   by	   its	   colocalisation	   with	   the	   upper	   band	   in	   the	   phospho-­‐p38	   blot	  (green	  in	  panel	  A)	  and	  merging	  the	  colours	  (yellow	  in	  panel	  A).	  The	  band	  shift	  of	  phospho-­‐p38δ	  was	  also	  observed	  in	  papillomas	  from	  p38γ-­‐/-­‐	  mice.	  p38α	  was	  used	  as	  control.	  	  Immunoblot	  analysis	  of	  p38δ	  in	  WT	  papillomas	  revealed	  that	  this	  is	  not	  only	  highly	  expressed	  in	  but	   also	   highly	   phosphorylated,	   which	   indicates	   a	   possible	   contribution	   of	   p38δ	   in	   the	   tumour	  growth	   and	   development	   (Fig.	   R-­‐4A).	   Phosphorylated	   p38δ	   suffered	   a	   band	   shift	   in	   its	  electrophoresis	   mobility	   and	   it	   could	   be	   also	   detected	   with	   the	   phospho-­‐p38	   antibody,	   which	  recognises	   all	   four	   phosphorylated	   p38	   isoforms.	   Importantly,	   the	   deficiency	   of	   p38γ	   did	   not	  influence	  the	  expression	  and	  phosphorylation	  of	  p38δ	  in	  skin	  papillomas	  (Fig.	  R-­‐4B).	  	  	  These	  results	  indicate	  that	  the	  activation	  of	  p38δ	  is	  important	  in	  skin	  tumour	  formation,	  which	  is	  consistent	  with	  our	  previous	  data	  showing	  that	  p38δ-­‐deficient	  mice	  (p38δ-­‐/-­‐	  and	  p38γ/δ-­‐/-­‐)	  were	  more	  resistant	  to	  DMBA/TPA	  protocol	  than	  p38δ-­‐expressing	  mice	  (WT	  and	  p38γ-­‐/-­‐).	  On	  the	  other	  hand,	  despite	  the	  low	  abundance	  of	  p38γ	  in	  skin	  papillomas,	  at	  this	  stage	  we	  could	  not	  rule	  out	  its	  role	  in	  skin	  tumorigenesis.	  
	  
1.3.2.	  β-­‐catenin,	  STAT3,	  Akt.	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Wnt/β-­‐catenin	   signalling	   has	   been	   shown	   to	   play	   an	   important	   role	   in	   a	   variety	   of	   human	  tumours.	  It	  has	  been	  described	  that	  nuclear	  localisation	  of	  β-­‐catenin,	  a	  hallmark	  of	  activated	  Wnt	  signalling,	  is	  also	  associated	  with	  the	  malignant	  transformation	  of	  squamous	  cell	  carcinoma	  of	  the	  oesophagus,	  adenocarcinoma	  of	  the	  stomach	  and	  adenocarcinoma	  of	  the	  colon	  (Ogasawara	  et	  al.,	  2006,	  Takayama	  et	  al.,	  1996).	  	  We	  have	  analysed	  β-­‐catenin	  localisation	  in	  skin	  papillomas	  by	  immunohistochemistry	  with	  anti-­‐β-­‐catenin	   antibody.	   Similarly	   to	   what	   had	   been	   demonstrated	   by	   Malanchi	   et	   al.	   (2008),	   some	  stainings,	  regardless	  of	  the	  genotype,	  displayed	  an	  increased	  accumulation	  of	  nuclear	  β-­‐catenin	  in	  the	   basal	   layer	   epithelium	   (Fig.	   R-­‐5),	  whereas	   the	   remaining	   epithelial	   cells	  were	   characterised	  mostly	  by	  membranous	  staining,	  which	  is	  typical	  for	  normal	  epithelium	  (Lee	  at	  al.,	  2012).	  	  
	  Figure	  R-­‐5.	   Immunohistochemistry	  staining	  of	  β-­‐catenin	   in	  a	  WT	  skin	  papilloma.	  The	  magnified	   image	  on	  the	  right	  is	  highlighted	  in	  the	  left	  picture.	  Black	  arrow:	  nuclear	  localisation	  of	  β-­‐catenin	  in	  the	  proximity	  to	  basal	  cells.	  White	  arrow:	  membranous	  localisation	  of	  β-­‐catenin	  in	  a	  non-­‐basal	  cell.	  No	  staining	  was	  detected	  in	  the	  absence	  of	  primary	  β-­‐catenin	  antibody.	  	  The	   analysis	   of	   β-­‐catenin	   in	   the	   papilloma	   samples	   from	   WT,	   p38γ-­‐	   and	   p38δ-­‐deficient	   mice	  revealed	   that	   there	   were	   no	   clear	   differences	   between	   the	   genotypes	   in	   either	   β-­‐catenin	  expression	  or	  its	  localisation	  (Fig.	  R-­‐6A).	  Additionally,	  we	  could	  not	  find	  clear	  pattern	  of	  β-­‐catenin	  expression	  within	  genotypes,	  some	  animals	  had	  higher	  β-­‐catenin	  expression	  in	  the	  tumours	  than	  in	  healthy	  skin	  and	  vice	  versa	  (Fig.	  R-­‐6B).	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Activation	   of	   the	   other	   protein,	   Akt,	   is	   also	   frequent	   in	   human	   cancers,	   including	   epithelial	  cancers.	   Genetically	   engineered	   squamous	   cell	   carcinoma	   lines,	   constitutively	   expressing	   Akt,	  have	   been	   shown	   to	   lose	   epithelial	   cell	   morphology	   and	   to	   acquire	   fibroblast-­‐like	   properties,	  undergoing	  epithelial-­‐to-­‐mesenchymal	  transition	  (Grille	  et	  al.,	  2003).	  	  We	   found	   that	   phosphorylated	   STAT3	   was	   detected	   mainly	   in	   nuclei	   of	   the	   cells	   forming	   the	  epithelium	   surrounding	   the	   tumour	   mass,	   whereas	   it	   was	   less	   abundantly	   expressed	   in	   more	  profoundly	  located	  cells.	  In	  contrast,	  phospho-­‐Akt	  was	  highly	  expressed	  in	  the	  cytoplasm	  of	  most	  of	  the	  epithelial	  cells	  of	  the	  papillomas.	  We	  observed	  similar	  levels	  of	  phosphorylated	  STAT3	  and	  phosphorylated	  Akt	  in	  all	  papilloma	  sections	  regardless	  of	  the	  genotype	  (Fig.	  R-­‐6A,	  B).	  Their	  total	  levels	  were	  similar	  too	  (Fig.	  R-­‐6B).	  	  	  The	  only	  exception	  concerning	  phosphorylated	  STAT3	  was	  found	  in	  the	  p38γ-­‐/-­‐	   tumour	  that	  was	  previously	   recognised	   as	   a	   progressed	   tumour	   (Fig.	   R-­‐7).	   Contrary	   to	   the	   benign	   papillomas,	  STAT3	  expression	  was	  increased	  in	  the	  majority	  of	  its	  cells,	  which	  supports	  the	  published	  data	  on	  its	  implication	  in	  squamous	  cell	  carcinoma	  progression	  (Chan	  et	  al.,	  2004).	  	  	  
	  Figure	  R-­‐7.	  Comparison	  of	  the	   localisation	  of	  phosphorylated	  STAT3	  between	  a	  benign	  skin	  papilloma	  (A)	  and	  a	  papilloma	  progressed	  to	  a	  carcinoma	  (B).	  The	  bottom	  images	  are	  enlarged	  sections	  highlighted	  in	  the	  upper	  images.	  Scale	  bars:	  200	  µm.	  
	  
1.4.	  Infiltration	  of	  inflammatory	  cells.	  It	  has	  been	  shown	   that	   there	   is	  an	   increase	   in	  neutrophils	   infiltrating	   the	   skin	  and	   the	   tumours	  during	  DMBA/TPA	  tumorigenesis.	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We	  confirmed	  the	  presence	  of	  neutrophils	  in	  the	  tumour	  epithelium	  and	  sub-­‐basal	  tumour	  stroma	  in	  skin	  papilloma	  samples	  by	   immunohistochemistry	  staining	  with	  anti-­‐myeloperoxidase	   (MPO)	  antibody	  and	  analysing	  MPO	  expression	  by	  immunoblotting	  (Fig.	  R-­‐8A,	  C).	  MPO	  might	  serve	  as	  a	  marker	   for	   tissue	   neutrophil	   content	   (Bradley	   et	   al.,	   1982).	   We	   observed	   that	   MPO-­‐positive	  neutrophils	  not	  only	  infiltrated	  the	  stroma,	  but	  also	  penetrated	  the	  basal	  membrane	  of	  the	  tumour	  in	  all	  genotypes	  (Fig.	  R-­‐8A).	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We	   did	   not	   observe	   differences	   in	   the	   levels	   of	   tumour-­‐infiltrating	   neutrophils	   between	   the	  genotypes	   (Fig.	   R-­‐8B).	   Contrary	   to	   the	   tumours,	   healthy	   skin	   from	   the	   same	   mouse	   was	  characterised	  by	  the	  absence	  of	  MPO	  expression	  detected	  by	  immunoblotting	  (Fig.	  R-­‐8C).	  
	  
1.5.	  Epithelial	  cell	  proliferation.	  Since	   epithelial	   cell	   proliferation	   is	   affected	   during	   tumorigenesis	   and	   uncontrolled	   growth	   of	  mutated	   cells	   leads	   to	   tumours	   formation,	   we	   analysed	   the	   proliferation	   in	   skin	   papillomas.	  Following	   the	   completion	   of	   the	   two-­‐stage	   skin	   tumorigenesis	   protocol,	   the	   proliferation	   was	  addressed	   in	   WT,	   p38γ-­‐/-­‐	   and	   p38δ-­‐/-­‐	   skin	   papilloma	   samples	   by	   BrdU	   staining	   and	   counting	  proliferating	  cells	  (Fig.	  R-­‐9A).	  No	  difference	  was	  observed	  between	  the	  genotypes	  (Fig.	  R-­‐9B).	  The	  average	  percentage	  of	  epithelial	   tumour	  cells	  undergoing	  proliferation	  (BrdU-­‐positive	  cells)	  was	  just	  above	  15%	  of	  total	  epithelial	  cells	  in	  each	  group.	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2.	  p38γ 	  and	  p38δ 	  are	  involved	  in	  early	  phases	  of	  skin	  tumorigenesis.	  	  In	  order	   to	   see	   if	  p38γ	   and	  p38δ	   regulate	   skin	   tumour	   formation	   in	   the	  early	   stages	  of	   the	   skin	  tumorigenesis	   we	   investigated,	   in	   WT,	   p38γ-­‐/-­‐,	   p38δ-­‐/-­‐	   and	   p38γ/δ-­‐/-­‐	   mice,	   epithelial	   cell	  proliferation,	  treating	  the	  skin	  with	  a	  single	  dose	  of	  TPA,	  and	  apoptosis	  after	  DMBA	  treatment.	  
	  
2.1.	  Epithelial	  cell	  proliferation.	  In	   a	   two-­‐stage	   tumorigenesis	   application	   of	   the	   promoter	   TPA,	   during	   the	   promotion	   stage,	  produces	  hyperplasia,	  which	  is	  an	  increased	  cells	  proliferation.	  	  	  WT,	  p38γ-­‐/-­‐,	  p38δ-­‐/-­‐	  and	  p38γ/δ-­‐/-­‐	  mice	  were	  treated	  once	  with	  TPA	  and	  sacrificed	  32	  hours	  later.	  The	  skin	  was	  excised	  and	  the	  samples	  were	  processed	  for	  HE	  and	  BrdU	  staining	  (Fig.	  R-­‐10).	  We	  have	   measured	   the	   increase	   in	   epithelial	   layer	   thickness	   caused	   by	   hyperplasia	   in	   HE-­‐stained	  sections.	   After	   TPA	   treatment	   the	   increase	   in	   epidermal	   thickness	  was	   significantly	   reduced	   in	  p38γ-­‐/-­‐,	  p38δ-­‐/-­‐	  and	  p38γ/δ-­‐/-­‐	  mice	  compared	  to	  WT	  mice	  (Fig.	  R-­‐10A).	  This	  reduction	  was	  similar	  in	   all	   p38-­‐deficient	   mice.	   We	   also	   found	   that	   the	   skin	   of	   p38γ-­‐/-­‐,	   p38δ-­‐/-­‐	   and	   p38γ/δ-­‐/-­‐	   mice	  contained	   fewer	   cells	   undergoing	   proliferation	   when	   compared	   with	   WT	   (Fig.	   R-­‐10B).	   These	  results	  correlated	  with	  the	  epidermal	  thickness	  measured	  in	  these	  samples	  and	  suggested	  that	  the	  affected	  proliferation	  can	  be,	  at	  least	  partially,	  a	  mechanism	  underlying	  the	  reduced	  sensitivity	  of	  p38δ-­‐/-­‐	  and	  p38γ/δ-­‐/-­‐	  mice	   to	  a	   two-­‐stage	  protocol.	  The	  results	  on	  p38γ-­‐/-­‐,	  however,	   indicate	   the	  existance	   of	   an	   additional	   factor(s),	   because	   the	   p38γ-­‐/-­‐	   response	   to	   the	   DMBA/TPA	   tumour	  induction	  resembled	  wild	  type	  phenotype.	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Figure	  R-­‐10.	  The	  previous	  page.	  (A)	  Upper	  panel:	  HE	  staining	  of	  epidermis	  and	  dermis	  in	  skin	  of	  WT,	  p38γ-­‐/-­‐,	  p38δ-­‐/-­‐	   and	   p38γ/δ-­‐/-­‐	   mice	   treated	   or	   not	  with	   TPA.	   Scale	   bars:	   100	  µm.	   Bottom	   panel:	  measurement	   of	  epidermal	  thickness	  (n=4).	  (B)	  Upper	  panel:	  Immunofluorescent	  staining	  of	  BrdU	  in	  WT,	  p38γ-­‐/-­‐,	  p38δ-­‐/-­‐	  and	  p38γ/δ-­‐/-­‐	   skin	   treated	  with	  TPA.	  Merge	   images	  represent	   total	  nuclei,	   including	  BrdU-­‐positive.	  Scale	  bars:	  50	  µm.	  Bottom	  panel:	  quantification	  of	  BrdU-­‐positive	  nuclei	  in	  12	  fields	  per	  mouse	  (n=4).	  (A,	  B)	  Results	  are	  means	  +/-­‐	  SEM.	  *P<0.05,	  **P<0.01,	  ***P<0.001	  compared	  with	  TPA-­‐treated	  WT	  (two-­‐tailed	  Student’s	  t-­‐test).	  
	  
2.2.	  Apoptosis.	  The	  carcinogen	  DMBA	  used	  in	  the	  initiation	  stage	  of	  the	  chemically-­‐induced	  skin	  carcinogenesis,	  apart	   from	   exerting	   a	  mutagenic	   effect	   on	   epidermal	   cells,	   also	   provokes	   apoptosis,	  which	  may	  contribute	  to	  an	  overall	  outcome	  of	  skin	  tumours	  in	  DMBA/TPA-­‐treated	  mice.	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By	  TUNEL	  staining	  we	  observed	  that	  DMBA	  induced	  cell	  apoptosis	  in	  the	  epidermis	  of	  all	  mice	  to	  a	  similar	   extent	   comparing	   with	   control	   WT	   mice	   (Fig.	   R-­‐11).	   This	   was	   observed	   both	   in	   the	  interfollicular	   epidermis	   and	   in	   epidermal	   cells	   forming	   hair	   follicles.	   Of	   note,	   the	   apoptosis	  predominantly	   took	   place	   in	   follicular	   epidermis	   and	   was	   less	   frequent	   in	   the	   proper	   skin	  epithelium.	  
	  
3.	  p38γ 	  and	  p38δ 	  are	  implicated	  in	  TPA-­‐induced	  skin	  inflammation.	  	  Acting	   as	   promoting	   agents,	   phorbol	   esters	   also	   drive	   inflammatory	   events	   in	   a	   two-­‐stage	   skin	  tumorigenesis.	  For	  this	  reason	  responses	  associated	  with	  TPA-­‐induced	  inflammation	  are	  routinely	  considered	   as	   markers	   of	   tumour	   promotion	   and	   include	   acute	   inflammatory	   events	   such	   as	  oedema,	   neutrophils	   infiltration	   and	   the	   production	   of	   inflammatory	  molecules.	   Since	   we	   have	  shown	  that	   lack	  of	  both	  p38γ	   and	  p38δ	   impaired	   the	   inflammatory	  response	   in	  different	  animal	  models	  such	  as	  septic	  shock	  (Risco	  et	  al.,	  2012),	  arthritis	  (Criado	  et	  al.,	  2014)	  or	  colitis	  (del	  Reino	  et	  al.,	  2014),	  we	  then	  analysed	  whether	  p38γ/δ	  deletion	  affected	  the	  skin	  inflammatory	  response	  to	  TPA	  and	  was	  a	  potential	  mechanism	  contributing	  to	  decreased	  tumorigenesis.	  	  
3.1.	  Oedema.	  The	  most	  visible	  marker	  after	  skin	  exposure	  to	  a	  phorbol	  is	  intercellular	  oedema,	  an	  accumulation	  of	   fluid	   in	   the	   dermal	   and	   hypodermal	   part	   of	   the	   skin	   in	   response	   to	   the	   chemical	   induction,	  which	  is	  easily	  observed	  in	  a	  standard	  HE	  staining.	  	  	  
	  	  	  	  	   	  Figure	  R-­‐12.	  (A)	  Representative	  pictures	  of	  HE	  staining	  of	  skin	  after	  TPA	  treatment.	  Scale	  bars:	  200	  µm.	  (B)	  Skin	  thickness	  measurement	  at	  different	  times	  after	  a	  single	  dose	  of	  TPA	  in	  WT	  and	  p38γ/δ-­‐/-­‐	  mice	  (n=3).	  Results	  are	  means	  +/-­‐	  SEM.	  	  We	  treated	  p38γ/δ-­‐/-­‐	  and	  WT	  mice	  with	  a	  single	  application	  of	  10	  µg	  of	  TPA	  onto	  shaved	  dorsal	  skin	   that	   led	   to	   an	   increase	   in	   skin	   thickness	   that	   was	   maintained	   for	   24	   hours	   (Fig.	   R-­‐12A).	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Histological	  analysis	  showed	  no	  significant	  differences	  in	  skin	  thickness	  between	  WT	  and	  p38γ/δ-­‐deficient	  mice	  (Fig.	  R-­‐12B).	  	  
3.2.	  Early	  production	  of	  inflammation	  mediators.	  The	  production	  of	  cytokines	  and	  chemokines	   in	  the	  skin	   is	  a	  common	  indicator	  of	   inflammatory	  processes	  in	  the	  tissue.	  Keratinocytes,	  fibroblasts	  and	  skin	  immune	  cells	  are	  the	  main	  sources	  of	  inflammation	  mediators	  during	  the	   first	  hours	  after	  exposure	  to	  TPA,	  because	  they	  are	  either	   in	  direct	   contact	   or	   in	   the	   closest	   proximity	   to	   the	   site	   of	   treatment.	   Immune	   cells,	   such	   as	  macrophages,	  neutrophils	  and	   lymphocytes	   infiltrating	  subcutis,	  dermis	  and	   finally	  dermis	   from	  skin	  blood	   vessels	   in	   response	   to	   skin-­‐derived	   chemokines,	   produce	   their	   own	   immune	   factors,	  contributing	   to	   the	   overall	   inflammation	   severity	   during	   the	   acute	   phase	   of	   skin	   inflammation	  (Tay	  et	  al.,	  2013).	  	  	  
	  	  	  	  
	  	  	  	  	  	  Figure	  R-­‐13.	  Expression	  of	  IL-­‐1β,	   IL-­‐6,	  TNF-­‐α,	  KC	  (CXCL1),	  MIP-­‐2	  (CXCL2)	  and	  TGF-­‐β	   in	  the	  skin	  from	  WT	  and	  p38γ/δ-­‐/-­‐	  mice	  treated	  or	  not	  with	  TPA	  and	  sacrificed	  at	  different	  times	  following	  the	  treatment.	  Results	  were	   normalised	   to	   GAPDH	   mRNA	   and	   represented	   in	   arbitrary	   units	   as	   means	   +/-­‐	   SEM,	   where	   one	  corresponds	   to	   a	   WT	   control	   (n=3).	   *P<0.05,	   ***P<0.001.	   Non-­‐significant	   P	   values	   <0.1	   are	   shown	   as	  numbers	  (two-­‐tailed	  Student’s	  t-­‐test).	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We	  then	  checked	  mRNA	  levels	  of	  cytokines	  and	  chemokines	  produced	  in	   inflamed	  skin	  after	  the	  treatment	  with	  TPA	  in	  WT	  and	  p38γ/δ-­‐/-­‐	  mice.	  We	  measured	  cytokines,	  such	  as:	  IL-­‐1β,	  IL-­‐6,	  TNF-­‐α	  and	  TGF-­‐β	  and	  two	  chemokines:	  keratinocyte-­‐derived	  chemokine	  (KC,	  known	  as	  CXCL1	  in	  human)	  and	  macrophage-­‐inflammatory	  protein-­‐2	  (MIP-­‐2	  or	  CXCL2).	  Mouse	  skin	  was	  treated	  once	  with	  10	  
µg	  of	  TPA	  and	  processed	  for	  total	  RNA	  extraction,	  cDNA	  production	  and	  RT-­‐qPCR	  analysis,	  after	  either	   4,	   8	   or	   12	   hours,	   according	   to	   the	   protocol	   described	   in	   paragraph	   3.3	   of	  Materials	   and	  Methods.	  The	  results	  are	  shown	  in	  Figure	  R-­‐13.	  	  We	   observed	   time-­‐dependent	   induction	   in	   mRNA	   levels	   of	   all	   genes	   in	   both	   WT	   and	   p38γ/δ-­‐deficient	   mice,	   which	   means	   that	   all	   the	   proteins	   take	   part	   in	   TPA-­‐induced	   inflammatory	  processes	   in	  mouse	   skin.	   In	  particular,	   the	  production	  of	   IL-­‐1β,	   IL-­‐6,	  KC	  and	  MIP-­‐2	   reached	   the	  highest	   level	   at	  4	  hours	   after	  TPA,	   in	  both	  WT	  and	  p38γ/δ-­‐/-­‐	   skin,	   and	  decreased	  afterwards.	   In	  contrast,	   the	   levels	   of	   TNF-­‐α	   and	  TGF-­‐β	  were	  moderately	   increased	   at	   4	   hours	   comparing	  with	  controls	  and	  reached	  the	  highest	  level	  at	  8	  hours,	  decreasing	  12	  hours	  after	  TPA.	  	  	  Interestingly,	  the	  expression	  of	  all	  genes	  in	  the	  skin	  of	  p38γ/δ-­‐deficient	  mice	  was	  smaller,	  except	  for	   TGF-­‐β,	   than	   in	  WT.	   In	   particular,	   the	   skin	   from	   p38γ/δ-­‐/-­‐	   mice	   had	   significantly	   (or	   almost	  significantly,	  P<0.1)	   less	   IL-­‐1β,	   IL-­‐6,	  KC,	  MIP-­‐2	  and	  TNF-­‐α	   than	  WT,	  mainly	  at	  8	  hours	  after	   the	  treatment.	  These	  observations	   indicate	   the	   implication	  of	  p38γ	  and/or	  p38δ	   in	   the	  regulation	  of	  the	  cytokine/chemokine-­‐based	  inflammatory	  status	  in	  TPA-­‐treated	  skin.	  	  To	  examine	  which	  p38	  isoform	  was	  the	  main	  regulator	  in	  skin	  cytokine	  production	  we	  measured	  the	  above	  mentioned	  genes	  in	  mice	  deficient	  in	  p38γ	  or	  deficient	  in	  p38δ	  alone.	  Having	  observed	  the	  most	  significant	  differences	  between	  WT	  and	  p38γ/δ-­‐/-­‐	  mice	  at	  8	  hours	  after	  TPA	  challenge,	  we	  decided	  to	  measure	  the	  mRNA	  levels	  in	  single	  knock-­‐out	  mice	  8	  hours	  after	  TPA	  (Fig.	  R-­‐14).	  	  As	   expected,	   there	   was	   no	   difference	   between	   the	   three	   genotypes	   in	   the	   case	   of	   TGF-­‐β.	   The	  deletion	  of	  p38δ	  alone	  in	  mice	  treated	  with	  TPA	  led	  to	  relatively	  smaller	  induction	  of	  IL-­‐1β,	  IL-­‐6,	  TNF-­‐α,	  KC	  and	  MIP-­‐2	  mRNA	   levels	   comparing	  with	  WT.	  However,	  only	   in	   the	  case	  of	  MIP-­‐2	   the	  difference	  was	  statistically	  significant	  (P<0.05).	  In	  the	  case	  of	  the	  p38γ	  deletion,	  it	  led	  to	  a	  smaller	  induction	   of	   TNF-­‐α	   and	   MIP-­‐2	   comparing	   with	   WT,	   although	   none	   of	   the	   differences	   was	  statistically	  significant.	  These	  data	  suggest	  an	  implication	  of	  both	  p38s	  in	  the	  regulation	  of	  some	  inflammatory	   mediators	   in	   the	   skin	   on	   the	   one	   hand,	   and	   a	   possible	   synergistic	   effect	   of	   the	  deletion	  of	  both	  p38s	  in	  these	  processes,	  on	  the	  other.	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  Figure	  R-­‐14.	  Expression	  of	  IL-­‐1β,	  IL-­‐6,	  TNF-­‐α,	  KC	  (CXCL1),	  MIP-­‐2	  (CXCL2)	  and	  TGF-­‐β	  in	  the	  skin	  from	  WT,	  p38γ-­‐/-­‐	   and	  p38δ-­‐/-­‐	  mice	   treated	  or	  not	  with	  TPA	  and	  sacrificed	  8	  hours	  after	   the	   treatment.	  Results	  were	  normalised	  to	  GAPDH	  mRNA	  and	  represented	  in	  arbitrary	  units	  as	  means	  +/-­‐	  SEM,	  where	  one	  corresponds	  to	  a	  WT	  control	  (n=3).	  *P<0.05.	  Non-­‐significant	  P	  values	  <0.1	  is	  indicated	  numerically	  (two-­‐tailed	  Student’s	  t-­‐test).	  	  	  
	  
3.3.	  Inflammatory	  cells	  infiltration.	  TPA	   treatment	   in	   its	  acute	  phase,	   just	  after	   the	  exposure,	   is	   also	   characterised	  by	   inflammatory	  cells	   infiltration	   into	   the	   skin,	   including	   lymphocytes	   and	   polymorphonuclear	   leukocytes,	  neutrophils.	  	  In	   order	   to	   examine	   lymphocytes	   recruitment	  we	   stained	   skin	   sections	   from	  WT	   and	   p38γ/δ-­‐/-­‐	  control	   mice	   and	   mice	   treated	   with	   TPA,	   12	   or	   24	   hours	   prior	   to	   sacrifice,	   with	   CD3-­‐specific	  antibodies	  and	  analysed	  by	  fluorescent	  microscopy	  (Fig.	  R-­‐15A).	  Anti-­‐CD3	  antibody	  recognises	  T	  cell	  lymphocytes.	  There	  was	  a	  time-­‐dependent	  increase	  in	  the	  lymphocyte	  population	  infiltrating	  inflamed	   skin	   after	  TPA	   treatment;	  however,	  we	  did	  not	  observe	  any	  differences	   in	  numbers	  of	  CD3-­‐positive	  cells	  between	  WT	  and	  p38γ/δ-­‐deficient	  mice	  (Fig.	  R-­‐15B).	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  Figure	  R-­‐16.	  Neutrophils	  recruitment	  in	  TPA-­‐treated	  skin	  in	  WT	  mice.	  (A)	  HE	  staining	  of	  the	  skin	  at	  12	  and	  24	   hours	   after	   TPA	   treatment	   showing	   neutrophils	   infiltrating	   dermal	   and	   hypodermal	   regions	   of	   skin	  (black	  arrows).	  Scale	  bars:	  20	  µm.	  (B)	  Immunoblot	  of	  MPO	  in	  total	  protein	  lysates	  from	  WT	  skin	  at	  different	  times	  after	  TPA	  challenge.	  ERK1/2	  was	  used	  as	  loading	  control.	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3.4.	  Late	  production	  of	  inflammation	  mediators.	  It	  has	  been	  demonstrated	   that	   the	  production	  of	   cytokines	  and	  chemokines	   in	  TPA-­‐treated	  skin	  might	  be	  restored	  in	  the	  presence	  of	  immune	  cells,	  accumulating	  in	  the	  inflamed	  skin	  (Gebhardt	  et	  al.,	  2008).	  Bearing	  this	  in	  mind,	  we	  supposed	  that	  the	  decrease	  in	  the	  production	  of	  inflammatory	  mediators	  observed	  at	  12	  hours	  following	  TPA	  treatment	  (Fig.	  R-­‐13)	  might	  only	  be	  transient.	  As	  expected,	   when	   we	   checked	   the	   mRNA	   production	   of	   the	   previously	   measured	   genes,	   we	  confirmed	  that	  at	  24	  hours	  there	  was	  a	  dramatic	  increase	  in	  the	  mRNA	  expression	  of	  three	  out	  of	  four	   measured	   genes:	   IL-­‐1β,	   IL-­‐6,	   MIP-­‐2	   (CXCL2)	   and	   TNF-­‐α.	   While	   MIP-­‐2	   was	   efficiently	  recovered,	   the	   level	   of	   IL-­‐6	  mRNA	  was	   lower	   at	   24	   hours	   than	   at	   12	   hours,	   indicating	   that	   the	  restoration	  did	  not	  take	  place	  (Fig.	  R-­‐18).	  The	  remaining	  two	  genes,	  Il-­‐1β	  and	  Tnf-­‐α	  were	  partially	  brought	  back	  to	  a	  higher	  level.	  	  
	   	  	  Figure	  R-­‐18.	  Production	  of	  IL-­‐1β,	  IL-­‐6,	  MIP-­‐2	  and	  TNF-­‐α	  in	  the	  WT	  skin	  at	  4,	  12,	  24	  and	  31	  hours	  after	  TPA	  treatment.	  Results	  were	  normalised	  to	  GAPDH	  mRNA	  and	  represented	  in	  arbitrary	  units	  as	  means	  +/-­‐	  SEM,	  where	  one	  corresponds	  to	  control	  (n=3).	  	  	  In	   order	   to	   establish	   a	   possible	   contribution	   of	   the	   p38γ/δ	   deficiency	   to	   the	   production	   of	  inflammatory	  factors	   in	  the	  skin	  at	   longer	  times	  after	  TPA	  treatment,	  WT	  and	  p38γ/δ	  knock-­‐out	  mice	  were	  treated	  once	  with	  TPA	  and	  sacrificed	  at	  12,	  24	  and	  31	  hours	  later.	  The	  mRNA	  levels	  of	  IL-­‐1β,	   IL-­‐6,	  MIP-­‐2	  (CXCL2)	  and	  TNF-­‐α	  were	  measured	  by	  qPCR	  in	  total	  RNA	  extracted	  from	  skin	  necropsies	   and	   shown	   in	   Figure	   R-­‐19.	   Expectedly,	   WT	   mice	   were	   characterised	   by	   a	   growing	  expression	  of	  IL-­‐1β,	  MIP-­‐2	  and	  TNF-­‐α	  at	  12	  and	  24	  hours	  and	  a	  subsequent	  decrease,	  whereas	  IL-­‐6	  was	  at	  the	  similar	  levels	  at	  12	  and	  24	  hours	  and	  close	  to	  control	  level	  at	  31	  hours.	  At	  24	  hours	  after	  TPA,	  mice	  deficient	   in	  both	  p38γ	   and	  p38δ	  had	  an	   impaired	  production	  of	   IL-­‐1β	   (*P<0.05)	  and	   MIP-­‐2	   (**P<0.01),	   and	   a	   slightly	   lower	   increase	   of	   TNF-­‐α	   (P<0.1),	   as	   compared	   with	   WT.	  Interestingly,	  the	  level	  of	  IL-­‐6,	  which	  did	  not	  grow	  at	  24	  hours	  in	  WT,	  was	  found	  to	  be	  significantly	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lower	   in	   p38γ/δ-­‐/-­‐	  mice,	   indicating	   a	   sooner	   decrease	   of	   this	   cytokine	   in	   the	  mutants	   under	   the	  same	  conditions.	  	  
	  	  	  	  	   	  	  
	  	  	  	  	  	  	  	  	   	  Figure	  R-­‐19.	  Expression	  of	   IL-­‐1β,	   IL-­‐6,	  TNF-­‐α	  and	  MIP-­‐2	  (CXCL2)	   in	   the	  skin	   from	  WT	  and	  p38γ/δ-­‐/-­‐	  mice	  treated	  or	  not	  with	  TPA	  and	  sacrificed	  at	  different	  times	  following	  the	  treatment.	  Results	  were	  normalised	  to	  GAPDH	  mRNA	  and	   represented	   in	   arbitrary	  units	   as	  means	  +/-­‐	   SEM,	  where	   one	   corresponds	   to	   a	  WT	  control	   (n=3).	   *P<0.05,	   **P<0.01.	   Non-­‐significant	   P	   value	   <0.1	   is	   represented	   numerically	   (two-­‐tailed	  Student’s	  t-­‐test).	  	  	  Overall,	   the	   time	   of	   the	   second	  wave	   of	   inflammation	  mediators’	   production	   in	   the	   skin	   of	  WT	  mice	   exposed	   to	   TPA	   coincides	   with	   the	   peak	   of	   lymphocytes	   and	   neutrophils	   infiltration	   as	  shown	   in	   section	  3.3	   of	  Results.	   The	   smaller	  numbers	  of	   neutrophils	   in	   the	  TPA-­‐treated	   skin	  of	  p38γ/δ-­‐deficient	  mice	  coincides,	  besides,	  with	  a	  decreased	  production	  of	  IL-­‐1β,	  IL-­‐6	  and	  MIP-­‐2,	  all	  evidenced	  to	  be	  products	  of	  neutrophils	  (Fridlender	  and	  Albelda,	  2012).	  	  	  
3.5.	  Signalling	  pathways	  activation	  in	  TPA-­‐treated	  skin.	  TPA	  is	  known	  to	  activate	  different	  signalling	  pathways	  implicated	  in	  skin	  inflammation.	  In	  order	  to	  check	  TPA-­‐dependent	  signalling	  activation	  in	  skin	  of	  WT,	  p38γ-­‐/-­‐,	  p38δ-­‐/-­‐	  and	  p38γ/δ-­‐/-­‐	  mice,	  we	  prepared	   total	   protein	   lysates	   from	   skin	   at	   different	   times	   after	   TPA	   treatment	   and	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immunoblotted	  them	  with	  specific	  antibodies	  for	  activated	  (phosphorylated)	  p38,	  JNK1/2,	  NFκB-­‐p105,	   STAT3	   and	   ERK1/2.	   Moreover,	   we	   checked	   total	   levels	   (phosphorylated	   and	   un-­‐phosphorylated)	   of	   these	   proteins,	   as	  well	   as	   the	   expression	   of	   p38γ	   and	   p38δ	   under	   the	   same	  conditions.	  	  
3.5.1.	  p38	  MAPKs.	  First	  we	  checked	  the	  activation	  of	  p38	  MAPKs	  in	  TPA-­‐treated	  skin	  of	  WT	  and	  p38γ/δ-­‐/-­‐	  mice	  using	  anti-­‐phospho	  p38	  antibody	  (Fig.	  R-­‐20).	  The	  p38α	  isoform	  was	  activated	  as	  early	  as	  at	  30	  min	  after	  the	   treatment	   in	   both	   genotypes	   (Fig.	   R-­‐20A).	   Phospho-­‐p38γ	   could	   also	   be	   detected	   by	  immunoblot	  from	  total	  lysates	  (Fig.	  R-­‐20A).	  The	  phosphorylation	  of	  p38γ	  and	  p38δ	  was	  checked	  by	   immunoprecipitation	   of	   these	   proteins	   from	   total	   protein	   lysates	   two	   hours	   after	   TPA	  treatment	   and	   immunoblotting	   with	   anti-­‐phospho	   p38	   antibody	   (Fig.	   R-­‐20B	   and	   R-­‐20C,	  respectively).	  	  
	  	  Figure	  R-­‐20.	  Activation	  of	  p38α,	  p38γ	  and	  p38δ	  in	  the	  skin	  from	  WT	  and	  p38γ/δ-­‐/-­‐	  mice	  in	  response	  to	  TPA.	  (A)	   Immunoblot	   of	   p38α,	   p38γ,	   p38δ	   and	   phospho-­‐p38	   at	   different	   times	   after	   the	   treatment.	   (B,	   C)	  Immunoblots	  of	  immunoprecipitation	  with,	  respectively,	  p38γ	  and	  p38δ	  antibodies	  in	  skin	  lysates	  from	  WT	  mice	  treated	  or	  not	  with	  TPA	  (2	  hours).	  The	  upper	  blots	  were	   incubated	  with	  anti-­‐phospho	  p38	  antibody	  and	  the	  bottom	  ones	  –	  with	  a	  specific	  anti-­‐p38γ	  (B)	  or	  p38δ	  (C)	  antibody.	  	  	  We	  then	  wanted	  to	  check	  if	  p38γ	   is	  also	  phosphorylated	  in	  p38δ-­‐/-­‐	  mice	  and	  p38δ	   in	  p38γ-­‐/-­‐	  mice	  under	   the	   same	   conditions	   (Fig.	   R-­‐21A).	   Since	   the	   phospho-­‐p38δ	   band	   was	   detected	   in	   a	   very	  close	   proximity	   to	   the	   phospho-­‐p38α	   band,	   the	   phosphorylation	   of	   p38δ	   in	   p38γ-­‐/-­‐	   mice	   was	  confirmed	   by	   immunoprecipitation	   (Fig.	   R-­‐21B).	   The	   results	   showed	   that	   TPA	   led	   to	   the	  phosphorylation	   of	   p38δ	   in	   these	   mice.	   Interestingly,	   we	   observed	   that	   TPA-­‐induced	   p38γ	  phosphorylation	   in	   mice	   lacking	   p38δ	   was	   severely	   impaired	   (Fig.	   R-­‐21A).	   Taking	   into	  consideration	   that	   the	   observed	   disruption	   in	   p38γ	   phosphorylation	   could	   be	   due	   to	   a	   delay	   in	  p38γ	  activation,	  we	  also	  checked	  the	  phospho-­‐p38γ	  at	  longer	  times	  following	  the	  TPA	  treatment	  in	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WT	  and	  p38δ-­‐/-­‐	  mice	  (Fig.	  R-­‐21C,	  D).	  This	  time,	  we	  observed	  a	  weak	  band	  not	  only	  at	  4	  hours	  but	  also	  at	  2	  hours	  in	  p38δ-­‐/-­‐	  mice.	  Nonetheless,	  we	  confirmed	  that	  p38γ	  phosphorylation	  was	  affected	  in	  these	  mice	  comparing	  with	  WT	  (Fig.	  R-­‐21C,	  D).	  	  
      
                                                                                                          Time (h)	  	  Figure	  R-­‐21.	  Activation	  of	  p38γ	  and	  p38δ	  in	  the	  skin	  from	  WT,	  p38γ-­‐/-­‐	  and	  p38δ-­‐/-­‐	  mice	  in	  response	  to	  TPA	  treatment.	   (A)	   Immunoblot	   of	   p38α,	   p38γ,	   p38δ	   and	   phospho-­‐p38	   at	   0,	   1	   and	   2	   hours	   after	   TPA.	   (B)	  Immunoblots	   of	   p38δ	   immunoprecipitation	   in	   skin	   lysates	   from	  WT	  and	  p38γ-­‐/-­‐	  mice	   treated	  or	  not	  with	  TPA	  (2	  hours).	  The	  upper	  blots	  were	  incubated	  with	  anti-­‐phospho	  p38	  antibody	  and	  the	  bottom	  ones	  –	  with	  specific	  anti-­‐p38δ	  antibody.	  (C)	  Immunoblot	  of	  p38α,	  p38γ,	  p38δ	  and	  phospho-­‐p38γ	  in	  WT	  and	  p38δ-­‐/-­‐	  mice.	  (D)	  Phospho-­‐p38γ	  bands	  intensity	  in	  WT	  and	  p38δ-­‐/-­‐	  mice	  normalised	  to	  total	  p38γ	  protein	  and	  represented	  in	  arbitrary	  units.	  	  	  We	  concluded	  that	  p38δ	  deficiency	  leads	  to	  a	  blockade	  in	  the	  phosphorylation	  of	  p38γ	   in	  skin	  in	  response	  to	  TPA,	  suggesting	  that	  p38δ	  regulates	  p38γ	  phosphorylation	  under	  these	  conditions.	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be	   due	   to	   the	   loading	   variability,	   phospho-­‐STAT3	   was	   diminished	   in	   p38γ/δ-­‐deficient	   mice	  compared	  with	  WT	  (Fig.	  R-­‐22C).	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In	   order	   to	   check	  whether	   the	   lack	   of	   either	   p38γ	   or	   p38δ	   alone	   affected	   STAT3	   signalling	  we	  measured	  phospho-­‐STAT3	   in	  p38γ-­‐/-­‐	   and	  p38δ-­‐/-­‐	  mice	  under	   the	   same	  conditions	  and	  compared	  them	  with	  WT	  (Fig.	  R-­‐22D).	   	   In	  both	  cases	  STAT3	  phosphorylation	  was	  affected	  only	  during	  the	  fist	  hour	  and	  resembled	  WT	  afterwards,	  reaching	  the	  maximum	  at	  4	  hours.	  	  
3.5.3.	  β-­‐catenin.	  Epithelial-­‐to-­‐mesenchymal	   transition	   (EMT)	   often	   occurs	   during	   the	   progression	   of	   many	  epithelial	  tumours	  and	  may	  be	  regulated	  by	  β-­‐catenin.	  There	  are	  published	  data	  on	  TPA-­‐induced	  EMT,	  in	  which	  β-­‐catenin	  plays	  important	  roles	  (Zucchini-­‐Pascal	  et	  al.,	  2013).	  There	  is	  also	  growing	  evidence	  that	  it	  is	  required	  for	  development	  of	  non-­‐melanoma	  skin	  cancers	  (Beronja	  et	  al.,	  2013).	  	  
	  	  	  	  	  	   	  	  	  	  	  	  	  	  	   	  Figure	  R-­‐23.	  β-­‐catenin	  expression	  in	  non-­‐treated	  and	  TPA-­‐treated	  skin.	  (A)	  Immunoblot	  of	  β-­‐catenin	  and	  HE	  staining	  of	  the	  skin	  of	  three	  WT	  mice:	  one	  in	  anagen	  (WT1)	  and	  two	  in	  telogen	  (WT2,	  WT3).	  Scale	  bars:	  100	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We	  observed	   that	  β-­‐catenin	   in	   the	   skin	   is	   abundantly	   expressed	   in	   keratinocytes	   found	  both	   in	  interfollicular	   epidermis	   (Fig.	   R-­‐23C)	   and	   hair	   follicles.	   To	   produce	   new	   hairs,	   existing	   hair	  follicles	  undergo	  cycles	  of	  growth	  (anagen),	  regression	  (catagen)	  and	  rest	  (telogen)	  (Alonso	  and	  Fuchs,	   2006).	   Unsurprisingly,	   therefore,	   the	   skin	   at	   growth	   phase	   of	   the	   hair	   cycle,	   which	   is	  characterised	  by	  the	  penetration	  of	  the	  follicular	  epidermis	  into	  deeper	  layers	  of	  the	  skin,	  contains	  much	  more	  β-­‐catenin	   than	   the	   skin	   in	   a	   resting	   phase	   as	   observed	   by	   immunoblotting	   (Fig.	   R-­‐23A).	  	  
We	   investigated	   whether	   the	   expression	   of	   β-­‐catenin	   in	   murine	   skin	   changes	   in	   response	   to	   a	  single	  topical	  TPA	  treatment	  at	  the	  concentration	  used	  in	  the	  DMBA/TPA	  protocol.	  We	  observed	  a	  decrease	   in	   β-­‐catenin	   expression	   between	   untreated	   and	   TPA-­‐treated	   skin	   in	   both	   WT	   and	  p38γ/δ-­‐/-­‐	  mice	  (Fig.	  R-­‐23B).	  This	  downregulation	  was	  detected	  at	  8	  hours	  after	  the	  treatment	  and	  the	  β-­‐catenin	  levels	  were	  even	  lower	  at	  12	  hours	  and	  started	  to	  recover	  afterwards.	  At	  48	  hours	  β-­‐catenin	  was	  expressed	  at	  the	  basal	  level	  (data	  not	  shown).	  The	  immunohistochemistry	  staining	  of	  
β-­‐catenin	   confirmed	   the	   decrease	   in	   β-­‐catenin	   expression	   in	   epidermal	   keratinocytes	   in	   both	  genotypes	  (Fig.	  R-­‐23B).	  The	  downregulation	  of	  β-­‐catenin	  was	  observed	  only	  at	  the	  protein	  level	  because	  its	  mRNA	  did	  not	  change	   after	   TPA	   treatment	   (Fig.	   R-­‐23D).	   This	   suggests	   an	   existence	   of	   β-­‐catenin	   post-­‐transcriptional	   regulation	   in	   TPA-­‐treated	   mouse	   skin,	   which	   is,	   however,	   independent	   on	   the	  p38γ/δ	  proteins.	  
	  
4.	  Xenograft	  A-­‐431	  tumour	  growth	  is	  dependent	  on	  p38γ 	  and	  p38δ .	  	  We	   had	   observed	   that	   the	   mice	   deficient	   in	   both	   p38γ	   and	   p38δ	   were	   highly	   resistant	   to	   an	  induced	  skin	  carcinogenesis	  in	  the	  DMBA/TPA	  protocol.	  We	  hypothesised,	  that	  the	  aggressiveness	  of	   cell	   growth	   in	   epithelial	   tumours	   might	   depend	   on	   the	   p38γ/δ	   expression.	   To	   address	   this	  question	  we	   performed	   xenotransplantation	   of	   human	   epidermoid	   (squamous)	   cancer	   cells	   (A-­‐431)	  (Giard	  et	  al.,	  1973)	  with	  depleted	  p38γ,	  p38δ	  and	  both	  p38γ	  and	  p38δ,	   into	  athymic	  (Swiss	  nu/nu	  Nu(Ico)-­‐Fox	  n1nu)	  mice.	  
	  
4.1.	  Establishment	  of	  p38γ-­‐	  and	  p38δ-­‐knock-­‐down	  A-­‐431	  cells.	  In	  order	   to	  obtain	   stable	   clones	  of	  A-­‐431	  cells	  deficient	   in	  p38γ	   and/or	  p38δ	  we	  used	   lentiviral	  transduction	   as	   described	   in	   sections	   2.3	   and	   2.4	   of	   Materials	   and	  Methods.	  We	   chose	   pLKO.1	  vectors	  with	  different	   short-­‐hairpin	  RNAs	  (shRNA),	  designed	   to	  downregulate	   the	  expression	  of	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either	  p38γ	  or	  p38δ	  (four	  with	  p38γ	  shRNA	  and	  six	  with	  p38δ	  shRNA).	  We	  screened	  these	  shRNAs	  for	  silencing	  efficiency	  (Fig.	  R-­‐24).	  Three	  p38γ	  shRNAs	  and	  three	  p38δ	  shRNAs	  highly	  silenced	  the	  expression	   of	   the	   corresponding	   genes,	   as	   observed	   by	   immunoblotting	  with	   specific	   anti-­‐p38γ	  and	  anti-­‐p38δ	  antibodies.	  
	  	  Figure	  R-­‐24.	  Immunoblot	  of	  p38γ	  (A)	  and	  p38δ	  (B)	  in	  30	  µg	  of	  total	  protein	  lysate	  from	  non-­‐transduced	  A-­‐431	   cells	   (no	   infection)	   and	   cells	   transduced	   with	   p38γ	   shRNAs	   (clones	   145,	   147,	   148,	   149)	   and	   p38δ	  shRNAs	  (clones	  428,	  827,	  828,	  973,	  978,	  979).	  The	  clones	  were	  selected	  in	  puromycin	  for	  10	  days.	  Asterisks	  indicate	  the	  most	  successful	  downregulations.	  α-­‐tubulin	  was	  used	  as	  loading	  control.	  	  Next,	  the	  highly	  efficient	  plasmids	  “145”	  (p38γ	  shRNA)	  and	  “827”	  (p38δ	  shRNA)	  (with	  over	  90%	  of	   expression	  decrease)	  were	   selected	   for	  double	  gene	   silencing	  by	  performing	   two	   consequent	  transductions	  as	  described	  in	  Materials	  and	  Methods.	  The	  A-­‐431	  clone	  “145”	  with	  knocked-­‐down	  p38γ	   gene	   was	   re-­‐transduced	   with	   a	   shRNA	   against	   p38δ	   called	   “827”	   (145/827).	   The	   second	  transduction	  in	  this	  p38γ-­‐knocked-­‐down	  clone	  led	  to	  a	  level	  of	  just	  above	  30%	  of	  the	  initial	  p38δ	  expression.	   The	   remaining	   clones	   were	   re-­‐transduced	   with	   an	   empty	   vector	   pLKO.1	   alone:	  pLKO/pLKO	  (2x	  pLKO),	  145/pLKO	  and	  827/pLKO	  (Fig.	  R-­‐25).	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4.2.	  Growth	  of	  A-­‐431	  xenotransplants	  and	  cell	  proliferation	  in	  vitro.	  We	  wanted	  to	  see	  whether	  or	  not	  the	  depletion	  of	  p38γ	  and/or	  p38δ	  in	  A-­‐431	  cells	  would	  change	  the	  growth	  of	  xenograft	   tumours	   in	  athymic	  nude	  mice.	  For	  this	  we	  used	  the	  established	  knock-­‐down	  cells:	   sh-­‐control	   (pLKO/pLKO),	   sh-­‐p38γ	   (145/pLKO),	   sh-­‐p38δ	   (827/pLKO)	   and	   sh-­‐p38γ/δ	  (145/827)	  (Fig.	  R-­‐26A).	  On	  day	  0	  mice	  received	  subcutaneous	  injections	  of	  106	  cells	  per	  flank	  (n	  =	  6	  flanks	  per	  group),	  as	  shown	  in	  Figure	  R-­‐26B.	  The	  tumour	  growth	  was	  measured	  every	  2	  –	  4	  days	  from	  day	  7	  until	  day	  19	  after	  the	  injection	  (Fig.	  R-­‐26C).	  	  WT	  (control),	  p38γ-­‐/-­‐	  and	  p38δ-­‐/-­‐	  xenograft	  tumours	  were	  characterised	  by	  similar	  growth	  during	  the	  whole	  experiment,	  reaching	  on	  average	  700	  –	  900	  mm3	  of	  volume	  at	  day	  19.	  Strikingly,	  the	  A-­‐431	  with	  downregulated	  expression	  of	  both	  p38γ	  and	  p38δ	  grew	  very	  slowly	  reaching	  about	  100	  mm3	   of	   volume	   at	   day	   19.	   We	   concluded	   that	   the	   absence	   of	   both	   p38γ/δ	   proteins	   in	   these	  epidermoid	  cancer	  cells	  diminished	  the	  tumour	  growth.	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1.	  Introduction.	  Published	  data	  highlight	   the	   importance	  of	  p38γ	   and	  p38δ	  MAPKs	   in	  malignant	   transformation.	  	  Cell-­‐based	   assays	   showed	   their	   functions	   in	   tumorigenesis,	   controlling	   processes	   such	   as	   cell	  proliferation,	  cell	  migration	  and	  cell	  contact	  inhibition	  (Faraone	  et	  al.,	  2009;	  Cerezo-­‐Guisado	  et	  al.,	  2011;	  Risco	   and	  Cuenda,	  2012;	  Yang	  et	   al.,	   2013).	   p38γ	   and	  p38δ	   are	   also	   implicated	   in	   linking	  inflammation	   and	   tumour	   promotion	   and/or	   progression,	   since	   impaired	   cytokine	   production	  was	   demonstrated	   in	   p38γ/δ-­‐deficient	   mice	   in	   different	   disease	   models	   such	   as	   septic	   shock,	  arthritis	  and	  colitis-­‐associated	  colon	  cancer	  (Risco	  et	  al.,	  2012;	  Criado	  et	  al.,	  2014,	  del	  Reino	  et	  al.,	  2014).	   In	   addition,	   in	   the	   two-­‐stage	   DMBA/TPA	   protocol,	   which	   depends	   on	   pro-­‐inflammatory	  processes	   in	  the	  skin	  (Swann	  et	  al.,	  2008),	  p38δ	  has	  a	  pro-­‐tumorigenic	  role.	  Mice	  that	   lack	  p38δ	  have	   reduced	   susceptibility	   to	   development	   of	   skin	   papillomas	   after	   DMBA/TPA	   treatment	  (Schindler	   et	   al.,	   2009).	   	   The	   authors	   claim	   that	   skin	   carcinogenesis	   in	   p38δ-­‐deficient	   mice	  involves	   a	   defect	   in	   proliferative	   responses	   associated	   with	   abnormal	   signalling	   through	   two	  major	   transformation-­‐promoting	   pathways,	   ERK1/2	   and	   STAT3.	   In	   this	   thesis,	  we	  have	   defined	  the	  importance	  of	  p38γ	  and	  of	  p38δ	  in	  mouse	  skin	  inflammation	  and	  tumorigenesis.	  	  
2.	  Expression	  and	  activation	  of	  p38γ 	  and	  p38δ 	  in	  the	  skin	  and	  skin	  papillomas.	  p38α	   and	   p38δ	   are	   the	   predominant	   p38	   isoforms	   in	   normal	   human	   and	  mouse	   keratinocytes,	  and	  it	  is	  commonly	  claimed	  that	  p38γ	  is	  virtually	  undetectable	  in	  normal	  epidermis	  (Junttila	  et	  al.,	  2007).	   Another	   study	   reported	   expression	   of	   p38α,	   p38β	   and	   p38δ	   in	   healthy	   and	   psoriatic	  keratinocytes	   (Johansen	   et	   al.,	   2005).	   Psoriasis	   is	   a	   chronic	   inflammatory	   skin	   disorder	  characterised	   by	   keratinocyte	   hyperproliferation	   and	   differentiation.	   The	   activity	   of	   the	   three	  isoforms	   is	   augmented	   in	   lesional	   compared	   with	   nonlesional	   psoriatic	   skin.	   The	   same	   study	  claimed	   that	  p38γ	   is	  undetectable	   in	  skin	   (Johansen	  et	  al.,	  2005).	  Whereas	  p38α	   and	  p38δ	  have	  been	  studied	  preferentially	  in	  skin	  and	  in	  skin-­‐derived	  cell,	  the	  role	  of	  p38γ	  has	  been	  neglected	  so	  far,	  and	  little	  is	  known	  about	  its	  functions	  in	  the	  skin.	  One	  study	  showed	  that	  activated	  p38γ	  could	  be	  involved	  in	  human	  melanoma	  cell	  death	  in	  response	  to	  genotoxic	  stresses	  such	  as	  UV	  radiation	  or	  cisplatin	  (Pillaire	  et	  al.,	  2000);	  another	  revealed	  increased	  p38γ	  expression	  in	  melanoma	  cells	  that	   overexpressed	   the	   platelet-­‐derived	   growth	   factor	   receptor	   (Faraone	   et	   al.,	   2009).	   Here	  we	  demonstrate	  that	  p38γ	   is	  expressed	  (although	  to	  a	  lesser	  extent	  than	  p38δ)	  in	  keratinocytes	  and	  skin.	  p38γ	  can	  be	  detected	  both	  at	  the	  mRNA	  level	  by	  qPCR	  and	  as	  a	  protein	  by	  immunoblotting.	  We	   cannot	   explain	  with	   certainty	   the	  differences	  between	   the	   results	  obtained	  by	  other	   groups	  and	   our	   own,	   although	   different	   antibodies/oligonucleotides,	   their	   specificity	   and/or	   exposure	  intensities	   when	   developing	   immunoblots	   could	   be,	   at	   least	   in	   part,	   the	   answer.	   Moreover,	   in	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contrast	  to	  our	  model,	  the	  cited	  studies	  used	  only	  human	  cells.	  Results	  of	  a	  recent	  work	  by	  Sano	  and	  Park	  (2014)	  on	  p38γ	  and	  p38δ	  expression	  in	  mouse	  skin	  coincide	  with	  our	  data;	   they	  show	  that	  both	  p38γ	  and	  p38δ	  are	  expressed	  in	  the	  epidermis	  and	  in	  isolated	  keratinocytes.	  p38γ,	  but	  not	  p38δ,	  is	  also	  expressed	  in	  the	  dermis	  (including	  dermal	  fibroblasts).	  	  
3.	  p38γ 	  and	  p38δ 	  in	  human	  SCC	  and	  in	  mouse	  skin	  papillomas.	  There	  are	  few	  published	  clinical	  data	  on	  p38γ	  and/or	  p38δ	  in	  skin	  cancer,	  including	  squamous	  cell	  cancer.	  The	  Oncomine/Compendia	  Bioscience	   (Life	  Technologies)	  database	  shows	  no	  consistent	  p38γ	  or	  p38δ	  expression	  patterns	  in	  the	  relatively	  few	  squamous	  cancer	  cases	  available	  (Fig.	  D-­‐1).	  For	   instance,	  p38δ	   expression,	  which	   is	  quite	  highly	  expressed	   in	   the	  oral	  cavity,	   is	   significantly	  downregulated	  in	  transformed	  OSCC	  tissue,	  whereas	  p38γ,	  normally	   less	  abundant	  than	  p38δ,	   is	  upregulated	  in	  this	  type	  of	  carcinoma	  (Peng	  et	  al.,	  2011).	  In	  contrast,	  p38γ	  and	  p38δ	  expression	  in	  tongue	  SCC	  cases	   is	  characterised	  by	  the	  opposite	  effect;	  p38γ	  expression	  is	  decreased	  in	  cancer	  tissue	  compared	  with	  healthy	  tissue,	  while	  p38δ	  is	  upregulated	  (Estilo	  et	  al.,	  2009).	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An	   epithelial	   fraction	   of	   skin	   papillomas	   is	   constituted	   by	   mutated	   hyperproliferating	  keratinocytes	   (Cataisson	   et	   al.,	   2012),	  which	   originate	  when	   the	  mouse	   epidermis	   undergoes	   a	  DMBA-­‐provoked	  mutational	   initiation,	   followed	  by	  TPA-­‐dependent	  promotion.	  p38δ	   is	  relatively	  abundant	   in	   this	   type	   of	   skin	   tumour,	   as	   observed	   in	  WT	   and	   p38γ-­‐/-­‐	  mice	   and	   compared	  with	  healthy	  skin;	  in	  contrast,	  p38γ	  expression	  is	  lower	  in	  tumours	  from	  WT	  and	  p38δ-­‐/-­‐	  mice	  than	  in	  healthy	   skin.	  These	  differences	   in	  p38γ	   and	  p38δ	   expression	   are	   comparable	   to	   those	  observed	  between	  WT	  keratinocytes	  and	  healthy	  skin.	  p38δ	  is	  expressed	  slightly	  more	  in	  keratinocytes	  than	  in	  whole	   skin,	  whereas	  p38γ	   is	   expressed	  more	   abundantly	   in	   skin	   than	   in	   keratinocytes	   alone.	  These	  findings	  indicate	  that	  p38γ	   is	  also	  expressed	  by	  cells	  other	  than	  keratinocytes	  (e.g.	  dermal	  fibroblasts),	   whereas	   p38δ	   is	   expressed	   predominantly	   in	   keratinocytes.	   	   These	   data	   are	  supported	   by	   the	   fact	   that	   tumour	   tissue	  where	   p38δ	   is	   highly	   expressed	   is	   formed	   largely	   by	  keratinocytes.	  	  In	   the	   WT	   and	   p38γ-­‐/-­‐	   tumours	   that	   develop	   in	   the	   DMBA/TPA	   protocol,	   p38δ	   is	   not	   only	  expressed	   strongly	   but	   is	   also	   highly	   phosphorylated,	   compared	  with	   healthy	   skin	   in	   the	   same	  mouse.	  	  In	  contrast,	  we	  detected	  no	  differences	  in	  p38α	  phosphorylation	  between	  papillomas	  and	  healthy	  skin.	  Moreover,	  phosphorylated	  p38α	   levels	  are	  comparable	  among	  all	  genotypes.	  These	  data	   highlight	   the	   possible	   importance	   of	   p38δ-­‐mediated	   processes	   in	   murine	   epidermal	   cells	  during	  tumorigenesis.	  	  
4.	  	  p38γ 	  and	  p38δ 	  isoform	  redundancy	  and	  synergism	  of	  the	  p38γ/δ 	  deficiency.	  Our	   results	   from	   the	   DMBA/TPA	   experiment	   are	   in	   agreement	   with	   observations	   of	   the	  tumorigenic	  role	  of	  p38δ	  in	  skin	  carcinogenesis	  (Schindler	  et	  al.,	  2009;	  Efimova,	  2010),	  which	  we	  also	  confirmed.	  We	  demonstrated	  that	  compared	  to	  all	  other	  genotypes,	  WT	  mice	  that	  underwent	  DMBA/TPA	   treatment	   showed	   the	   greatest	   susceptibility	   to	   skin	   tumour	   development.	   In	  contrast,	   mice	   deficient	   in	   both	   p38γ	   and	   p38δ	   were	   the	  most	   resistant	   to	   skin	   tumorigenesis,	  whereas	  p38γ-­‐/-­‐	  and	  p38δ-­‐/-­‐	  mice	  had	  an	  intermediate	  phenotype;	  the	  p38γ	  knock-­‐outs	  were	  more	  susceptible	  (partially	  resembling	  WT)	  and	  p38δ	  knock-­‐outs	  were	  slightly	  more	  resistant.	  	  This	   intermediate	  phenotype	  of	  p38γ-­‐/-­‐	  and	  p38δ-­‐/-­‐	  compared	  to	  WT	  and	  p38γ/δ-­‐/-­‐	  mice	  could	  be	  due	  to	  partial	   isoform	  redundancy,	  with	  predominance	  of	  neither	   isoform.	  Functional	  overlap	  of	  the	  two	  isoforms	  has	  been	  reported	  (Criado	  et	  al.,	  2014;	  Risco	  et	  al.,	  2012)	  and	  might	  account	  for	  the	   partial	   effects	   observed	   in	   p38γ-­‐/-­‐	   and	   p38δ-­‐/-­‐	   mice.	   In	   vitro	   experiments	   in	   MEF	   also	  demonstrated	   this	   redundancy.	   SAP97/hDlg	   (synapse-­‐associated	   protein	   97/human	   discs	   large	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homolog	  1)	  is	  a	  physiological	  p38γ	  substrate	  that	  in	  WT	  cells	  is	  normally	  phosphorylated	  at	  Ser158,	  Thr209	  and	  Ser442.	  In	  p38γ-­‐/-­‐	  cells,	  this	  substrate	  is	  also	  phosphorylated	  by	  the	  remaining	  isoforms,	  p38δ	  (at	  Thr209),	  p38α	  and	  p38β	  (both	  at	  Ser442)	  (Sabio	  et	  al.,	  2005).	  	  Our	   results	   emphasise	   the	   existence	   of	   p38γ	   and	   p38δ	   functions	   associated	   with	   tumour	  development	   and	   indicate	   the	   synergistic	   impact	   of	   p38γ	   and	   p38δ	   deficiency	   on	   skin	   during	  chemically	   induced	   tumorigenesis.	   	   Reduced	   incidence	   of	   tumours,	  with	   no	   apparent	   change	   in	  size	   or	   growth,	   in	   p38γ-­‐/-­‐	   and	  p38δ-­‐/-­‐	   compared	  with	  WT	  mice	   further	   suggests	   a	   role	   for	   these	  isoforms	  in	  skin	  tumour	  initiation	  rather	  than	  its	  progression.	  	  
5.	  	  Crosstalk	  between	  p38γ 	  and	  p38δ 	  in	  skin	  and	  in	  transformed	  keratinocytes.	  In	   light	   of	   our	   in	   vivo	   findings	   on	   p38γ,	   we	   could	   not	   rule	   out	   possible	   functions	   in	   healthy	   or	  transformed	   epithelium,	   or	   in	   conditions	   such	   as	   TPA-­‐induced	   skin	   tumour	   promotion	   in	   the	  DMBA/TPA	  protocol.	  	  This	  idea	  is	  also	  supported	  by	  in	  vitro	  and	  in	  vivo	  data	  from	  our	  experiments	  on	  human	  A-­‐431	  epidermoid	  cancer	  cells.	  	  We	  showed	  that	  wild	  type	  A-­‐431	  cells	  not	  only	  express	  p38γ	  and	  p38δ,	  but	  are	  also	  characterised	  by	  phosphorylation	  of	  both	  p38	  isoforms	  in	  response	  to	  TPA	  treatment;	  p38α	  is	  also	  phosphorylated	  in	  these	  cells	  after	  TPA	  treatment	  (Fig.	  D-­‐2).	  
	  Figure	   D-­‐2.	   Phosphorylation	   of	   p38α,	   p38γ	   and	   p38δ	   in	   wild	   type	   A-­‐431	   cells	   and	   in	   p38γ-­‐	   and	   p38δ-­‐deficient	  clones	  in	  response	  to	  TPA	  treatment	  (300	  ng/ml;	  20	  min).	  	  	  Given	  that	  p38γ	  expression	  is	  higher	  in	  healthy	  skin	  than	  in	  keratinocytes	  or	  skin	  papillomas,	  we	  hypothesised	  that	  p38γ	   functions	   in	  skin	  might	  not	  be	  restricted	  to	  keratinocytes.	  This	   idea	  was	  supported	  by	  our	  observations	  of	  the	  effect	  of	  TPA	  treatment	  on	  skin	  in	  mice	  and	  on	  A-­‐431	  cells,	  in	  the	  absence	  of	  either	  p38γ	  or	  p38δ.	  We	  show	  that	  a	  single	  TPA	  treatment	  had	  a	  different	  effect	  on	  p38γ	  and	  on	  p38δ	  phosphorylation	  in	  mouse	  skin,	  depending	  on	  the	  presence/absence	  of	  the	  other	   isoform.	  Specifically,	  TPA	   treatment	   induced	  p38γ	   and	  p38δ	   phosphorylation	   in	  WT	  mice,	  whereas	  p38δ-­‐deficient	  mice	  did	  not	  phosphorylate	  p38γ	   to	   the	  extent	  observed	   in	  WT	  mice.	   In	  contrast,	   p38γ	   deficiency	   did	   not	   impede	   p38δ	   phosphorylation	   (Fig.	   D-­‐3).	   This	   effect	   was	   not	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observed	  in	  A-­‐431	  cells	  in	  which	  p38δ	  expression	  was	  silenced.	  p38γ	  was	  phosphorylated	  in	  the	  p38δ-­‐/-­‐	  clone	  after	  TPA	  treatment	  and	  vice	  versa	  (Fig.	  D-­‐2).	  These	  results	  suggest	  the	  existence	  of	  a	  crosstalk	  between	  p38γ	  and	  p38δ	  in	  the	  skin	  that	  does	  not	  necessarily	  take	  place	  in	  isolated	  A-­‐431	  cells.	  Our	   in	  vivo	  results	  thus	  indicate	  that	  p38γ	  and	  p38δ	  can	  each	  modulate	  phosphorylation	  of	  the	   other,	   probably	   in	   different	   skin	   compartments	   by	   a	   mechanism	   that	   needs	   further	  clarification.	  	  
	  	  Figure	  D-­‐3.	  Hypothetical	  crosstalk	  between	  p38γ	  and	  p38δ	  in	  the	  skin	  of	  WT,	  p38γ-­‐/-­‐	  and	  p38δ-­‐/-­‐	  mice	  in	  the	  context	  of	  TPA-­‐induced	  p38γ/δ	  phosphorylation.	  	  	  A-­‐431	  cells	  express	  an	  extremely	   large	  number	  of	  EGF	  receptors	  on	  their	  surface	  (3	  x	  106/cell);	  this	   is	   due,	   at	   least	   in	   part,	   to	  EGFR	  gene	   amplification	   (Janmaat	   et	   al.,	   2003).	   For	   comparison,	  normal	   human	   fibroblasts	   have	   a	   much	   lower	   EGFR	   density,	   approximately	   105/cell.	   The	  physiology	  of	   the	   transformed	  A-­‐431	  cells	   thus	  does	  not	  exactly	   reflect	   the	  processes	   in	  normal	  keratinocytes,	   especially	   after	   TPA	   treatment,	   which	   is	   known	   to	   activate	   EGFR.	   TPA-­‐induced	  receptor	  activation	  was	  demonstrated	  by	  chemical	  inhibition	  of	  EGFR,	  which	  resulted	  in	  effective,	  dose-­‐dependent	   reduction	   of	   EGFR	   tyrosine	   phosphorylation	   (Lu	   et	   al.,	   2007).	   Since	  we	   cannot	  exclude	  possible	  reciprocal	  regulation	  of	  p38γ	  and	  p38δ	   in	  healthy	  keratinocytes,	  it	  is	  difficult	  to	  determine	  precisely	  whether	  conserved	  p38γ	  phosphorylation	  in	  the	  p38δ-­‐/-­‐	  A-­‐431	  clone	  is	  due	  to	  high	   EGFR	   or	   is	   a	   consequence	   of	   other	   keratinocyte	   transformation	   events.	   Another	   possible	  explanation	  is	  that	  p38δ	  downregulation	  is	  incomplete	  and	  the	  remaining	  p38δ	  protein	  (~10%	  of	  the	  control	  clone)	  is	  sufficient	  to	  facilitate	  TPA-­‐induced	  p38γ	  phosphorylation.	  	  Regulation	  of	  p38γ	   and	  p38δ	   expression	  and	  activity	   in	  mouse	  skin	  cells	  might	   thus	  be	  context-­‐dependent,	   and	   probably	   differs	   between	   cell	   types	   and	   between	   steady	   state	   and	  inflammatory/tumorigenic	   conditions.	   Resistance	   of	   p38δ-­‐/-­‐	   mice	   to	   skin	   tumorigenesis	   could	  result	  from	  reduced	  p38γ	  activity	  during	  tumour	  promotion	  rather	  than	  from	  lack	  of	  p38δ	  alone;	  this	   is	   supported	  by	   the	  observation	  of	   increased	   tumour	   suppression	   in	  p38γ/δ-­‐/-­‐	   compared	   to	  p38δ-­‐/-­‐	  mice.	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6.	  p38γ 	  and	  p38δ 	  in	  epidermis	  proliferation.	  As	  disruption	  of	  cell	  cycle	  control	  contributes	  to	  malignant	  transformation,	  increased	  proliferation	  is	  a	  common	  indicator	  of	  tumorigenesis.	  Tumour	  promoters	  used	  in	  skin	  carcinogenesis	  models,	  such	   as	   TPA,	   have	   several	   activities	   including	   generation	   of	   epidermal	   hyperplasia	   through	  induction	   of	   skin	   keratinocyte	   division	   (Aldaz	   et	   al.,	   1985).	  We	   showed	   that	   after	   a	   single	   TPA	  treatment,	   the	   skin	   of	   mice	   deficient	   in	   p38γ	   or	   p38δ	   or	   both	   showed	   fewer	   proliferating	  epidermal	   cells	   compared	  with	  WT	  mice.	   This	  was	   also	   reflected	   in	   epidermis	   thickening,	  most	  noticeable	  in	  WT	  mice,	  whereas	  this	  layer	  was	  thinner	  in	  the	  remaining	  genotypes	  (p38γ-­‐/-­‐,	  p38δ-­‐/-­‐,	  p38γ/δ-­‐/-­‐).	   These	   results	   are	   in	   accordance	   with	   observations	   from	   the	   Efimova	   group,	   who	  studied	  p38δ	  functions	  in	  TPA-­‐treated	  skin	  and	  obtained	  similar	  data	  showing	  that	  p38δ-­‐null	  skin	  is	  proliferation-­‐deficient	  (Schindler	  et	  al.,	  2009).	  	  At	  difference	  from	  epidermis	  treated	  with	  TPA	  alone,	  the	  epithelium	  of	  papillomas	  that	  developed	  in	   the	   DMBA/TPA	   protocol	   showed	   similar	   numbers	   of	   proliferating	   cells	   in	   WT,	   p38γ-­‐/-­‐	   and	  p38δ-­‐/-­‐	   mice.	   	   	   The	   Efimova	   group	   found	   that	   in	   p38δ-­‐/-­‐	   mice,	   besides	   its	   reduction	   in	   skin,	  epithelial	   cell	   proliferation	  was	   also	   diminished	   in	   skin	  papillomas	   (Schindler	   et	   al.,	   2009);	   this	  contradicts	  our	  observations.	  	  We	  hypothesise	  that	  this	  difference	  is	  due	  to	  the	  distinct	  protocols	  used	   in	   the	   two	   studies.	   	  We	   analysed	   proliferation	   in	   papillomas	   10	  weeks	   after	   the	   last	   TPA	  treatment	   (at	  week	   29),	  whereas	   Schindler	   et	   al.	   examined	   the	   papilloma	   samples	   immediately	  after	  the	  final	  TPA	  treatment	  (at	  week	  19).	  	  This	  would	  suggest	  that	  the	  implication	  of	  p38δ	  (and	  p38γ)	   in	   control	   of	   proliferation	   depends	   on	   the	   accompanying	   TPA	   induction	   in	   the	   skin	   and	  tumour	  epithelium.	  	  The	  proliferative	  effect	  of	  TPA	  treatment	  manifested	  by	  epidermal	  hyperplasia	  is	  also	  associated	  with	   important	  molecular	  changes.	  Signalling	  pathways	   induced	   in	  TPA-­‐treated	  skin	  are	  defined	  by	   the	   activation	   of	   factors	   such	   as	  MAPK	   (p38α,	   p38γ,	   p38δ,	   ERK1/2,	   JNK1/2)	   and	   STAT3,	   all	  transiently	   phosphorylated	   in	   skin	   cells.	   STAT3	   is	   a	   common	   oncogenic	   transcription	   factor	   in	  many	   tumours	   and	   its	   activation	   mediates	   malignant	   cell	   proliferation	   and	   their	   escape	   from	  apoptosis	  (Yu	  et	  al.,	  2007).	  Its	  role	  in	  promoting	  DMBA/TPA-­‐induced	  epithelial	  hyperproliferation	  was	  highlighted	  by	  a	   report	  of	   suppressed	  skin	  cell	  division	  by	  a	  STAT3	  antagonist	   (Chan	  et	  al.,	  2004).	   Multistage	   skin	   carcinogenesis	   assays	   in	   skin-­‐specific	   gain	   and	   loss	   of	   STAT3	   function	  transgenic	   mice	   showed	   that	   STAT3	   is	   necessary	   for	   tumour	   initiation	   and	   tumour	   promotion	  through	  regulation	  of	  survival	  and	  proliferation,	  respectively.	  This	  regulation	  leads	  to	  survival	  of	  DNA-­‐damaged	  stem	  cells	  and	  the	  maintenance	  of	  proliferation	  necessary	  for	  clonal	  expansion	  of	  initiated	   cells.	   STAT3	   also	   plays	   a	   role	   in	  malignant	   progression	   of	   skin	   tumours,	   by	   regulating	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genes	  involved	  in	  angiogenesis	  and	  invasion	  (Kim	  et	  al.,	  2007).	  We	  show	  that	  the	  vast	  majority	  of	  epithelial	   cells	   in	   a	   progressed	   skin	   tumour,	   which	   are	   found	   in	   both	   peripheral	   and	   interior	  tumour	  masses,	   are	  marked	   by	   nuclei	  with	   phosphorylated	   STAT3,	  whereas	   benign	   papillomas	  were	  phospho-­‐STAT3-­‐positive	  mainly	   in	   the	  outermost	   tumour	   stroma-­‐surrounding	   epithelium.	  Nonetheless,	  we	   found	  no	  differences	   in	   STAT3	  phosphorylation	   among	  WT,	  p38γ-­‐/-­‐	   and	  p38δ-­‐/-­‐	  mice.	   Total	   STAT3	   expression	   in	   skin	   papillomas	   was	   also	   similar	   among	   the	   genotypes.	   In	  contrast,	   in	  the	  acute	  skin	  inflammation	  experiment	  with	  TPA	  alone,	  we	  observed	  a	  significantly	  less	  STAT3	  phosphorylation	  in	  the	  skin	  of	  p38γ/δ	  knock-­‐out	  mice	  compared	  with	  WT	  mice	  during	  the	   first	   four	   hours	   after	   skin	   exposure	   to	   TPA.	   We	   therefore	   hypothesised	   that	   the	   reduced	  proliferation	  of	  epidermal	  keratinocytes	  in	  these	  mice	  might	  be	  due,	  at	  least	  in	  part,	  to	  disrupted	  STAT3	   signalling.	   STAT3	   activation	   in	   p38γ-­‐/-­‐	   and	  p38δ-­‐/-­‐	  mice	   in	   the	   same	   conditions	  was	   only	  affected	   at	   shorter	   times	   post-­‐TPA	   treatment.	   At	   longer	   times,	   STAT3	   phosphorylation	   was	  comparable	   with	   WT	   mice,	   which	   suggests	   a	   synergistic	   role	   of	   p38γ/δ	   deficiency	   in	   STAT3	  signalling	   regulation,	   as	   well	   as	   involvement	   of	   additional	   mechanism(s)	   that	   underlie	   the	   cell	  proliferation	  reduction	  in	  single	  p38γ	  and	  p38δ	  knock-­‐out	  mice.	  	  
7.	  Inflammation	  as	  a	  pro-­‐tumorigenic	  factor.	  A	   broad	   range	   of	   experimental	   and	   clinical	   evidence	   highlights	   the	   central	   role	   of	   chronic	  inflammation	  in	  promoting	  tumour	  development	  (Hanahan	  and	  Weinberg,	  2000).	  The	  molecular	  mechanisms	   that	   convert	   transient	   inflammatory	   reactions	   in	   tissues,	   including	   the	   skin,	   into	   a	  tumour-­‐promoting	   microenvironment	   nonetheless	   remain	   largely	   unknown.	   Keratinocytes	  undergo	   transformation	   in	   the	   course	   of	   the	   DMBA/TPA	   protocol,	   leading	   to	   skin	   papilloma	  growth,	   which	   is	   dependent	   on	   clonal	   expansion	   of	   mutated,	   initiated	   cells.	   Since	   not	   all	   skin	  papillomas	   culminate	   as	   differentiated	   skin	   outgrowths,	   but	   rather	   disappear	   (Kopp-­‐Schneider	  and	  Portier,	   1992),	   the	  molecular	   events	   that	   lead	   to	   epithelial	   cell	   transformation	  during	  early	  stages	  of	  skin	  tumour	  promotion	  must	  be	  very	  complex	  and	  highly	  contextual.	  DMBA/TPA-­‐treated	  epidermal	   cells	   are	   subject	   to	   molecular	   changes	   that	   are	   reflected	   in	   the	   constitutive	  phosphorylation	   of	   proteins	   such	   as	   p38δ,	   Akt	   and	   STAT3	   in	   the	   skin	   tumours,	   as	   shown	   by	  immunoblot	   and/or	   immunohistochemistry	   staining	   in	   our	   papilloma	   biopsies.	   As	   predicted,	  these	  proteins	  were	  also	  activated	  in	  inflamed	  skin.	  	  Skin	   inflammation	   underlies	   development	   and	   progression	   of	   a	   number	   of	   disorders	   including	  psoriasis,	  atopic	  dermatitis	  and	  skin	  cancer.	  The	  infiltration	  of	  immune	  cells	  such	  as	  neutrophils,	  T	  lymphocytes	  and	  macrophages,	  as	  well	  as	   local	  production	  of	   inflammatory	  cytokines	  and	  other	  mediators	   are	   essential	   during	   skin	   carcinogenesis.	   Resistance	   to	   DMBA/TPA-­‐induced	   skin	  
	  	  
Discussion	   	  	   	  
104	  
tumorigenesis	   is	   linked	   to	   a	   defect	   in	   sustaining	   inflammation	   during	   the	   promotion	   phase	  (Gebhardt	   et	   al.,	   2008).	   Another	   study	   suggested	   that	   p38	   MAPK-­‐dependent	   responses	   might	  include	   inflammatory	   reactions,	   whose	   onset	   can	   be	   determined	   by	   interleukin	   production	  (Lilleholt	  et	  al.,	  2011).	   In	  that	  study,	  WT	  and	  p38β/p38δ	  double	  knock-­‐out	  mice	  were	  examined	  for	  their	  response	  to	  TPA.	  The	  authors	  observed	  lower	  IL-­‐1β	  protein	  production	  in	  p38β/δ-­‐/-­‐	  than	  in	  WT	  mice,	  while	  mRNA	  production	  was	  unaffected.	  They	  claimed	  that	  p38β	  and/or	  p38δ	  might	  be	  involved	  in	  the	  post-­‐transcriptional	  regulation	  of	  this	  cytokine,	  although	  the	  exact	  contribution	  of	   either	   isoform	  was	   not	   specified	   (Lilleholt	   et	   al.,	   2011).	   Recent	   publications	   have	   shown	   the	  synergistic	   anti-­‐inflammatory	   effect	   of	   p38γ/δ	   deficiency	   in	   several	  mouse	  models	   such	   as	   LPS-­‐induced	  septic	  shock,	  rheumatoid	  arthritis	  and	  colitis-­‐associated	  colon	  cancer	  (Risco	  et	  al.,	  2012;	  Criado	  et	  al.,	  2014;	  del	  Reino	  et	  al.,	  2014).	  We	  hypothesised	  that	   induced	  epithelial	  proliferation	  and	  altered	  cell	  signalling	  in	  skin	  chronically	  exposed	  to	  TPA	  during	  tumour	  promotion	  and	  after	  single	  TPA	  administration	  could	  be	  a	  result,	  at	  least	  in	  part,	  of	  inflammatory	  conditions.	  	  
8.	  p38γ 	  and	  p38δ 	  in	  cytokine	  production	  in	  inflamed	  skin.	  Neutrophil-­‐derived	   products	   have	   critical	   roles	   at	   different	   stages	   of	   tumour	   progression,	   from	  initial	   genotoxic	   insult	   to	   metastasis	   to	   distant	   sites.	   Although	   early	   studies	   indicated	   that	  neutrophils	   might	   be	   cytotoxic	   to	   tumour	   cells	   (particularly	   in	   their	   regulation	   of	   cytotoxic	  T	  cells),	   recent	  work	   has	   shown	   overwhelmingly	   that	   neutrophils	   promote	   tumour	   progression	  via	   angiogenesis,	   matrix	   degradation,	   immune	   surveillance,	   as	   well	   as	   secretion	   of	   chemokines	  (including	   KC	   and	  MIP-­‐2)	   and	   cytokines	   (IL-­‐1β,	   IL-­‐6,	   IL-­‐12,	   TNF-­‐α),	   and	   production	   of	   reactive	  oxygen	   species,	   all	   of	   which	   contribute	   to	   the	   pro-­‐tumorigenic	   environment	   and	   metastasis	  (Gregory	  and	  Houghton,	  2011;	  Fridlender	  and	  Albelda,	  2012).	  MIP-­‐2	   (or	  CXCL2	   in	  humans)	   is	  a	  CXC	  chemokine	  (with	  two	  N-­‐terminal	  cysteine	  residues	  separated	  by	  one	  amino	  acid)	  has	  potent	  neutrophil	  chemotactic	  activity	  as	  well	  as	  mitogenic	  activity	  for	  epithelial	  cells	  in	  a	  rat	  lung	  model	  (Driscoll	  et	  al.,	  1995).	  Several	   in	  vitro	   studies	  also	  demonstrated	  that	  non-­‐immune	  cells,	   such	  as	  epithelial	   cells	  or	   fibroblasts,	   also	  produce	  MIP-­‐2	   (Driscoll,	  2000).	  Chemokine	  production	   in	   the	  skin	   is	  cell	   type-­‐dependent	  and	  their	  expression	  patterns	  at	   inflammation	  sites	  might	  reflect	  the	  temporally	  ordered	  contribution	  of	  distinct	  cell	  types.	  In	  the	  inflammation-­‐associated	  skin	  injury	  model,	   distinct	   CXC	   chemokines	   show	   restricted	   expression	   in	  myeloid	   versus	   non-­‐myeloid	   cell	  types	   (Armstrong	   et	   al.,	   2004).	   In	   this	   model,	   dermal	   fibroblasts	   and	   endothelial	   cells	   are	  primarily	   responsible	   for	   KC	   expression	   in	   the	   skin,	   whereas	   MIP-­‐2	   production,	   especially	   at	  longer	   times	   after	   injury,	   appears	   to	   be	   restricted	   to	   infiltrating	   inflammatory	   leukocytes,	  including	  neutrophils	  and	  monocytes.	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Here	  we	  report	  that,	  in	  comparison	  with	  WT	  mice,	  TPA-­‐treated	  skin	  of	  p38γ/δ-­‐deficient	  mice	  not	  only	  produces	  less	  IL-­‐1β,	  IL-­‐6	  and	  TNF-­‐α,	  but	  also	  shows	  reduced	  KC	  and	  MIP-­‐2	  expression.	  Since	  leukocyte	   recruitment	   to	   inflammatory	   sites	   is	   a	   process	   largely	   orchestrated	   by	   chemokines	  (Garin	   and	   Proudfoot,	   2011),	   the	   reduction	   in	   KC	   and	   MIP-­‐2	   levels	   coincides	   with	   lower	  neutrophil	  myeloperoxidase	  expression	  in	  skin	  and	  fewer	  neutrophils	  infiltrating	  TPA-­‐challenged	  skin	  in	  p38γ/δ-­‐/-­‐	  than	  in	  WT	  mice.	  	  Cytokine	   production	   in	   the	   skin	   is	   also	   crucial	   for	   epithelial	   hyperproliferation.	   IL-­‐6	   induces	  epidermal	  dysplasia	  through	  STAT3	  induction	  (Yu	  et	  al.,	  2007).	  In	  our	  study,	  although	  there	  was	  no	  second	  IL-­‐6	  production	  peak	  at	  24	  h	  post-­‐TPA	  treatment,	  p38γ/δ-­‐/-­‐	  mice	  expressed	  significantly	  lower	   levels	   of	   this	   cytokine	   compared	   with	   WT	   mice.	   The	   protective	   effect	   of	   the	   p38γ/δ	  deficiency	   in	  DMBA/TPA-­‐treated	   skin	   could	  be	   therefore	   explained,	   at	   least	   in	   part,	   by	   reduced	  IL-­‐6	  expression	  linked	  to	  lower	  STAT3	  phosphorylation	  and	  less	  proliferation	  in	  TPA-­‐treated	  skin.	  We	  hypothesise	   that	  both	  p38γ	   and	  p38δ	   are	   important	   for	   the	   regulation	  of	   skin	   inflammation	  after	  TPA	   treatment,	   and	   that	   their	  deletion	  has	  an	  anti-­‐inflammatory,	   anti-­‐tumorigenic	   role	  via	  mechanisms	  that	  involve	  signalling	  regulation	  and	  cell	  proliferation	  in	  the	  epithelium.	  Both	  skin-­‐residing	   and	   skin-­‐infiltrating	   immune	   cells	   could	   drive	   local	   inflammation,	   whose	   regulation	  might	  depend,	  to	  a	  certain	  extent,	  on	  functional	  p38γ	  and	  p38δ	  proteins.	  	  We	  also	  showed	  that	  TPA-­‐induced	  proliferation	  of	  epidermal	  cells	  is	  reduced	  in	  p38γ-­‐/-­‐	  and	  p38δ-­‐/-­‐	  compared	  with	  WT	  mice.	   The	   absence	   of	   one	   isoform	   alone	   is	   thus	   sufficient	   to	   exert	   an	   anti-­‐proliferative	  effect.	  	  STAT3	  phosphorylation	  is	  not	  affected	  in	  these	  mice	  to	  the	  extent	  observed	  in	  p38γ/δ-­‐/-­‐	  mice,	   however,	   and	  with	   one	   exception,	   cytokine	   production	   in	   single	   knock-­‐out	  mice	  resembles	  the	  WT	  phenotype.	  Other	  tumour-­‐promoting	  contributors,	  dependent	  on	  p38γ	  and/or	  p38δ,	   should	   undoubtedly	   be	   considered.	   It	   remains	   to	   be	   determined	   whether	   the	   decrease	  observed	   in	   TPA-­‐induced	   cytokine	   and	   chemokine	   production	   in	   p38γ/δ-­‐/-­‐	  mice	   compared	  with	  WT,	  is	  due	  only	  to	  a	  synergistic	  effect	  of	  the	  lack	  of	  both	  isoforms	  in	  the	  same	  cell	  type	  in	  skin,	  or	  is	  due	   to	   reduced	   leukocyte	   (mainly	   neutrophil)	   infiltration,	   both	   of	   which	   would	   contribute	   to	  overall	  inflammation.	  	  
	  
9.	  Concluding	  remarks.	  It	   is	  very	   likely	  that	  cells	  other	  than	  keratinocytes,	  such	  as	  dermal	   fibroblasts,	  skin-­‐resident	  and	  skin-­‐infiltrating	  immune	  cells,	  as	  well	  as	  biological	  factors	  produced	  in	  the	  skin,	  are	  all	  important	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during	  TPA-­‐induced	  skin	  inflammation,	  including	  the	  promotion	  stage	  of	  skin	  tumorigenesis.	  The	  exact	  contribution	  of	  p38γ/δ	  deficiency	  in	  each	  skin	  compartment	  remains	  to	  be	  established.	  	  We	   have	   shown	   that	   whereas	   the	   lack	   of	   p38γ	   or	   p38δ	   alone	   does	   not	   reduce	   A-­‐431	   tumour	  growth	  when	   these	  cells	  are	   injected	  subcutaneously	   into	  nude	  mice,	  deletion	  of	  both	  p38γ	   and	  p38δ	  affects	  this	  growth	  acutely/really	  a	  lot.	  This	  observation	  supports	  the	  synergism	  observed	  in	  our	  experiments	  on	  skin	  tumorigenesis	  and	  sheds	  light	  on	  possible	  applications	  of	  dual	  p38γ	  and	  p38δ	  inhibitors	  in	  clinical	  trials	  for	  treatment	  of	  inflammatory	  diseases,	  including	  human	  skin	  SCC.	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   1. p38γ	   y	   p38δ	   tienen	   un	   papel	   oncogénico	   en	   el	   modelo	   de	   cáncer	   de	   piel	   inducido	   por	  DMBA/TPA	  ya	  que	  la	  falta	  de	  ambas	  isoformas	  produce	  una	  reducción	  en	  la	  formación	  de	  tumores	  en	  este	  modelo.	  	   2. La	  proliferación	  celular,	  infiltración	  de	  neutrófilos	  y	  activación	  de	  rutas	  de	  señalización	  en	  los	   tumores	   de	   piel	   no	   depende	   de	   la	   presencia	   o	   ausencia	   de	   p38γ	   y	   p38δ	   en	   los	  papilomas,	   indicando	   que	   las	   isoformas	   p38γ	   y	   p38δ	   están	   implicadas	   en	   el	   estadio	   de	  promoción	  dependiente	  de	  TPA.	  	   3. La	  respuesta	  de	  la	  piel	  al	  tratamiento	  con	  DMBA	  no	  depende	  de	  p38γ	  y/o	  p38δ,	  ya	  que	  el	  epitelio	   tratado	   con	   este	   compuesto	   contiene	   comparables	   cantidades	   de	   células	  apoptóticas	  independientemente	  de	  la	  ausencia	  o	  presencia	  de	  p38γ	  y	  p38δ.	  	   4. Las	   dos	   proteínas	   p38γ	   y	   p38δ	   controlan	   la	   proliferación	   de	   las	   células	   de	   la	   epidermis	  inducida	   por	   TPA.	   	   Le	   falta	   de	   una	   de	   las	   dos	   o	   de	   ambas	   isoformas	   de	   p38	   causa	   una	  reducción	  de	  las	  células	  epiteliales	  BrdU-­‐positivas.	  	   5. La	  pronunciada	  resistencia	  de	  los	  ratones	  p38γ/δ-­‐/-­‐	  en	  el	  protocolo	  de	  la	  tumorigénesis	  de	  piel,	  comparando	  con	  los	  ratones	  silvestres,	  puede	  deberse	  a	  la	  insuficiente	  producción	  de	  citoquinas	   y	   quimioquinas	   tras	   el	   tratamiento	   con	   TPA,	   coincidiendo	   con	   un	   menor	  reclutamiento	  de	  neutrófilos	  y	  un	  descenso	  en	  la	  fosforilación	  de	  STAT3.	  	   6. La	   activación	   de	   p38γ	   en	   la	   piel	   tratada	   con	   TPA	   está	   regulada	   por	   p38δ,	   ya	   que	   la	  fosforilación	  de	  p38γ	  en	  los	  ratones	  deficientes	  en	  p38δ	  está	  severamente	  reducida.	  	   7. p38γ	   y	   p38δ	   desempeñan	   un	   papel	   oncogénico	   en	   la	   línea	   celular	   de	   queratinocitos	  humanos	  A-­‐431,	  puesto	  que	  la	  reducción	  de	  expresión	  de	  las	  dos	  quinasas	  en	  estas	  células	  afecta	   la	  proliferación	   tanto	   in	  vitro	   como	   in	  vivo	   en	   los	   xenotransplantes	  en	   los	   ratones	  atímicos.	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